Diagnosing and treating atopic dermatitis, psoriasis, and / or mycosis fungoides

Abstract

The present disclosure relates to methods for diagnosing and / or treating atopic dermatitis, psoriasis, or mycosis fungoides in a patient, and to methods for predicting a patient's response to a treatment for atopic dermatitis, psoriasis, or mycosis fungoides.

Description

[0001] DIAGNOSING AND TREATING ATOPIC DERMATITIS, PSORIASIS, AND / OR MYCOSIS FUNGOIDES

[0002] CROSS REFERENCE TO RELATED APPLICATIONS

[0003] This application claims priority to U.S. Provisional Application No. 63 / 591,118, filed October 18, 2023, and U.S. Provisional Application No. 63 / 489,737, filed March 10. 2023, the disclosures of each of which are incorporated by reference in their entirety.

[0004] FIELD OF THE DISCLOSURE

[0005] The present disclosure relates to methods for diagnosing and / or treating patients with atopic dermatitis, psoriasis, and / or mycosis fungoides.

[0006] BACKGROUND

[0007] Updates in the molecular understanding of common and often debilitating skin diseases such as atopic dermatitis (AD), psoriasis, and mycosis fungoides have led to the development of multiple novel systemic drugs targeting those disease pathways. Optimal response to these medications relies on the correct diagnosis in addition to clinical, personal, and genetic factors unique to each patient. Currently, clinical presentation and patient comorbidities contribute heavily to the development of a therapeutic plan for patients with AD and psoriasis. On the other hand, the molecular mechanisms underlying each patient’s disease are not routinely considered when developing a treatment plan. This empirical approach to treatment selection could delay the optimal therapeutic response and lead to increased costs to healthcare systems. Therefore, understanding an individual patient’s disease at the molecular level could better inform treatment decisions. There is a need for more accurate identification of atopic dermatitis, psoriasis, and mycosis fungoides skin lesions using non-invasive sampling from a subject.

[0008] SUMMARY

[0009] There is a need in the art for a more accurate method of differentiating between atopic dermatitis, psoriasis lesions, mycosis fungoides, and non-lesional skin in a subject. Disclosed herein methods to differentiate between atopic dermatitis, psoriasis lesions, mycosis fungoides, and non-lesional skin with greater accuracy than previously developed tests. Also disclosed herein methods to predict a patient’s response to a treatment for atopic dermatitis, psoriasis lesions, mycosis fungoides. In one aspect, this disclosure provides methods for diagnosing and treating a patient suspected of having atopic dermatitis, psoriasis, or mycosis fungoides, the method comprising:

[0010] (a) obtaining a diagnosis identifying a skin sample as atopic dermatitis, psoriasis, mycosis fungoides, or non-lesional from the skin sample from the patient, wherein the diagnosis was obtained by :

[0011] (1 ) determining the expression levels of at least 5 genes in a gene set;

[0012] (2) comparing the expression levels of the at least 5 genes in the gene set from the sample to the expression levels of the at least 5 genes in the gene set from a predictive training set to generate a probability score;

[0013] (3) providing the diagnosis identifying the skin sample as atopic dermatitis, psoriasis, mycosis fungoides, or non-lesional based on the probability score generated in step (2); and

[0014] (b) administering to the patient an appropriate treatment when the determination is made in the affirmative that the patient has atopic dermatitis, psoriasis, or mycosis fungoides.

[0015] In some embodiments, the at least 5 genes in the gene set are selected from ACTR3BP2, ANP32AP1, ARL8B, ATP2B2, ATP6V0CP3, C3orf36, CASKIN1, CCDC88B, CLDN19, CXCL3, EEF2K, ELL, EMC4, FAM134C, FAM83F, F0X03B, GLUD2, HN1, H0MER1, HRNR. HSPA7, IL17A, KRTAP10.3, LOC100I30673, LRRC10, LRRK1, MY ADM, MYH9. NANOGNB. NSFL1C, OR52I2, OR6K2, 0VCH2, PCDHB3, PPP2R3B, RNASE1, SEL1L, SSR2, TAS2R8, TFRC, TUBB4A, VSIG8, WSB1 , XPOT, and ZNF165. In some embodiments, the at least 5 genes in the gene set are used to diagnose the patient as having mycosis fungoides. In some embodiments, the at least 5 genes in the gene set are used to diagnose the patient as having atopic dermatitis or psoriasis.

[0016] In some embodiments, the at least 5 genes in the gene set are selected from A2M, ARHGEF10L, ARRDC1, ASH1L.AS1, BAX, CD68, CD97, CPLX3, CUL1, GBAP1, GGT8P, GJA1, HSP90AA1, IER3, IFNA17, IL13, IL17A, LOC283070, LOC646214, LOC650293. MED13L, MLLT1, MTMR1, MTRNR2L8, OCA2, OGFR. OR14J1, OST4, PKP1, PSMB7, PTPRE. RACGAP1P. RNF130, RNF213, SAP18, SH3BGRL. SN0RA1, SNRNP70, TCEB3CL, TMEM123, TMEM39A, TNFAIP8, TOP1P2, UCKL1, and XDH. In some embodiments, the at least 5 genes in the gene set are used to diagnose the patient as having atopic dermatitis. In some embodiments, the at least 5 genes in the gene set are used to diagnose the patient as having psoriasis. In another aspect, this disclosure provides methods for diagnosing a patient suspected of having atopic dermatitis, psoriasis, or mycosis fungoides the method comprising:

[0017] (a) obtaining a diagnosis identifying a skin sample as atopic dermatitis, psoriasis, mycosis fungoides, or non-lesional from the skin sample from the patient, wherein the diagnosis was obtained by:

[0018] (1) obtaining a skin sample from a patient suspected of having atopic dermatitis, psoriasis, or mycosis fungoides;

[0019] (2) determining the expression levels in the skin sample of at least 5 genes in a gene set;

[0020] (3) comparing the expression levels of the at least 5 genes in the gene set from the sample to the expression levels of the at least 5 genes in the gene set from a predictive training set to generate a probability score; and

[0021] (4) providing the diagnosis identifying the skin sample as atopic dermatitis, psoriasis, mycosis fungoides, or non-lesional based on the probability score generated in step (2).

[0022] In some embodiments, the at least 5 genes in the gene set are selected from ACTR3BP2, ANP32AP1, ARL8B, ATP2B2, ATP6V0CP3, C3or£36, CASKIN1, CCDC88B, CLDN19, CXCL3, EEF2K, ELL, EMC4, FAM134C, FAM83F, F0X03B, GLUD2, HN1, H0MER1, HRNR. HSPA7, IL17A, KRTAP10.3, LOC100I30673, LRRC10, LRRK1, MY ADM, MYH9. NANOGNB. NSFL1C, OR52I2, OR6K2, 0VCH2, PCDHB3, PPP2R3B, RNASE1, SEL1L, SSR2, TAS2R8, TFRC, TUBB4A, VSIG8, WSB1 , XPOT, and ZNF165. In some embodiments, the at least 5 genes in the gene set are used to diagnose the patient as having mycosis fungoides. In some embodiments, the at least 5 genes in the gene set are used to diagnose the patient as having atopic dermatitis or psoriasis.

[0023] In some embodiments, the at least 5 genes in the gene set are selected from A2M, ARHGEF10L, ARRDC1, ASH1L.AS1, BAX, CD68, CD97, CPLX3, CUL1, GBAP1, GGT8P, GJA1, HSP90AA1, IER3, IFNA17, IL13, IL17A, LOC283070, LOC646214, LOC650293. MED13L, MLLT1, MTMR1, MTRNR2L8, OCA2, OGFR. OR14J1, OST4, PKP1, PSMB7, PTPRE. RACGAP1P. RNF130, RNF213, SAP18, SH3BGRL. SN0RA1, SNRNP70, TCEB3CL, TMEM123, TMEM39A, TNFAIP8, TOP1P2, UCKL1, and XDH. In some embodiments, the at least 5 genes in the gene set are used to diagnose the patient as having atopic dermatitis. In some embodiments, the at least 5 genes in the gene set are used to diagnose the patient as having psoriasis. In some embodiments of the methods, skin sample is obtained using a non-invasive method. In some embodiments, the expression level of each gene in a gene set is determined by RNA-sequencing or by RT-PCR. In some embodiments, the probability score is between 0 and 1, and wherein a value of 1 indicates a higher probability of an atopic dermatitis, psoriasis, or mycosis fungoides lesion than a value of 0. In some embodiments, the probability score has a sensitivity of at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%. or 99%, and / or has a specificity of at least 90%. 91%. 92%. 93%. 94%. 95%. 96%. 97%, 98%, or 99%. In some embodiments, the probability score has a positive predictive value (PPV) of at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, and / or has a negative predictive value (NPV) of at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%. 98%. or 99%.

[0024] In yet another aspect, this disclosure provides for kits comprising primer pairs suitable for the detection and quantification of nucleic acid expression of at least 5 genes. In some embodiments, the at least 5 genes in the gene set are selected from ACTR3BP2, ANP32AP1, ARL8B, ATP2B2, ATP6V0CP3, C3orf36, CASKIN1, CCDC88B, CLDN19, CXCL3, EEF2K, ELL, EMC4, FAM134C. FAM83F, FOXO3B. GLUD2. HNL HOMER1. HRNR. HSPA7, IL17A, KRTAP10.3, LOC100130673, LRRC10, LRRK1, MY ADM, MYH9, NANOGNB, NSFL1C, OR52I2, OR6K2, OVCH2, PCDHB3, PPP2R3B, RNASE1, SEL1L, SSR2, TAS2R8, TFRC, TUBB4A, VSIG8, WSB1, XPOT, and ZNF165. In some embodiments, the at least 5 genes in the gene set are selected from A2M. ARHGEF10L, ARRDC1 , ASH1L.AS 1 , BAX, CD68, CD97, CPLX3, CULL GBAP1 , GGT8P, GJA1 , HSP90AA1, IER3, IFNA17, IL13, IL17A, LOC283070, LOC646214, LOC650293, MED13L, MLLT1, MTMR1, MTRNR2L8, OCA2, OGFR, OR14J1, OST4, PKP1, PSMB7, PTPRE, RACGAP1P, RNF130, RNF213, SAP18, SH3BGRL, SNORA1, SNRNP70, TCEB3CL, TMEM123, TMEM39A, TNFAIP8, TOP1P2, UCKL1, and XDH.

[0025] In a further aspect, this disclosure provides methods for predicting response to a treatment for a patient having atopic dermatitis and administering the treatment to the patient, the method comprising:

[0026] (a) obtaining a skin sample from the patient having atopic dermatitis.

[0027] (b) determining the expression levels of at least 5 genes in a gene set;

[0028] (c) comparing the expression levels of the at least 5 genes in the gene set from the sample to the expression levels of the at least 5 genes in the gene set from a predictive training set to generate a probability score; (d) providing an indication as to whether the patient responds to the treatment for atopic dermatitis based on the probability score generated in step (c); and

[0029] (e) administering the treatment to the patient.

[0030] In some embodiments, the treatment is one or more of IL-4R inhibitor, an IL-13 inhibitor, and a JAK inhibitor. In some embodiments, the treatment is selected from dupilumab. tralokinumab, upadacitinib, and abrocitinib.

[0031] In some embodiments, the at least 5 genes in the gene set are selected from the genes disclosed in Table 3.

[0032] In yet a further aspect, this disclosure provides methods for predicting response to a treatment for a patient having psoriasis and administering the treatment to the patient, the method comprising:

[0033] (a) obtaining a skin sample from the patient having psoriasis,

[0034] (b) determining the expression levels of at least 5 genes in a gene set;

[0035] (c) comparing the expression levels of the at least 5 genes in the gene set from the sample to the expression levels of the at least 5 genes in the gene set from a predictive training set to generate a probability score; and

[0036] (d) providing an indication as to whether the patient responds to the treatment for psoriasis based on the probability score generated in step (c); and

[0037] (e) administering the treatment to the patient.

[0038] In some embodiments, the treatment one or more of a PDE4 inhibitor, a TNF inhibitor, an IL- 12 / 23 inhibitor, an IL-23 inhibitors, an IL-17 A inhibitor, an IL-17A / F inhibitor, an IL-17R, and a TYK2 inhibitor. In some embodiments, the treatment is selected from apremilast, etanercept, adalimumab, certolizumab. infliximab, ustekinumab, risankizumab, guselkumab, tildrakizumab, ixekizumab, secukinumab, bimekizumab. brodalumab, and deucravacitinib.

[0039] In some embodiments, the at least 5 genes in the gene set are selected from the genes disclosed in Table 4.

[0040] Other aspects, embodiments, and implementations will become apparent from the following detailed description and claims, with reference, where appropriate, to the accompanying drawings.

[0041] BRIEF DESCRIPTION OF THE DRAWINGS

[0042] FIG. 1 shows a non-invasive skin sample collection technique.

[0043] FIG. 2 shows genes are differentially expressed in lesional and non-lesional skin from patients with atopic dermatitis or psoriasis. FIG. 3 shows immune and inflammatory pathways are enriched in atopic dermatitis and psoriasis lesions.

[0044] FIG. 4 shows genes are differentially expressed between atopic dermatitis and psoriasis lesions.

[0045] FIG. 5A - 5G show gene expression differences in mycosis fungoides, atopic dermatitis, and psoriasis.

[0046] FIG. 6 shows volcano plots of differential gene expression between psoriasis / AD and MF after matching for clinical features. Genes downregulated in MF (left) and upregulated in MF (right) by comparison to patients with psoriasis / AD.

[0047] FIG. 7 shows boxplots demonstrating differential gene expression of 45 candidate genes between psoriasis / AD (‘"not MF’?) and mycosis fungoides (MF) after matching for clinical features.

[0048] FIG. 8 shows volcano plots of differential gene expression between psoriasis (PSO) and atopic dermatitis (AD) after matching for clinical variables such as age and location. Genes downregulated in psoriasis (left) and genes upregulated (right) in psoriasis compared to AD. FIG. 9 shows boxplots of differential gene expression of 45 candidate genes between psoriasis (PSO) and atopic dermatitis (AD) after matching for clinical features.

[0049] FIG. 10A - IOC show gene expression differences in responders versus non-responders to atopic dermatitis therapy dupilumab.

[0050] DETAILED DESCRIPTION

[0051] There is a need in the art for a more accurate method of differentiating between atopic dermatitis, psoriasis, and mycosis fungoides, lesions and non-lesional skin. Disclosed herein are methods and kits to differentiate between atopic dermatitis, psoriasis, and mycosis fungoides lesions and non-lesional skin with greater accuracy than previously developed tests. Also provided herein are methods to predict response to treatments for atopic dermatitis, psoriasis, and / or mycosis fungoides.

[0052] In one aspect, this disclosure provides methods for diagnosing and treating a patient suspected of having atopic dermatitis, psoriasis, or mycosis fungoides, the method comprising:

[0053] (a) obtaining a diagnosis identifying a skin sample as atopic dermatitis, psoriasis, mycosis fungoides, or non-lesional from the skin sample from the patient, wherein the diagnosis was obtained by :

[0054] (1) determining the expression levels of at least 5 genes in a gene set; (2) comparing the expression levels of the at least 5 genes in the gene set from the sample to the expression levels of the at least 5 genes in the gene set from a predictive training set to generate a probability score;

[0055] (3) providing the diagnosis identifying the skin sample as atopic dermatitis, psoriasis, mycosis fungoides, or non-lesional based on the probability score generated in step (2); and

[0056] (b) administering to the patient an appropriate treatment when the determination is made in the affirmative that the patient has atopic dermatitis, psoriasis, or mycosis fungoides.

[0057] In some embodiments, the at least 5 genes in the gene set are selected from ACTR3BP2, ANP32AP1, ARL8B, ATP2B2, ATP6V0CP3, C3orf36, CASKIN1, CCDC88B, CLDN19, CXCL3. EEF2K, ELL, EMC4, FAM134C. FAM83F, F0X03B. GLUD2. HN1. H0MER1, HRNR, HSPA7, IL17A, KRTAP10.3, LOC100130673, LRRC10, LRRK1, MY ADM, MYH9, NANOGNB, NSFL1C, OR52I2, OR6K2, 0VCH2, PCDHB3, PPP2R3B, RNASE1, SEL1L, SSR2, TAS2R8, TFRC, TUBB4A, VSIG8, WSB1, XPOT, and ZNF165. In some embodiments, the at least 5 genes in the gene set are used to diagnose the patient as having mycosis fungoides. In some embodiments, the at least 5 genes in the gene set are used to diagnose the patient as having atopic dermatitis or psoriasis.

[0058] In some embodiments, the at least 5 genes in the gene set are selected from A2M, ARHGEF10L, ARRDC1, ASH1L.AS1, BAX, CD68, CD97, CPLX3, CULL GBAP1, GGT8P, GJA1, HSP90AAL IER3, IFNA17, IL13, IL17A, LOC283070, LOC646214, LOC650293, MED13L, MLLT1 , MTMR1 , MTRNR2L8, OCA2, OGFR, OR14J1 , OST4, PKP1, PSMB7, PTPRE, RACGAP1P, RNF130, RNF213, SAP18, SH3BGRL, SN0RA1, SNRNP70, TCEB3CL, TMEM123, TMEM39A, TNFAIP8, TOP1P2, UCKL1, and XDH. In some embodiments, the at least 5 genes in the gene set are used to diagnose the patient as having atopic dermatitis. In some embodiments, the at least 5 genes in the gene set are used to diagnose the patient as having psoriasis.

[0059] In another aspect, this disclosure provides methods for diagnosing a patient suspected of having atopic dermatitis, psoriasis, or mycosis fungoides the method comprising:

[0060] (a) obtaining a diagnosis identifying a skin sample as atopic dermatitis, psoriasis, mycosis fungoides, or non-lesional from the skin sample from the patient, wherein the diagnosis was obtained by:

[0061] (1) obtaining a skin sample from a patient suspected of having atopic dermatitis, psoriasis, or mycosis fungoides; (2) determining the expression levels in the skin sample of at least 5 genes in a gene set;

[0062] (3) comparing the expression levels of the at least 5 genes in the gene set from the sample to the expression levels of the at least 5 genes in the gene set from a predictive training set to generate a probability score; and

[0063] (4) providing the diagnosis identifying the skin sample as atopic dermatitis, psoriasis, mycosis fungoides. or non-lesional based on the probability score generated in step (2).

[0064] In some embodiments, the at least 5 genes in the gene set are selected from ACTR3BP2, ANP32AP1, ARL8B, ATP2B2, ATP6V0CP3, C3or£36, CASKIN1, CCDC88B, CLDN19, CXCL3. EEF2K, ELL, EMC4, FAM134C. FAM83F, F0X03B. GLUD2. HNL H0MER1, HRNR, HSPA7, IL17A, KRTAP10.3, LOC100130673, LRRC10, LRRK1, MY ADM, MYH9, NANOGNB, NSFL1C, OR52I2, OR6K2, 0VCH2, PCDHB3, PPP2R3B, RNASE1, SEL1L, SSR2, TAS2R8, TFRC, TUBB4A, VSIG8, WSB1, XPOT, and ZNF165. In some embodiments, the at least 5 genes in the gene set are used to diagnose the patient as having mycosis fungoides. In some embodiments, the at least 5 genes in the gene set are used to diagnose the patient as having atopic dermatitis or psoriasis.

[0065] In some embodiments, the at least 5 genes in the gene set are selected from A2M, ARHGEF10L, ARRDC1, ASH1L.AS1, BAX, CD68, CD97, CPLX3, CULL GBAP1, GGT8P, GJA1, HSP90AA1. IER3, IFNA17, IL13, IL17A, LOC283070, LOC646214, LOC650293, MED13L, MLLT1 , MTMR1 , MTRNR2L8, OCA2, OGFR, OR14J1 , OST4, PKP1, PSMB7, PTPRE, RACGAP1P, RNF130, RNF213, SAP18, SH3BGRL, SNORA1, SNRNP70, TCEB3CL, TMEM123, TMEM39A, TNFAIP8, TOP1P2, UCKL1. and XDH. In some embodiments, the at least 5 genes in the gene set are used to diagnose the patient as having atopic dermatitis. In some embodiments, the at least 5 genes in the gene set are used to diagnose the patient as having psoriasis.

[0066] In some embodiments of the methods, skin sample is obtained using a non-invasive method. In some embodiments, the expression level of each gene in a gene set is determined by RNA-sequencing or by RT-PCR. In some embodiments, the probability’ score is between 0 and 1, and wherein a value of 1 indicates a higher probability of an atopic dermatitis, psoriasis, or mycosis fungoides lesion than a value of 0. In some embodiments, the probability score has a sensitivity' of at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%. or 99%, and / or has a specificity of at least 90%. 91%. 92%. 93%. 94%. 95%. 96%. 97%, 98%, or 99%. In some embodiments, the probability score has a positive predictive value (PPV) of at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, and / or has a negative predictive value (NPV) of at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%.

[0067] In a further aspect, this disclosure provides methods for predicting response to a treatment for a patient having atopic dermatitis and administering the treatment to the patient, the method comprising:

[0068] (a) obtaining a skin sample from the patient having atopic dermatitis.

[0069] (b) determining the expression levels of at least 5 genes in a gene set;

[0070] (c) comparing the expression levels of the at least 5 genes in the gene set from the sample to the expression levels of the at least 5 genes in the gene set from a predictive training set to generate a probability score;

[0071] (d) providing an indication as to whether the patient responds to the treatment for atopic dermatitis based on the probability score generated in step (c); and

[0072] (e) administering the treatment to the patient.

[0073] In some embodiments, the skin sample is obtained using a non-invasive method. In some embodiments, the expression levels of the genes are normalized.

[0074] In some embodiments, the treatment is one or more of IL-4R inhibitor, an IL-13 inhibitor, and a JAK inhibitor. In some embodiments, the treatment is selected from dupilumab. tralokinumab, upadacitinib, and abrocitinib. In some embodiments, the treatment is dupilumab.

[0075] In some embodiments, the at least 5 genes in the gene set are selected from the genes disclosed in Table 3.

[0076] In yet a further aspect, this disclosure provides methods for predicting response to a treatment for a patient having psoriasis and administering the treatment to the patient, the method comprising:

[0077] (a) obtaining a skin sample from the patient having psoriasis,

[0078] (b) determining the expression levels of at least 5 genes in a gene set;

[0079] (c) comparing the expression levels of the at least 5 genes in the gene set from the sample to the expression levels of the at least 5 genes in the gene set from a predictive training set to generate a probability score; and

[0080] (d) providing an indication as to whether the patient responds to the treatment for psoriasis based on the probability score generated in step (c); and

[0081] (e) administering the treatment to the patient. In some embodiments, the skin sample is obtained using a non-invasive method. In some embodiments, the expression levels of the genes are normalized.

[0082] In some embodiments, the treatment one or more of a PDE4 inhibitor, a TNF inhibitor, an IL- 12 / 23 inhibitor, an IL-23 inhibitors, an IL-17A inhibitor, an IL-17A / F inhibitor, an IL-17R, and a TYK2 inhibitor. In some embodiments, the treatment is selected from apremilast, etanercept, adalimumab, certolizumab. infliximab, ustekinumab, risankizumab, guselkumab, tildrakizumab, ixekizumab. secukinumab, bimekizumab. brodalumab, and deucravacitinib. In some embodiments, the treatment is risankizumab.

[0083] In some embodiments, the at least 5 genes in the gene set are selected from the genes disclosed in Table 4.

[0084] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as would be commonly understood by one of ordinary skill in the art to which the claimed invention belongs. Although methods and materials similar or equivalent to those described herein can be used to practice the methods and kits disclosed or claimed herein, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and are not intended to be limiting. Other features and advantages of the claimed invention will be apparent from the following detailed description.

[0085] As used herein, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. For example, reference to "a nucleic acid" means one or more nucleic acids.

[0086] As used herein, ranges and amounts can be expressed as "about" a particular value or range. The term "about" also includes the exact amount. For example, "about 5%" means "about 5%" and also "5%." The term "about" can also refer to ± 10% of a given value or range of values. Therefore, about 5% also means 4.5% - 5.5%, for example. Additionally, "about" or "comprising essentially of' can mean a range of up to ±10%. Furthermore, particularly with respect to biological systems or processes, the terms can mean up to an order of magnitude or up to 5-fold of a value. When particular values or compositions are provided in the application and claims, unless otherwise stated, the meaning of "about" or "comprising essentially of' should be assumed to be within an acceptable error range for that particular value or composition. Unless otherwise clear from context, all numerical values provided herein are modified by the term "about." It is noted that terms like "preferably," "commonly," and "typically" are not utilized herein to limit the scope of the claimed invention or to imply that certain features are critical, essential, or even important to the structure or function of the claimed invention. Rather, these terms are merely intended to highlight alternative or additional features that can or cannot be utilized in a particular embodiment disclosed or claimed herein.

[0087] As used herein, the terms "polynucleotide." "nucleotide." "oligonucleotide," and "nucleic acid" can be used interchangeably to refer to nucleic acid comprising DNA. cDNA. RNA, rnRNA, derivatives thereof, and / or combinations thereof.

[0088] As used herein, the terms "skin lesion" or "suspicious skin lesion" refer to any tissue on or in the skin that has abnormal characteristics. For example, any lesions on the skin that are inflamed, itchy, scaly or scaly patches of discolored skin, red. white scales or silvery- white scales, or bumps and plaques with a greasy, yellow scale.

[0089] As disclosed herein, a skin sample is obtained through a non-invasive sampling method. The non-invasive skin sample is obtained from a subject using a method that does not require inserting an instrument through the skin or into a body opening of the subject. For example, the superficial epidermis of lesional and non-lesional skin from subjects with, or suspected of having, atopic dermatitis, psoriasis, or mycosis fungoides can be collected by gently scraping the skin with a curette and immediately preserving the sample in a buffer (see Figure 1). Curettes come in many handle styles with either round or oval heads of vary ing sizes from about 1 mm to about 10 mm and can be made of metal (e.g. stainless steel) or plastic.

[0090] Atopic dermatitis (also referred to as eczema) is a condition that causes inflammation, redness, dryness and irritation of the skin. It is common in children, but can occur at any age. Atopic dermatitis is long lasting (chronic) and tends to flare sometimes.

[0091] Psoriasis is an autoimmune condition that causes inflammation in skin. Psoriasis causes a rash with itchy, scaly patches of discolored skin, most commonly on the knees, elbows, trunk and scalp. Psoriasis is a common, chronic disease with no cure. It can be painful, interfere with sleep and make it hard to concentrate. There are several types of psoriasis, including, erythrodermic psoriasis, guttate psoriasis, inverse psoriasis, nail psoriasis, plaque psoriasis, pustular psoriasis, and sebopsoriasis. Erythrodermic psoriasis is a rare but severe form of psoriasis characterized by red, scaly skin over most of the body (more than 90%). It can be triggered by a bad sunbum or taking certain medications, such as corticosteroids. Erythrodermic psoriasis often develops in people who have a different type of psoriasis that is not well controlled, and it can be very serious. It causes widespread skin discoloration and skin shedding. Guttate psoriasis outbreaks are often triggered by an upper respiratory tract infection, such as treptococcal infection. It looks like small, red, dropshaped scaly spots and often affects children and young adults. Inverse psoriasis appears as smooth, red patches in skin folds, such as beneath the breasts or in the groin or armpits. Rubbing and sweating can make it worse. It causes thin plaques without scales. Nail psoriasis causes skin discoloration, pitting and changes to fingernails and toenails. Plaque psoriasis is the most common type of psoriasis. About 80% to 90% of people with psoriasis have plaque psoriasis. It appears as raised, red patches of skin that are covered by silvery- white scales. The patches usually develop in a symmetrical pattern on the body and tend to appear on the scalp, trunk, and limbs, especially the elbows and knees. Pustular psoriasis has small, pus-filled bumps on top of plaques. It usually affects the hands and feet, but there is a form that covers most of the body. Symptoms can be triggered by medications, infections, stress, or certain chemicals. Sebopsoriasis typically appears on the face and scalp as bumps and plaques with a greasy, yellow scale. This is a cross between psoriasis and seborrheic dermatitis.

[0092] Mycosis fungoides is a blood cancer that occurs when T-cells transform into malignant cells. With mycosis fungoides, the malignant cutaneous T-cell lymphoma (CTCL) affect the skin of a subject and cause itchiness, rashes, plaques, or tumors. Mycosis fungoides stages include a premycotic phase during which a scaly skin rash forms. It appears on parts of the body not usually exposed to the sun, like your lower belly, thighs, butt and chest. In the patch phase, the skin around the rash becomes thin. It may be itchy and dry, like eczema. During the plaque phase, the skin forms small, raised bumps or hard bumps, and during the tumor phase, raised areas of skin that penetrate more deeply than plaques, form on skin. The most common locations include the thighs, groin, armpits and the inside of your elbow. In the most severe stages, many cancerous T-cells circulate in a subject’s blood. At this point, they’re called Sezary cells, and high levels of Sezary cells may cause mycosis fungoides to evolve into Sezary syndrome. Sezary syndrome may result in a red rash all over a subject’s body, called ery throderma.

[0093] The phrase "measuring the gene-expression levels" or "determining the geneexpression levels," as used herein, refers to determining or quantifying RNA or proteins expressed by the gene or genes. The term "RNA" includes mRNA transcripts, and / or specific spliced variants of mRNA. The term "RNA product of the gene," as used herein, refers to RNA transcripts transcribed from the gene and / or specific spliced variants. Gene expression can be determined either at the RNA level (i.e., mRNA or noncoding RNA (ncRNA)) (e.g.. miRNA, tRNA, rRNA, snoRNA, siRNA and piRNA) or at the protein level. Measuring gene expression at the mRNA level includes measuring levels of cDNA corresponding to mRNA. Levels of proteins in a sample can be determined by any known techniques in the art, e.g., HPLC, mass spectrometry, or using antibodies specific to selected proteins (e.g., IHC or ELISA). In some embodiments, mRNA is converted to cDNA before the gene expression levels are measured. With respect to proteins, gene expression refers to proteins translated from the RNA transcripts transcribed from the gene. The term "protein product of the gene" refers to proteins translated from RNA products of the gene. A number of methods can be used to detect or quantify the level of RNA products of the gene or genes within a sample, including microarrays, Real-Time PCR (RT-PCR; including quantitative RT-PCR), nuclease protection assays, RNA-sequencing (RNA-seq). and Northern blot analyses. In one embodiment, the methods as disclosed herein use RNA-sequencing (RNA-seq). In addition, a person skilled in the art will appreciate that a number of methods can be used to determine the amount of a protein product of a gene of the methods disclosed herein, including immunoassays such as immunohistochemistry, Western blots, ELISA, and immunoprecipitation followed by SDS-PAGE and immunocytochemistry.

[0094] A person skilled in the art will appreciate that a number of detection agents can be used to determine gene expression. For example, to detect RNA products of the biomarkers, probes, primers, complementary nucleotide sequences, or nucleotide sequences that hybridize to the RNA products can be used. In another example, to detect cDNA products of the biomarkers, probes, primers, complementary nucleotide sequences, or nucleotide sequences that hybridize to the cDNA products can be used. To detect protein products of the biomarkers, ligands or antibodies that specifically bind to the protein products can be used.

[0095] As used herein, the term "hybridize" refers to the sequence specific non-covalent binding interaction with a complementary nucleic acid. In one embodiment, the hybridization is under high stringency conditions. Appropriate stringency conditions that promote hybridization are known to those skilled in the art.

[0096] As used herein, the terms "probe" and "primer" refer to a nucleic acid sequence that will hybridize to a nucleic acid target sequence. In one example, the probe and / or primer hybridizes to an RNA product of the gene or a complementary nucleic acid sequence. In another example, the probe and / or primer hybridizes to a cDNA product. The length of probe or primer depends on the hybridizing conditions and the sequences of the probe or primer and nucleic acid target sequence. In one embodiment, the probe or primer is at least 8, 10, 15, 20, 25, 50, 75, 100, 150, 200, 250, 400, 500, or more than 500 nucleotides in length. Probes and / or primers may include one or more label. Probes and / or primers may be commercially sourced from various providers (e.g., ThermoFisher Scientific). In certain embodiments, a label may be any substance capable of aiding a machine, detector, sensor, device, or enhanced or unenhanced human eye from differentiating a labeled composition from an unlabeled composition. Examples of labels include, but are not limited to: a radioactive isotope or chelate thereof, dye (fluorescent or non-fluorescent), stain, enzyme, or nonradioactive metal. Specific examples include, but are not limited to: fluorescein, biotin, digoxigenin, alkaline phosphates, biotin, streptavidin,3H,14C,32P,35S, or any other compound capable of emitting radiation, rhodamine, 4-(4'-dimethylamino-phenylazo)benzoic acid; 4-(4'-dimethylamino-phenylazo)sulfonic acid (sulfonyl chloride); 5-((2-aminoethyl)- amino)-naphtalene-l -sulfonic acid; Psoralene derivatives, haptens, cyanines, acridines, fluorescent rhodol derivatives, cholesterol derivatives; ethylene-diamine-tetra-acetic acid and derivatives thereof, or any other compound that may be differentially detected. The label may also include one or more fluorescent dyes. Examples of dyes include, but are not limited to: CAL-Fluor Red 610, CAL-Fluor Orange 560, dRl 10, 5-FAM, 6FAM, dR6G. JOE, HEX, VIC. TET. dTAMRA. TAMRA. NED, dROX, PET, BHQ+, Gold540, and LIZ.

[0097] As used herein, the terms "differentially expressed" or "differential expression" refer to a difference in the level of expression of the genes that can be assayed by measuring the level of expression of the products of the genes, such as the difference in level of messenger RNA transcript expressed (or converted cDNA) or proteins expressed of the genes. In one embodiment, the difference can be statistically significant. The term "difference in the level of expression" refers to an increase or decrease in the measurable expression level of a given gene as measured by the amount of messenger RNA transcript (or converted cDNA) and / or the amount of protein in a sample as compared with the measurable expression level of a given gene in a control, or control gene or genes in the same sample (for example, a nonrecurrence sample). In another embodiment, the differential expression can be compared using the ratio of the level of expression of a given gene or genes as compared with the expression level of the given gene or genes of a control, wherein the ratio is not equal to 1.0. For example, an RNA. cDNA. or protein is differentially expressed if the ratio of the level of expression in a first sample as compared with a second sample is greater than or less than 1.0. For example, a ratio of greater than 1, 1.2, 1.5, 1.7, 2, 3, 3, 5, 10, 15, 20, or more than 20, or a ratio less than 1, 0.8, 0.6, 0.4, 0.2, 0.1, 0.05, 0.001, or less than 0.0001. In yet another embodiment, the differential expression is measured using p-value. For instance, when using p-value, a biomarker is identified as being differentially expressed as between a first sample and a second sample when the p-value is less than 0.1, less than 0.05, less than 0.01, less than 0.005, or less than 0.001.

[0098] The terms "increased expression" or "decreased expression," as used herein, refer to an expression level of one or more genes, or prognostic RNA transcripts, or their corresponding cDNAs, or their expression products that has been found to be differentially expressed in atopic dermatitis, psoriasis, or mycosis fungoides skin lesions versus healthy skin or normal skin lesions. In some embodiments, increased expression can be at least about 1.25-fold, at least about 1.5-fold, at least about 2-fold, at least about 3-fold, at least about 4- fold, at least about 5-fold, at least about 10-fold, at least about 20-fold, at least about 30-fold, at least about 40-fold, or at least about 50-fold increase in gene and / or protein levels compared to a control level or amount. In some embodiments, decreased expression can be at least about 1.25-fold, at least about 1.5-fold, at least about 2-fold, at least about 3-fold, at least about 4-fold, at least about 5-fold, at least about 10-fold, at least about 20-fold, at least about 30-fold, at least about 40-fold, or at least about 50-fold decrease in gene and / or protein levels compared to a control level or amount.

[0099] References herein to the "same" level of biomarker indicate that the level of biomarker measured in each sample is identical (re., when compared to the selected reference). References herein to a "similar" level of biomarker indicate that levels are not identical but the difference between them is not statistically significant (z.e., the levels have comparable quantities).

[0100] As used herein, the terms "control" and "standard" refer to a specific value that one can use to determine the value obtained from the sample. In one embodiment, a dataset may be obtained from samples from a group of subjects known to have a skin lesion diagnosed as atopic dermatitis, psoriasis, and / or mycosis fungoides. The expression data of the genes in the dataset can be used to create a control (standard) value that is used in testing samples from new subjects. In such an embodiment, the "control" or "standard" is a predetermined value for each gene or set of genes obtained from subjects with atopic dermatitis, psoriasis, and mycosis fungoides skin lesion whose gene expression values and skin lesion types are known. In some embodiments, a control population may comprise healthy individuals, individuals with atopic dermatitis, psoriasis, or mycosis fungoides, or a mixed population of individuals with or without atopic dermatitis, psoriasis, or mycosis fungoides.

[0101] In some embodiments, the amount of RNA transcribed from the genes in the gene set includes normalized expression. Expression levels can be normalized following detection and quantification as appropriate for the particular platform using methods routinely practiced by those of ordinary skill in the art. Normalizing is done to remove technical variability inherent to a platform to give a quantity or relative quantity (e.g., of expressed genes). Normalization ensures accurate comparison of expression of a discriminant gene between different samples. In some embodiments, raw read counts were normalized to counts per million per sample.

[0102] In some embodiments, the amount of RNA transcribed from the genes in the gene set includes one or more control genes in the sample. The amount of RNA of one or more control genes (normalizing genes or housekeeping genes) in the sample can also be measured and used to normalize or calibrate the expression of the 5 or more genes (i.e. the 5 or more discriminant genes).

[0103] The terms "normalizing genes" and "housekeeping genes" refer to the genes whose expression is used to calibrate or normalize the measured expression of the gene of interest (e.g., the 5 or more discriminant genes). The expression of normalizing genes should be independent of the diagnosis of atopic dermatitis, psoriasis, or mycosis fungoides, and the expression of the normalizing genes is very similar among all samples.

[0104] As used herein, the term "normal" when used with respect to a sample population refers to an individual or group of individuals that does / do not have a particular disease or condition (e.g., atopic dermatitis, psoriasis, and mycosis fungoides) and is also not suspected of having or being at risk for developing the disease or condition. The term "normal" is also used herein to qualify a biological specimen or sample (e.g., a skin sample or a biological fluid) isolated from a normal or healthy individual or subject (or group of such subjects), for example, a "normal control sample." The "normal" level of expression of a marker is the level of expression of the marker in cells in a similar environment or response situation, in a patient not afflicted with atopic dermatitis, psoriasis, and / or mycosis fungoides. A normal level of expression of a marker may also refer to the level of expression of a "reference sample" (e.g., a sample from a healthy subject not having the marker associated disease). A reference sample expression may be comprised of an expression level of one or more markers from a reference database. Alternatively, a "normal" level of expression of a marker is the level of expression of the marker in healthy cells in a similar environment or response situation from the same patient that the atopic dermatitis, psoriasis, and / or mycosis fungoides skin lesion sample is derived from.

[0105] As used herein, the terms "gene set," "gene-expression profile," "GEP," or "geneexpression profile signature" refer to any combination of genes, the measured messenger RNA transcript expression levels, cDNA levels, or direct DNA / RNA expression levels, or immunohistochemistry levels of which can be used to distinguish between two biologically different corporal tissues and / or cells and / or cellular changes and / or predict response to a treatment.

[0106] In certain embodiments, a gene-expression profile is comprised of the expression levels of at least about 5,000, 4,000, 3,000, 2,000, 1,000, 900, 800, 700, 600, 500, 400, 300, 200, 100. 75. 70, 69, 68, 67, 66, 65, 64, 63, 62, 61, 60, 59, 58, 57, 56. 55. 54, 53, 52, 51, 50, 49. 48. 47. 46, 45, 44, 43, 42, 41, 40, 39, 38, 37. 36. 35. 34. 33. 32, 31, 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, or 5 genes. In one embodiment, the gene-expression profile is comprised of about 75 genes. In another embodiment, the gene-expression profile is comprised of about 74 genes. In another embodiment, the gene-expression profile is comprised of about 73 genes. In another embodiment, the gene-expression profile is comprised of about 72 genes. In another embodiment, the gene-expression profile is comprised of about 71 genes. In another embodiment, the gene-expression profile is comprised of about 70 genes. In another embodiment, the gene-expression profile is comprised of about 69 genes. In another embodiment, the gene-expression profile is comprised of about 68 genes. In another embodiment, the gene-expression profile is comprised of about 67 genes. In another embodiment, the gene-expression profile is comprised of about 66 genes. In another embodiment, the gene-expression profile is comprised of about 65 genes. In another embodiment, the gene-expression profile is comprised of about 64 genes. In another embodiment, the gene-expression profile is comprised of about 63 genes. In another embodiment, the gene-expression profile is comprised of about 62 genes. In another embodiment, the gene-expression profile is comprised of about 61 genes. In another embodiment, the gene-expression profile is comprised of about 60 genes. In another embodiment, the gene-expression profile is comprised of about 59 genes. In another embodiment, the gene-expression profile is comprised of about 58 genes. In another embodiment, the gene-expression profile is comprised of about 57 genes. In another embodiment, the gene-expression profile is comprised of about 56 genes. In another embodiment, the gene-expression profile is comprised of about 55 genes. In another embodiment, the gene-expression profile is comprised of about 54 genes. In another embodiment, the gene-expression profile is comprised of about 53 genes. In another embodiment, the gene-expression profile is comprised of about 52 genes. In another embodiment, the gene-expression profile is comprised of about 51 genes. In another embodiment, the gene-expression profile is comprised of about 50 genes. In another embodiment, the gene-expression profile is comprised of about 49 genes. In another embodiment, the gene-expression profile is comprised of about 48 genes. In another embodiment, the gene-expression profile is comprised of about 47 genes. In another embodiment, the gene-expression profile is comprised of about 46 genes. In one embodiment, the gene-expression profile is comprised of about 45 genes. In another embodiment, the geneexpression profile is comprised of about 44 genes. In another embodiment, the geneexpression profile is comprised of about 43 genes. In another embodiment, the geneexpression profile is comprised of about 42 genes. In another embodiment, the geneexpression profile is comprised of about 41 genes. In another embodiment, the geneexpression profile is comprised of about 40 genes. In another embodiment, the geneexpression profile is comprised of about 39 genes. In another embodiment, the geneexpression profile is comprised of about 38 genes. In another embodiment, the geneexpression profile is comprised of about 37 genes. In another embodiment, the geneexpression profile is comprised of about 36 genes. In another embodiment, the geneexpression profile is comprised of about 35 genes. In another embodiment, the geneexpression profile is comprised of about 34 genes. In another embodiment, the geneexpression profile is comprised of about 33 genes. In another embodiment, the geneexpression profile is comprised of about 32 genes. In another embodiment, the geneexpression profile is comprised of about 31 genes. In another embodiment, the geneexpression profile is comprised of about 30 genes. In another embodiment, the geneexpression profile is comprised of about 29 genes. In another embodiment, the geneexpression profile is comprised of about 28 genes. In another embodiment, the geneexpression profile is comprised of about 27 genes. In another embodiment, the geneexpression profile is comprised of about 26 genes. In another embodiment, the geneexpression profile is comprised of about 25 genes. In another embodiment, the geneexpression profile is comprised of about 24 genes. In another embodiment, the geneexpression profile is comprised of about 23 genes. In another embodiment, the geneexpression profile is comprised of about 22 genes. In another embodiment, the geneexpression profile is comprised of about 21 genes. In another embodiment, the geneexpression profile is comprised of about 20 genes. In another embodiment, the geneexpression profile is comprised of about 19 genes. In another embodiment, the geneexpression profile is comprised of about 18 genes. In another embodiment, the geneexpression profile is comprised of about 17 genes. In another embodiment, the geneexpression profile is comprised of about 16 genes. In another embodiment, the gene- expression profile is comprised of about 15 genes. In another embodiment, the geneexpression profile is comprised of about 14 genes. In another embodiment, the geneexpression profile is comprised of about 13 genes. In another embodiment, the geneexpression profile is comprised of about 12 genes. In another embodiment, the geneexpression profile is comprised of about 11 genes. In another embodiment, the geneexpression profile is comprised of about 10 genes. In another embodiment, the geneexpression profile is comprised of about 9 genes. In another embodiment, the geneexpression profile is comprised of about 8 genes. In another embodiment, the geneexpression profile is comprised of about 7 genes. In another embodiment, the geneexpression profile is comprised of about 6 genes. In another embodiment, the geneexpression profile is comprised of about 5 genes.

[0107] In certain embodiments, the genes in a gene set are selected from: ACTR3BP2, ANP32AP1, ARL8B, ATP2B2, ATP6V0CP3, C3orf36, CASKIN1, CCDC88B, CLDN19, CXCL3, EEF2K, ELL, EMC4, FAM134C, FAM83F, FOXO3B, GLUD2, HN1, HOMER1, HRNR, HSPA7, IL17A, KRTAP10.3, LOCI00130673. LRRC10, LRRKL MY ADM, MYH9, NANOGNB, NSFL1C, OR52I2, OR6K2. OVCH2. PCDHB3, PPP2R3B, RNASEL SEL1L, SSR2, TAS2R8, TFRC, TUBB4A, VSIG8, WSB1, XPOT, and ZNF165

[0108] In certain embodiments, the genes in a gene set are selected from: A2M, ARHGEF10L, ARRDC1, ASH1L.AS1, BAX, CD68, CD97, CPLX3, CULL GBAP1, GGT8P, GJA1, HSP90AAL IER3, IFNA17, IL13, IL17A, LOC283070, LOC646214, LOC650293, MED13L, MLLT1 , MTMR1 , MTRNR2L8, OCA2, OGFR, OR14J1 , OST4, PKP1, PSMB7, PTPRE, RACGAP1P, RNF130, RNF213, SAP18, SH3BGRL, SNORA1, SNRNP70, TCEB3CL, TMEM123, TMEM39A, TNFAIP8, TOP1P2, UCKL1, and XDH

[0109] In certain embodiments, the genes in a gene set are selected from the genes recited in Table 3. In certain embodiments, the genes in a gene set comprise one or more of the gene sets recited in Table 3.

[0110] In certain embodiments, the genes in a gene set are selected from: A2M.AS1, A2ML1, AACS, AADAC. AAED1, AAMP, AARD, AATF, AATK, ABCA2, ABC A3, ABCB10, ABCB6, ABCCL ABCD3. ABCG1, ABHD1, ABHD12, ABHD12B, ABHD16A, ABHD16B, ABHD2, ABHD3, ABHD5, ABHD8, ABP1, ABTB1, ABTB2, ACAD8, ACAD9, ACADVL, ACAP1, ACAP2, ACAP3, ACBD4, ACD, ACER1, ACER2, ACLY, ACO2, ACOT7, ACPI, ACP5, ACPP, ACSL1, ACSL3, ACSL4, ACTA2, ACTBL2, ACTL7A, ACTL9, ACTNL ACTR1A, ACTR1B, ACTR2. ACTR3, ACTR3BP2, ACTRT1, ACTRT2, ADAM11, ADAM19, ADAM21P1, ADAM23, ADAM8, ADAMTS1, AD AMTS 10, ADAMTS15, ADAMTS4, ADAMTSL4, ADAMTSL5, ADAP2, ADAR, ADCK5, ADCY7, ADIPOR1, ADIPOR2. ADO, ADPGK, ADRA2B, ADRA2C, AD RBI. ADRBK1, ADSL, ADSSL1, AES, AFF1, AFTPH, AGAP3, AGAP5, AGL, AGPAT3, AGPAT9, AGRN, AGSK1, AGTPBP1, AGXT, AHCY, AIDA, AIF1, AIF1L, AIFM3, AIM1, AJAP1, AK1, AK2, AK3, AKAP13, AKAP8L, AKIRIN1, AKNA, AKR1B10, AKR1CL1, AKR7A2P1, AKT1. AKT1S1, ALCAM, ALDH3A1, ALDOC, ALG14, ALKBH5, ALOX12, ALOX5. ALOX5AP, AMMECR1, AMN1. AMPD2. AMPD3. AMZ2. ANAPC16, ANGPTL4, ANKLE2, ANKRD10, ANKRD12, ANKRD13A, ANKRD13B, ANKRD13C, ANKRD16, ANKRD17, ANKRD20A9P, ANKRD33B, ANKRD35, ANKRD36BP1, ANKRD37, ANKRD44, ANKRD52, ANKRD65, ANO1, ANO10, ANO8, ANO9. ANP32AP1, ANP32C, ANPEP. ANXA11, ANXA2R, ANXA3, ANXA4, ANXA7, ANXA8, ANXA8L1, ANXA9, AP1G2, AP1S2, AP2A1, AP2M1, AP3B1, AP3D1, AP3S1, AP5B1, APBB1, APBB2, APEX1, APH1A, API5, APLP1, APOB, APOBEC3A, APOBEC3G, AP0C1P1, APOC2, APOE, APOL6, APP, APPL2, APRT. AQP3, AQP5, AQP7P1, AQP8. ARAP1, ARAP2, ARCN1, AREG, ARF1, ARF4. ARF5, ARFGAP3, ARG2. ARHGAP1, ARHGAP10. ARHGAP18. ARHGAP25, ARHGAP27, ARHGAP29. ARHGAP30, ARHGAP31, ARHGAP4, ARHGAP42, ARHGAP9, ARHGDIB, ARHGEF10L, ARHGEF12, ARHGEF2, ARHGEF26, ARHGEF28, ARHGEF35, ARHGEF37, ARID1B, ARID4A, ARID5B, ARIH2, ARL14, ARL16, ARL4C, ARL5A, ARL6IP4, ARL6IP5, ARL6IP6. ARL8A, ARMC2, ARNT. ARNTL. ARNTL2, ARPC1A. ARPC1B, ARPC3, ARPC4, ARPC5, ARPC5L, ARRB2, ARRDC1, ARRDC2, ARRDC4, ARSF, AS API, ASCL4, ASMTL, ASPDH, ASS1, ASXL2, ATG2A, ATG3, ATG9A, ATHL1, ATIC, ATL2. ATOH1, ATOH7, ATP11B. ATP13A4, ATP1A1, ATP1B2, ATP2B1, ATP2B2, ATP5A1, ATP5B, ATP5D. ATP5G1, ATP5G2, ATP5G3, ATP5H, ATP5I, ATP5J2, ATP5O, ATP6V0B, ATP6V0C, ATP6V0CP3, ATP6V1B2, ATP6V1C1, ATP6V1D, ATP6V1H, ATP7A, ATPIF1, ATRAID, ATXN3L, ATXN7L3, AUP1, AURKAPS1, AVPI1, AXL, AZGP1P1, B3GAT1, B3GNT3, B3GNT5, B4GALT1, B4GALT5, BAG3, BAG6, BAGE2, BAD, BAIAP2, BAIAP2L1, BAK1, BANF1. BAP1, BASP1, BATF, BATF3. BAX, BAZ1A, BBS2. BBX, BCAS1. BCAS2, BCAT1, BCAT2. BCCIP, BCKDK, BCL2, BCL2A1, BCL2L1, BCL2L11, BCL6, BCL9L, BCR, BCS1L, BEST1, BEST4, BHLHA15, BHLHE22, BHLHE23, BHLHE40, BICD2, BIN2, BIN3, BIRC3, BIRC5, BIRC8, BLID, BLMH, BL0C1S3, BL0C1S6, BMP2. BMP6. BNIP3, BNIPL, BOC, BPIFB3, BRAF, BRD4, BRD7, BRI3, BRWD1. BSDC1, BSG, BSPRY, BST2, BTBD1, BTBD19, BTC, BTF3, BTF3P11, BTG1, BTG2, BTN2A2, BUB3, BUD31, BZW2, ClOorflO, C10orfll6, C10orfll8, C10orf54, C10orf55, C10orf62, C10orf76, C10orf99, CllorflO. Cllorf31, Cl lorf83, Cl lorf96, C12orf29, C12orf57. C12orf68, C14orfl, C14orfl62, C14orfl78, C14orf2, C15orf52, C15orf59, C15orf62, C16orf59, C16orf70, C16orf82, C16orf92, C17orf49, C17orf58, C17orf82, C17orf85, C19orfl0, C19orf33, C19orf43, C19orf59, C19orf6, C19orf73, Clorfl06, Clorfl l6, Clor£21, Cl orf229, Clorf50, Clorf65, Cl QB, C1QBP. C1QC, C2. C20orfl ll, C20orfll2, C21orfll9. C2CD2, C2orfl8, C2orf57, C2orf81, C3orl36, C5orfl5, C5orf20, C5orf43, C5orf46, C5orf55, C6orfl, C6orfl06, C6orfl32, C6orfl41, C6orf223, C6orl226, C6orf47, C6orf62, C7orf29, C7orf41, C7orf65, C7orf73, C8orf4, C8orf73, C9orfl23, C9orfl42, C9orfl69, C9orfl72. C9orf47, C9orf53, C9orf89, CA11, CA12, CA2, CACNB1, CACNB4, CAHM, CALC0C01. CALD1, CALM2, CALM3, CALML3, CALU, CAMKID, CAMK2N1, CAMK4, CAMLG, CAMP, CAMSAP2, CAMTA2, CANX, CAPG, CAPN1, CAPN14, CAPNS1, CAPNS2, CAPRIN1, CAPS, CAPZA1, CAPZB, CARD11, CARD14, CARD16, CARD18, CARD9, CASP2, CASP4, CASP9, CASS4, CAST, CASZ1, CAT, CAV2, CBFA2T3. CBFB, CBLC, CBWD2, CBWD5, CBX3, CBX4, CBX6, CC2D1B, CCDC106. CCDC107. CCDC12, CCDC130, CCDC142. CCDC153. CCDC19, CCDC3.

[0111] CCDC47, CCDC54, CCDC57, CCDC6, CCDC64B, CCDC69, CCDC7, CCDC71L, CCDC8, CCDC84, CCDC85B, CCDC88A, CCDC89, CCDC90A, CCDC91, CCDC96, CCL1, CCL18, CCL20, CCL26, CCL27, CCL4, CCL5, CCM2, CCND1, CCND2, CCNDBP1, CCNE1, CCNG2, CCNH, CCNK. CCNY, CCR4. CCR7. CCRN4L, CCSAP, CCT5. CCT8L2, CCZ1, CD101, CD109, CD14, CD151, CD163, CD164, CD1A, CD1B, CD1C, CD207, CD22, CD226, CD247, CD248, CD27, CD28, CD2AP, CD2BP2, CD300A, CD300E, CD34, CD36, CD37, CD38, CD3D, CD3E, CD3G, CD4, CD44, CD48, CD5, CD63, CD69, CD80. CD81, CD86, CD8A, CD9, CD93, CD96. CD97, CDC123. CDC14C, CDC16, CDC37, CDC40, CDC42BPG, CDC42SE1, CDC42SE2, CDC73, CDH16, CDH24, CDH26, CDH3, CDK11B, CDK13, CDK14, CDK2AP1, CDK2AP2, CDK5R2, CDK6, CDK7, CDR1, CDRT15L2, CDS2, CDV3, CDY2A, CDY2B, CDYL, CEACAM1, CEACAM3, CEACAM5, CEACAM6, CEBPA, CEBPA.AS1, CEBPD, CECR1. CECR2, CECR6, CELF5. CEMP1. CENPB, CENPT, CEP 170, CEP 192, CEP72, CERK, CERS1, CERS3, CERS5, CERS6, CES4A, CETN1, CFP, CGA, CGN, CGNL1, CH25H, CHAC1, CHCHD2, CHD1, CHD3, CHD6, CHFR, CHI3L1, CHI3L2, CHIC2, CHMP1A, CHMP2B, CHMP3, CHMP4C, CHP2, CHRM4, CHRNA1, CHRNE, CHST11, CHST7, CIB1, CIC, CIDEA, CIDEC. CIITA. CIRBP, CISD3, CISH, CKAP4. CKMT1A. CKMT1B, CKS1B, CLASP1, CLCA2, CLCA4, CLCN6, CLCN7, CLDN17, CLDN19, CLDN23, CLDN24, CLDN25, CLDN8, CLEC10A, CLEC14A, CLEC16A, CLEC1A, CLEC2A, CLEC2B, CLEC2D, CLEC4A. CLEC4D, CLEC4E, CLEC4M, CLEC5A. CLEC6A, CLEC7A, CLEC9A, CLIC2, CLIC3, CLIC4, CLINT1, CLIP1, CLIP4, CLK1, CLK3, CLN3, CLN8, CLNS1A, CLPX, CLTC, CMTM3, CMTM6, CMTM7, CNBP, CNDP2, CNIH4, CNKSR3, CNN2, CNNM4, CNOT3, CNOT6L, CNOT7, CNPPD1, CNPY2, CNST, CNTROB, COASY, COL12AE COL16AE COL17A1, COL18A1, COL1A2, COL3A1, COL4A5, COL5A1, COL6A1. COL9A3, C0MMD3, COMT. COPE. COPG1, COPS2. COPS8, COPZ1, COQ4, CORO1A, CORO1C, COTL1, COX16, COX17, COX20, COX4I1, COX5A, COX6A1, COX6B1, COX7C, CPA3, CPAMD8, CPD, CPEB4, CPLX3, CPM, CPNE3, CPSF1, CPSF4, CPSF6, CPT1A, CPVL, CR2, CRAT, CRBN, CREB3, CREBRF, CREBZF, CRELD1, CRELD2. CRIP2. CRLF2, CRNN, CRSP8P. CRTAM, CRTAP. CRTC2, CRYAB, CRYZ, CRYZL1, CSDA, CSDAP1, CSE1L, CSF1, CSF1R, CSF2, CSF3, CSGALNACT2, CSNK1A1, CSNK1D, CSNK2A2, CSRNP1, CST6, CST7, CSTA, CTAGE11P, CTAGE9, CTDNEP1, CTDSP1, CTDSPL2, CTIF, CTLA4, CTNNA1, CTNNB1, CTNNBL1. CTRB2, CTSA, CTSC, CTSD, CTSG, CTSH, CTSL1, CTSL2, CTSS, CTSZ, CTTNBP2NL, CUL1, CUL3, CUL4B. CUXE CWC25. CXADR. CXADRP2, CXCL1, CXCL10, CXCL11, CXCL14, CXCL17, CXCL6, CXCR2P1, CXCR4, CXorf27, CXorf49, CYB561D1, CYB5B, CYB5R1, CYBA, CYCS, CYCSP52, CYFIP2, CYLD, CYP1A1, CYP20A1, CYP21A2, CYP24A1, CYP2E1, CYP2S1, CYP3A5, CYP4B1, CYP4F11, CYP4F2. CYP51A1. CYSTM1, CYTH2, CYTH3, CYTH4. CYTIP, DAAM1, DAB2IP, DADI, DALRD3, DANCR, DAP3, DAPK1, DAPL1, DAPP1, DAZAP1, DAZAP2, DBI, DBIL5P, DBIL5P2, DCAF13P3, DCAF5, DCAF8L2, DCK, DCN, DCPS, DCSTAMP, DCTN2, DCTPPE DCUN1D3, DDB2, DDHD1, DDOST, DDR1, DDT, DDX10, DDX17, DDX2E DDX39A, DDX39B, DDX3X, DDX3Y, DDX51, DDX52, DDX53, DDX58, DDX60, DEFA1B, DEGS2, DEK, DENND1A, DENND1C, DENND2C, DENND3, DENND4B, DENND5A, DEPDC1, DGAT2, DGCR2, DGKA, DGKI, DHCR24, DHCR7, DHRS1, DHRS9, DHX32, DIAPH1, DICER1, DIO2, DIO3, DIO3OS, DIP2B, DIRC2, DKFZP434A062, DKFZp434L192, DKFZp566F0947. DLEU2L, DLG5, DLX3, DMBXE DMCE DMPK, DMRTC2, DNAH17, DNAJA1, DNAJA2, DNAJA4. DNAJB1, DNAJB14, DNAJC11, DNAJC13, DNAJC21, DNAJC3, DNAJC30, DNAJC5, DNASE1L1, DNASE1L2, DNASE1L3, DND1, DNLZ, DNM3OS, DNTTIP2, DOC2B, DOCK1, DOCKIO, DOCK1E DOCK2, DOCK4, DOCK5, DOCK6, DOCK8, DOK1, DOK2, D0K4. DOT1L, DPEP2. DPMI, DPM3, DPP7. DPP A3, DPY19L2P4, DQXE DRAME DRAPE DRD5, DRG1, DSC1, DSC2, DSCR3, DSTN, DTX2, DUOXAE DUSP14, DUSP22, DUSP4, DUSP5. DUSP6, DUSP8, DUX4L4, DVL1, DYNC1I2, DYNLL1, DYNLRB1, DYNLT1, E2F4. E2F6, E4F1, EAF1, EBF2, EBLN1. EBLN2, EBNA1BP2, EBPL, ECE1, ECEL1P2, ECM1, EDARADD, EDEME EDF1, EEF1A2, EEF1B2, EEPD1, EFHD2, EFNA1, EFS, EGFL8, EGLN2, EGR2, EGR3, EHBP1L1, EHD1, EHD4, EI24, EIDE EID2B, EID3, EIF1AX, EIF2B2, EIF2B5, EIF2S3, EIF3C, EIF3E, EIF3F, EIF3IP1, EIF3K, EIF3L, EIF3M, EIF4AE EIF4A2, EIF4A3, EIF4B, EIF4E, EIF4E2, EIF4EBP1, EIF4EBP2, EIF4ENIF1, EIF4G1, EIF4G2, EIF4G3. EIF5, EIF5ALE EIF5B. ELF1, ELF3, ELL. ELM03, ELMODl, ELMOD3, ELMSAN1, ELOVL1, ELOVL4, ELOVL5, ELOVL6, EMB, EMC3, EMC4, EMILIN2, EML2, EML3, EMP1, EMP2, EMR1, EMR2, ENDOD1, ENKUR, ENPP1, ENPP4, ENS A, ENTPD1, ENY2, EOGT, EP300, EPB41L3, EPG5, EPHA1, EPHB4, EPHB6, EPM2AIP1, EPS15LL EPS8L2. EPSTI1, EPT1, ERALL ERAS. ERBB2, ERBB2IP, ERBB3, ERC2.IT1, ERCC1, EREG, ERGIC1, ERGIC3, ERH, ERMP1, ERN1, EROIL, ERP29, ESRP1, ESRP2, ESYT1, ESYT2, ESYT3, ETFDH, ETHE1, ETNK2, ETV3, ETV6, EVC2, EVI2A, EVPL, EWSR1, EXOC5, EXOC6B, EXOSC7, EXT1, EZR, FUR, F13A1, F2, F2RL1, F8A1, FAAH2, FABP3, FABP5, FADS2, FAIM2, FAM100A, FAM104B, FAM105A. FAM106CP. FAM108A1, FAM109A. FAM110A, FAM110B, FAM115C, FAM117A, FAM120A, FAM120B, FAM126B, FAM127B, FAM129A, FAM129B, FAM133B, FAM134C, FAM135A, FAM136A, FAM138B, FAM156B, FAM157B, FAM169A, FAM173A, FAM18A, FAM190A, FAM195B, FAM209A, FAM20C, FAM213A, FAM213B, FAM214A, FAM223A. FAM226A, FAM26D, FAM32A, FAM40A, FAM40B, FAM45A, FAM45B, FAM47B, FAM48B2, FAM49A, FAM49B, FAM57A, FAM58BP, FAM59A, FAM60A, FAM65B, FAM65C, FAM71A, FAM73B, FAM78A, FAM83A, FAM83B. FAM83F, FAM83H, FAM84A, FAM84B, FAM91A1, FAM92A1P2, FANCE, FANCF, FAS, FAT1. FAT2, FAU, FBLL1, FBRS, FBXL18, FBXL5, FBXOIO, FBXO11, FBXO3, FBXO36, FBXO42, FBXO45, FBXO6, FBXW12, FBXW2, FBXW4P1, FBXW5, FCAR, FCGBP, FCGR1A, FCGR1C, FCGR2B, FCGR3A, FCHO1, FDPS, FDX1, FERMT3, FFAR2, FGF16, FGF22, FGFBP1, FHOD1, FIBIN, FIBP. FIGN, FIS1, FKBP1A, FKBP2, FKBP4, FKBP8, FLJ11235, FLJI3224. FLJI6779, FLJ25328, FLJ25758, FLJ30679, FLJ36777, FLJ42393. FLJ42627. FLJ43663, FLNB, FLNC, FLOT1, FLOT2, FLT3, FLVCR2, FMN1, FMNL1, FMNL2, FMNL3, FNBP4, FNDC3B, FNIP2, FOSL1, FOSL2, FOXC2, FOXD1, FOXD3, FOXD4, FOXD4L1, FOXD4L6, FOXG1, FOXJ3, FOXL1, FOXL2, FOXN3.AS2, FOXO1. FOXO3, FOXO3B, FOXP3, FOXR2, FOXS1, FP588, FPGS, FPR2, FRAT1, FRMD4B, FRMPD1, FRY, FSCB, FTH1P3, FTMT, FTO, FTSJ3, FUK, FUNDC2, FURIN, FUT4, FUT8, FXC1, FXYD5, FYC01, FYN, FZD1, FZD7. FZD8, G3BP1, G3BP2, GAA, GAB2, GABARAPL1, GADD45A, GADD45G. GADD45GIP1, GAK. GALC. GALNS. GALNT1, GALNT4, GALNT7, GAMT, GAN, GAPVD1, GARS, GART, GAS1, GAS5.AS1, GAS7, GATAD2A, GATAD2B, GBA, GBAP1, GBP1, GBP4, GBP5, GCH1, GCN1L1, GCNT4, GCSAM, GCSAML, GDA, GDE1, GDI1, GDI2, GDPD3, GET4, GFOD1, GGA1, GGCT, GGH, GID4, GIGYF2, GIPR, GJA10, GJB5, GJB6, GJC3, GK2, GLA, GLB1, GLB1L3. GLDC, GLIPR2. GLIS2. GLOE GLRX, GLRX3. GLRX5. GLS. GLT25D2. GLTP. GLTPD1, GLTSCR2, GLUD1, GLYR1, GMCL1P1, GMFG, GMIP, GMPS, GNA15, GNAI2, GNAI3, GNAQ, GNAT1, GNB1, GNB2, GNG10, GNG12, GNG2, GNG5, GNG8, GNL2, GNL3, GNLY, GNPNAT1, GOLGA2, GOLGA4, GOLGA6L10, GOLGA6L5, GOLGA7, GOLGA7B, GOLGA8B, GOLGA8CP, GOLGA8F, GPCE GPC4, GPCPD1, GPR125, GPR135, GPR137B, GPR141, GPR148, GPR150, GPR153, GPR155, GPR160, GPR174, GPR27, GPR32, GPR45, GPR6, GPR62, GPR87, GPRIN2, GPRIN3, GPS1, GPSM1, GPSM3, GPT2, GPX1, GPX3, GPX4, GRAMD1B, GRAMD3, GRB2, GREB1, GRHL1, GRHL2, GRINA, GRK6, GRM2, GRPELE GRPEL2, GRSFE GSDMC, GSDMD, GSE1, GSK3A, GSN. GSPT1, GSPT2. GSTK1, GSTM2PE GSTT2, GTF2A1, GTF2F2, GTF2IRD1, GTF3A, GTF3C1, GTPBP1, GTPBP2, GTSF1L, GUSBP3, GUSBP5, GZMA, GZMH, H1FNT, H1FX, H2AFB1, H2AFV, H2AFX, H2AFY, H2AFY2, H3F3C, H6PD, HABP4, HADHA, HAPLN3, HAUS1, HAVCR1P1, HAVCR2, HBD, HBG2, HCAR1, HCG26, HCG4, HCLS1, HCST. HDACE HD AC 10, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDGF, HDLBP, HEBP2, HECA, HECTD1 , HECTD4, HEG1, HERC2P2, HERC2P4, HERC3, HERC4, HERC5, HERC6, HERPUD1, HES4, HEXA.AS1, HEXIM1, HGC6.3, HIATL1, HIF1A, HIF1AN, HIGD2A, HILS1, HINT1, HIP1, HIPK2, HIPK3, HIST1H1D, HIST1H1E. HIST1H2AA, HIST1H2AB, HIST1H2AD, HIST1H2AE, HIST1H2AG, HIST1H2AH, HIST1H2AI, HIST1H2AK, HIST1H2BA, HIST1H2BE, HIST1H2BG, HIST1H2BH, HIST1H2BI, HIST1H2BL, HIST1H2BM, HIST1H2BN, HIST1H3A, HIST1H3B, HIST1H3C, HIST1H3D, HIST1H3F, HIST1H3G, HIST1H3I, HIST1H3J, HIST1H4A, HIST1H4B, HIST1H4C. HIST1H4G, HIST1H4H, HIST1H4I, HIST1H4K, HIST1H4L. HIST2H2AB, HIST2H2AC. HIST2H2BC, HIST2H3D, HIST3H2A, HIST3H2BB, HIST3H3, HK1, HK2, HLA.A, HLA.C, HLA.DMA, HLA.DOA, HLA.DOB, HLA.L, HMG20B, HMGA1, HMGB1, HMGB2, HMGB3P1, HMGCL, HMGCS1, HMGN2, HMHA1, HN1, HNF4G, HNRNPAO, HNRNPA1, HNRNPA2B1, HNRNPA3P1, HNRNPC, HNRNPD, HNRNPF, HNRNPHE HNRNPH3, HNRNPK, HNRNPL, HNRNPM, HNRPDL, HOMER1, HOMER2, HOMER3, HOOK3, HP1BP3, HPD. HPDL, HPS3, HPSE, HPX, HPYR1, HRAS, HRCT1, HRH3, HRNR, HS3ST6, HS6ST1. HSBP1, HSBP1L1, HSD11B2, HSD17B10, HSD17B11, HSD17B4, HSDL2, HSF1, HSF4, HSH2D, HSP90AA1, HSP90AB1, HSP90B1, HSPA13, HSPA2, HSPA4, HSPA4L, HSPA6, HSPA8, HSPB3, HSPB6, HSPB9, HSPD1, HSPE1, HSPH1, HTR1B, HTR7P1, HTRA1, HTRA2, HUS1B, HYMAI, IAH1, IARS, IARS2, ICAM1, ICAM5, ICK, ICMT, ICOSLG. ICT1, ID1. ID2, IDH2, IDH3G, IDI1, IDO1, IDS, IER3IP1, IER5L, IFFO2, IFI27, IFI35. IFI44, IFI6, IFIT3. IFIT5, IFITM3, IFITM4P. IFNA1, IFNA10, IFNA16, IFNA17, IFNA2, IFNA22P, IFNA4, IFNA5, IFNE, IFNG, IFNGR2, IFNW1, IFRD2, IFT43, IGF2BP2, IGF2R, IGFBP4, IGFL2, IGFL3, IGJ, IGSF6, IKBKB, IKZF1, IKZF2, IL10RA, IL10RB, IL12B, IL13, IL17F, IL17RA, IL17RB, IL18RAP, ILIA, IL1F1O, IL1R1, IL20, IL20RB, IL21R, IL22. IL23A. IL24, IL28A, IL2RB, IL2RG, IL3, IL32, IL36B, IL36G, IL37, IL4R, IL6, IL6R, IL6ST, IL7R, ILF2, ILF3, ILK, ILVBL, IMPDH1, IMPDH2, INF2, INGX, INHBA, INO80E, INPP5B, INPP5D, INPPL1, INSMI, INSM2, INTS1, IPCEF1, IPO7, IPPK, IQCB1, IQGAP2, IQSEC3, IRAK2, IRAK3, IRF2BPL, IRF3, IRF4, IRF7, IRF8, IRS2, IRX3, ISCU, ISG20, ISM2, ITCH, ITFG2, ITGA1. ITGA5, ITGA6, ITGA8, ITGAL, ITGAM. ITGAV, ITGAX. ITGB2, ITGB4. ITGB8. ITIH5. ITM2A, ITM2C. ITPKC, ITPR1, ITPRIPL2, ITSN2, IZUMO4, JAGN1, JAK1, JAK2, JAK3, JARID2, JMJD1C, JMJD6, JMJD8, JMY, JOSD1, JOSD2, JRKL, JTB, JUND, KAAG1, KANK1, KANSL1.AS1, KAT2B, KBTBD2, KBTBD7. KCMF1, KCNAB2, KCNE1L, KCNH4, KCNJ11, KCNK1, KCNK7, KCNQ1OT1, KCNQ3, KCTD12, KCTD15. KCTD17, KCTD2, KCTD21, KDELR1, KDELR2, KDM4C, KDM5B, KDM5C, KDM5D, KDM6B, KHDRBS1, KHSRP, KIAA0100, KIAA0195, KIAA0226, KIAA0247, KIAA0317, KIAA0391, KIAA0513, KIAA0664, KIAA0754, KIAA0913, KIAA0922, KIAA0930, KIAA1143, KIAA1147. KIAA1383, KIAA1432, KIAA1468, KIAA1522, KIAA1551, KIAA2026, KIDINS220, KIF19, KIF1C, KIF2B, KIF5B, KIFC3, KIR3DL2, KLC3, KLF10, KLF14, KLF3, KLF6, KLF8, KLF9, KLHDC2, KLHDC3, KLHDC4, KLHDC7A, KLHL14, KLHL18, KLHL21, KLHL26, KLHL6, KLHL9, KLK11, KLK12, KLK13, KLK14, KLK7, KLK8, KERB I . KLRK1, KMO, KPNA1, KPNA2, KPNA4, KPNA6, KPNA7, KPNB1. KRBOX1, KREMEN1, KRR1, KRT16P3, KRT19. KRT19P2. KRT25, KRT27. KRT31, KRT33B. KRT37, KRT39, KRT4, KRT71, KRT72, KRT75, KRT78, KRT79, KRT81, KRT86, KRT8P41, KRT9, KRTAP1.1, KRTAP1.5, KRTAP10.1, KRTAP10.12, KRTAP10.2, KRTAP10.3, KRTAP10.5, KRTAP10.6, KRTAP10.7, KRTAP10.8, KRTAP12.2, KRTAP12.3. KRTAP12.4, KRTAP13.1, KRTAP13.3, KRTAP16.1, KRTAP17.1, KRTAP19.1, KRTAP19.2, KRTAP19.3, KRTAP19.4, KRTAP19.6, KRTAP2.2, KRTAP2.4, KRTAP20.3, KRTAP22.2, KRTAP23.1, KRTAP24.1, KRTAP25.1, KRTAP26.1, KRTAP27.1. KRTAP3.1, KRTAP3.2. KRTAP3.3, KRTAP4.1. KRTAP4. i l, KRTAP4.12, KRTAP4.4, KRTAP4.7, KRTAP4.8, KRTAP4.9, KRTAP5.i l, KRTAP5.4, KRTAP5.5, KRTAP5.7, KRTAP6.2, KRTAP6.3, KRTAP7.1, KRTAP9.1, KRTAP9.2, KRTAP9.3, KRTAP9.4, KRTAP9.8, KRTAP9.9, KRTCAP2, KTI12, KTN1, KXD1, LAD1, LAG3, LAMB3, LAMP2, LAMP3, LAMT0R2, LAMT0R4, LAMT0R5, LAP3, LAPTM4A, LAT, LATS1, LAX1, LBH, LCE3C, LCK, LCMT2, LCP2. LCTL. LDHA. LDHAL6B, LDHB, LDLRAD4, LEFTY1, LENG9, LEPR0TL1, LETMD1, LGALS1, LGALS2, LGALS3, LGALS3BP, LGALS4, LGALS7B, LGALS9, LGALSL, LIF, LILRA3, LILRA6, LILRB2, LILRB3, LILRB5, LIMCH1, LIMD1, LIMD2, LIMK2, LIMSI, LIN28A, LIN7C, LINC00115, LINC00162, LINC00273, LINC00312, LINC00341, LINC00346, LINC00477, LINC00488, LINC00552, LINC00597, LINC00602, LINC00628, LINC00641, LINC00675, LIPA, LIPE, LIPK, LIPM, LIPN, LITAF, LIX1L, LMAN2L, LMNA, LMO1, LMO7, LMTK2, LMTK3, LNX1, LOC100093631, LOC100126784, LOC100128023, LOC100128292, LOC100128505, LOC100129034. LOC100129961. LOC100130673, LOC100131496. LOC100132287. LOC100132831. LOC10013316L LOC100133612. LOC100170939, LOC100190940, LGC100190986, LOC100216546, LOC100240734, LGC100270804, LOC100271836, LOC100286922, LGC100287042, LOC100287177, LOC100287632, LGC100288069, LOC100288748, LGC100289230. LOC100289341, LOC10028936L LGC100303749. LOC100335030. LOC100499489. LOC100505540. LOG 100505622, LOC 10050 123, LOC 100506730, LOC 100506994, LOC 100507127, LGC100507206, LGC100507299, LOC144742, LOC145474, LOC148696, LOC149086, LOC150185, LOC150197. LOC158376, LOC158696, LOC202781, LOC221122, LOC255512. LOC283070. LOC283299, LOC283922, LOC284023, LOC284578, LOC285548, LOC339240, LOC340113, LOC341056, LOC349196, LOC375196, LOC389332, LOC390705, LOC392364, LOC399815, LGC401010, LOC401074, LOC401127, LOC401321, LOC401397, LOC440173, LOC440434, LOC440896, LOC440925. LOC441455. LOC494127, LOC553103, LOC554206, LOC606724, LOC613038. LOC641515. LOC642361, LOC643387, LOC643955, LOC644189, LOC644936, LOC644961, LOC645166, LOC646214, LOC646471, LOC646862, LOC646903, LOC646999, LOC647012, LOC648987, LOC650293, LOC650623, LOC653653, LOC727896. LOC728554, LOC728643, LOC728752, LOC728819, LOC729020. LOC729080. LOC729737, LOC732275, LOC84931, LOC90246, LOH12CR1, LONP1, LONRF1, LPAR2, LPCAT1, LPCAT3, LPCAT4, LPHN2, LPPR2, LRBA, LRCH4, LRG1, LRIG3. LRP10, LRP11, LRP4, LRRC10B, LRRC15, LRRC25. LRRC3O, LRRC37A6P, LRRC37BP1. LRRC59, LRRC6. LRRC8C, LRRFIP1, LRRFIP2, LRRK1, LRRK2, LSM12, LSM7, LSP1P3, LST1, LTA, LTB, LTB4R2, LTBR, LTF, LTK, LUC7L2, LURAP1L, LY6D, LY6G6E, LY6G6F, LY96, LYN, LYNX1, LYPD5, LYPD6B, LYPLA1, LZTR1, M6PR, MAB21L1, MACF1, MAD2L2, MAF1, MAFB, MAFG, MAGEA5, MAGEA9B, MAGEE2, MAGEH1, MAGEL2, MAGT1, MAL2, MALL, MALTL MAML2, MAN1AL MAN2A2, MANF. MANSCL MAOA, MAP1LC3A. MAP1LC3B2, MAP1S, MAP2, MAP2K1, MAP2K2, MAP3K1, MAP3K14, MAP3K5, MAP3K6, MAP3K8, MAP4K1, MAP4K4, MAP7, MAP7D1, MAPK13, MAPK14, MAPK3, MAPK8IP3, MAPK9, MAPKAPK2, MAPKAPK3, MAPKAPK5, MAPRE2, MARK2P9, MARK4, MARS, MARS2, MARVELD2, MASI. MAST4, MAT2A, MAT2B. MAZ, MB21D2. MBDL MBD2, MBD3L1, MBOAT2, MC1R, MC4R, MC5R, MCAM, MCC, MCL1, MCM3, MCM4, MCM5, MCU, MDFI, MDH1, MDH2, MEI, MECP2, MED12, MED13L, MED15, MED18, MED8, MEF2D, MEGF9, MEIS3P1, MERTK, METTL16, METTL3. METTL9, MFAP3L. MFN1, MFSDL MFSD3, MFSD6L, MGAM, MGAT3, MGC12916. MGC16142. MGC2752. MGC39372. MGC57346, MGEA5, MGLL. MGRNL MGST2. MGST3, MICAL2, MIEN1, MIER2, MIIP, MILR1, MINK1, MINPP1, MIR1307, MIR155HG, MIR181D, MIR205HG, MIR31HG, MIR3907, MIR490, MIR548I1, MIR548I2, MITD1, MKL1, MKLN1, MKRN1, MKRN3. MLEC, MLF1IP, MLL, MLL4, MLL5, MLLT4, MMD, MMP10, MMP13, MMP2, MMP25, MMP27, MNDA, MOB1A, MOB3B, MOB3C, MOCOS, MOGS, MORC2, MOS, MOSPD3, MPC1, MPDU1, MPHOSPH6, MPP7, MPV17, MPZL2, MPZL3, MRC1, MREG, MRFAP1L1, MRGPRD, MRGPRX1, MRGPRX4, MRPL20. MRPL24, MRPL3, MRPL32, MRPL33, MRPL39, MRPL4, MRPL42P5, MRPL43, MRPL46, MRPL51. MRPL53, MRPS10, MRPS18B, MRPS21, MS4A4A, MS4A7, MSANTD3, MSGN1, MSH5, MSIL MSL1, MSL2, MSMOL MSRA, MST1, MST1R, MSTO2P, MSX2P1, MT1A, MT1DP, MT1H, MT1IP, MT1M, MT1X, MT2A, MTA1, MTA2, MTCH2, MTFP1, MTG1, MTHFR, MTHFS, MTMR1, MTMR11, MTMR12, MTMR3. MTMR9, MTPN, MTRNR2L10, MTRNR2L2, MTRNR2L4.

[0112] MTRNR2L5, MTRNR2L6, MTRNR2L7. MTSS1, MTVR2, MTX1, MTX2. MUC2. MUC20, MUC4, MUCL1, MUS81, MVD, MX1, MX2, MXI1, MY ADM, MYD88, MYEOV2, MYH14, MYH4, MYH6, MYH9, MYL12A, MYL12B, MYL9, MYO18A, MYOID, MYO1E, MYO1F, MY06, MYO7B, MYO9B, MYOF, MZB1, NAA20. NAA35, NAAA, NACA2, NACAP1, NADKD1, NADSYN1, NAGA. NANOG, NANOGNB, NANOS2, NAP1L1, NAP1L2, NAP1L4, NARF, NARS, NAT9, NBEAL2, NBN, NBPF10, NBR1, NCAPD2, NCBP1, NCF1, NCF1B, NCF2, NCF4, NCK1, NCKAP1, NCKAP1L, NCL, NCLN, NC0A2, NC0A3, NC0A7, NCSTN. NDFIP1. NDFIP2. NDN, NDRG1, NDRG4, NDUFA1, NDUFA4, NDUFA4L2, NDUFA6, NDUFA7, NDUFA8, NDUFAF3, NDUFB11, NDUFB7, NDUFB8, NDUFB9, NDUFS2, NDUFS3, NDUFS5, NDUFS8, NDUFV2, NEBL, NECAP2, NEDD4, NEDD8, NEK11, NEK7, NELF, NE01, NES, NET1, NEU1, NEU3, NFATC2, NFE2L1, NFE2L2, NFIA, NFIX, NFKBIE, NFYA, NFYB, NGFRAP1, NGLY1, NHP2L1, NICN1. NINJ2. NIPAL2. NIPAL3, NKAPL. NKX2.6, NLK, NLRC5, NLRP1, NLRP10, NLRX1, NMRAL1, NOA1, NOB1, NOLC1, NOPIO, NOP56, NOP58, NOSIP, NOTCH1, NOTCH2, NOTCH2NL, NOTCH3, NPBWR2, NPC1, NPC2, NPDC1, NPEPL1, NPEPPS. NPLOC4, NPPA, NPR2, NQO2, NR1D1. NR1H3, NR3C1, NR4A1, NRAS, NRBF2, NRBP1. NREP. NSF. NSFL1C, NSFP1, NSG1, NSMAF, NSMCE2, NSUN5P1, NT5C, NT5C2, NT5DC2, NUAK1, NUB1, NUDT17, NUDT3, NUDT4, NUDT5, NUDT9P1, NUFIP2, NUP188, NUP54, NUP98, NUS1, NXF1, OAF, OAS1, OAS3, OASL, OAZ1, OBP2A, OBSL1, OCA2, OCLM, OCLN, ODC1, ODF3B, OGDH, OGFRL1, OLFML2B, OLR1, OPN3. OR10A5, OR10AD1, OR10C1, OR10G2, OR10G3, OR10G4, OR10G8. OR10G9. OR10H2, OR10H3. OR10H5. OR10J1. OR10J3. OR10K1, OR10P1, OR10Q1, OR10R2, OR10S1, OR10V1, OR10W1, OR10Z1, OR11A1, OR11G2, OR11H12, OR11H2, OR11H4, OR11H6, OR11L1, OR12D2, OR12D3, OR13C3, OR13C9, OR13D1, OR13H1, OR14C36, OR14I1, OR14J1, OR1A1, OR1A2, OR1D2, OR1D4, OR1D5, OR1F1, OR1F2P, OR1J1. OR1J2, OR1K1. OR1L3, OR1L6. OR1L8, 0R1M1, OR1N1, OR1N2, OR1 Q1, OR1 S1, OR1 S2, OR2A20P, OR2A25, OR2A5, OR2A9P, OR2AG1, OR2AG2, OR2AK2, OR2AT4, OR2B11, OR2B2, OR2B3, OR2B6, OR2C1, OR2D2, OR2F1, OR2F2, OR2G2, OR2G3, OR2G6, OR2H2, OR2J2, OR2J3, OR2K2, OR2L2. OR2L3, OR2M2, OR2M4, OR2M5, OR2M7. OR2S2, OR2T1. OR2T10, OR2T11, OR2T29, OR2T3, OR2T33, OR2T35, OR2T4, OR2T6, OR2V2, OR2W3, OR2W5, OR2Y1, OR3A1, OR3A2, OR3A4P, OR4A47, OR4B1, OR4C11, OR4C13, OR4C15, OR4C16, OR4C6, OR4D1, OR4D10, OR4D6, OR4F15, OR4F17, OR4K1, OR4K15, OR4L1, 0R4M1, OR4M2, OR4N4, OR4N5, OR4S1, OR4S2, OR4X1. OR4X2, OR51A2. OR51A7, OR51B2, OR51B6, OR51D1. OR51F1. OR51F2, OR51G2, OR51I1, OR51I2. OR51L1, 0R51M1, OR51Q1, OR51S1, OR51T1, OR51V1, OR52A5, OR52B2, OR52B4, OR52D1, OR52E4, OR52E6, OR52E8, OR52K1, OR52K2, OR52N1, OR52N4, OR52N5, OR56A1, OR56A3, OR56A4, OR56B4. OR5A1, OR5A2, OR5AK2, OR5AN1, OR5AR1. OR5AS1, OR5AU1, OR5B12, OR5B17, OR5B2. OR5B21, OR5C1, OR5D13. OR5D14, OR5D18, OR5F1, OR5H1, OR5H14, OR5H15, OR5H2, OR5I1, OR5J2, OR5K2, OR5K4, 0R5L1, OR5L2, 0R5M1, OR5M10, OR5M3, OR5P2, OR5P3. 0R5R1, OR5W2, 0R6B1, 0R6C1, OR6C4. OR6C65, OR6C70, OR6C74, 0R6F1, OR6K2, OR6K6, 0R6M1, OR6N2, 0R6P1, 0R6Q1, 0R6S1, 0R6TL 0R6V1, 0R6W1P, 0R6Y1, OR7A10, OR7A5, 0R7C1, OR7C2, OR7D4, OR7E37P, 0R7G1, OR7G3, 0R8A1, OR8B2, OR8B4, OR8B8, 0R8D1, OR8G2, OR8G5, 0R8H1, OR8H2, OR8H3, OR8I2, 0R8J1, OR8J3, OR8K3, 0R8U1, OR9A2, OR9A4, 0R9G1, OR9G4, 0R9I1, OR9K2, OR9Q2. 0RM2, 0SBP2, 0SBPL1A. OSGIN2, OSM, OST4, OSTC, OSTF1, OTUB1, OTUB2, 0TUD1, OTUD5. OVCH2. OVOL2, OXSR1, P2RX6, P2RX7, P2RY1, P2RY10, P2RY13, P2RY2, P2RY4, P4HB, PA2G4, PABPC1L2A, PABPC3, PABPC4, PABPN1, PACS1, PACSIN2, PADI1, PADI2, PAFAH1B3, PAG1, PAIP1, PAIP2, PAK1, PAK2, PALD1, PALMD, PAPL, PAPOLB, PAQR5, PAQR7, PARI, PAR4. PARD3, PARD6B, PARD6G. PARK7, PARM1, PARP1, PARP10, PARP12, PARP14, PARP4, PARVG, PBX4, PBXIP1, PCBP1, PCCA, PCDH1, PCDHB1, PCDHB10, PCDHB12, PCDHB13, PCDHB17, PCDHB18, PCDHB3, PCDHB4, PCDHB5, PCDHB7. PCDHB9, PCED1A, PCGF6, PCIF1, PCK1, PCMTD2, PCNAP1, PCNP, PCNXL2, PCSK6, PCYT1A, PDCD4. PDE2A, PDE4DIP, PDE7A, PDGFB. PDGFRA, PDGFRB, PDHA2. PDIA2, PDIA3P, PDIA4. PDLIM2. PDLIM7, PDS5A. PDXK, PEA 15, PEC AMI, PEF1, PEG10, PELP1, PERI, PER4, PFDN5, PFKFB2, PFKL, PFKP, PFN1P2, PFN3, PGA4, PGAM1, PGAM4, PGBD4, PGD, PGF, PGK1, PGK2, PGLYRP2, PGLYRP4, PGM3, PGRMC2, PHB, PHC1, PHF1, PHF19, PHF20, PHF5A. PHGDH. PHLDA2, PHLDB3, PHLPP2, PHPT1, PHTF2, PI4K2A. PI4KAP2, PIAS3. PIC ALM, PIEZO1, PIEZO2, PTGC, PIGN, PIGV, PTK3CD, PIK3CG, PIK3IP1, PIK3R5, PIKFYVE, PILRA, PILRB, PIM1, PIM2, PIM3, PIN1P1, PINK1, PINLYP, PIP4K2A, PIP4K2C, PIP5K1C. PIPSL. PITPNA, PJA2, PKD1P1, PKD2, PKDREJ, PKN1. PKP1, PKP3, PLA2G12A, PLA2G16, PLA2G4B, PLA2G4D, PLA2G4E, PLA2R1, PLAC2, PLAGL1, PLAT, PLBL PLBD1, PLBD2, PLCB2, PLCD1, PLCXD1, PLD2, PLD3, PLEC, PLEK, PLEKHA2, PLEKHA3, PLEKHA8, PLEKHB2, PLEKHG1, PLEKHG4B, PLEKHM1, PLEKHM2, PLEKHM3, PLEKHO1, PLEKHO2, PLEKHS1, PLK2, PLLP, PLP2, PLS3, PLSCR3, PLVAP, PLXDC2, PLXNAL PLXNB2, PLXND1, PMAIP1, PMCHL1, PMEPA1, PML, PMML PMM2, PMS2P3, PMS2P5, PNKD. PNLIPRP3, PNP, PNPLA2, PNPLA3, PNPLA6, PODXL, POGLUT1, POLD2, POLG, POLR2A, POLR2B, POLR2E, POLR2F, POLR2G, POLRMT, POM121L12, POM121L2, POM121L4P, POMZP3, POR, PORCN, POSTN, POU2F3, POU3F1, POU3F2, POU3F3, POU5F1B, POU5F1P3, PP12613, PPA1, PPA2, PPAP2B, PPAP2C, PPARG, PPBP. PPDPF, PPFIA3, PPFIA4, PPFIBP2, PPIAL4A, PPIAL4E, PPIAL4F, PPIB, PPP1CA, PPP1CB, PPP ICC, PPP1R13B, PPP1R13L, PPP1R14B, PPP1R18, PPP1R2P3. PPP1R2P9, PPP1R3B, PPP1R3E, PPP1R3G, PPP1R9B, PPP2CA, PPP2CB, PPP2R1A, PPP2R1B, PPP2R2A, PPP3R1, PPP4C, PPP4R1, PPP4R2, PPP6R1, PPP6R3, PPT2, PPTC7, PQLC1, PRDX2, PRDX5, PRELID1, PRELP, PREP, PREXI, PRG1, PRICKLE2, PRKACG, PRKAG2, PRKAR1A, PRKCB, PRKCD, PRKD3, PRKDC, PRKRIR, PRKX, PRM1, PRM3, PR0M2, PR0RSD1P, PRPF19, PRPF31, PRPF40A, PRPF8. PRR13, PRR14, PRR14L, PRR19, PRR23A, PRR23B, PRR24. PRR9, PRRC2A. PRRC2B, PRRC2C. PSCA. PSENEN, PSIMCT.l, PSMA1, PSMA7, PSMB4, PSMB8, PSMB9, PSMC5, PSMD1, PSMD2, PSMD3, PSMD4, PSMD6, PSMD8, PSME1, PSME3, PSME4, PSMF1, PSPN, PSTPIP1, PTBP3, PTENP1, PTGER3, PTGER4, PTGES2, PTGES3, PTGS2, PTK2B, PTK7, PTOV1, PTP4A2. PTP4A3. PTPN1, PTPN11, PTPN12, PTPN13, PTPN2, PTPN3, PTPN5, PTPN6, PTPRA, PTPRE, PTRF, PTRH1, PTTG1IP, PTTG2, PURB, PURG, PVR, PVRL1, PVRL4, PWP2, PXDC1, PXK, PXMP4, PYCARD, PYGB, PYGL, PYGO2, QKI, QPCT, QPRT, R3HDM4, RAB10, RAB11FIP1, RAB11FIP3, RAB12. RAB I 3. RAB14, RAB18, RABI A, RAB20, RAB2E RAB23, RAB26, RAB27B, RAB30, RAB32, RAB35, RAB38. RAB3B, RAB3GAPE RAB40C, RAB43. RAB5A. RAB5C. RAB6A, RAB6C, RAB7A, RAB8A, RAB8B, RAB9BP1, RABAC1, RABEP2, RABGEF1, RABGGTA, RABGGTB, RABL2A, RAC1, RAC2, RAC3, RACGAP1P, RAD21, RAE1, RAET1E, RALBP1, RALGAPA1, RALGAPA2, RALGAPB, RALY, RAMPL RANBP1, RANBP3, RANBP6, RANGAP1, RAP1A, RAP IB, RAP 1 GAP, RAP2C, RAPGEF4, RAPGEFL1, RARG. RARRES2, RARRES3, RASA4, RASA4CP, RASAL1, RASAL3, RASD1, RASD2, RASGEF1B, RASGRP4, RASSF2, RASSF3, RASSF4, RASSF5, RB1CC1, RBBP4, RBCK1, RBFOX2, RBM12B.AS1, RBM17, RBM25, RBM27, RBM3, RBM39, RBM47, RBM6, RBM8A, RBMS1, RBMS2, RBMX2, RBP1, RBPJ. RBX1. RC3H1, RCAN3, RCN1, RDBP, RDH13, RDH8, RDX, REC8, RECQL4, REEP4, REEP5, REL, RELA, RELB, RELT, REPS1, REPS2, RER1, REXO2, RFC1, RFTN1, RFX5, RGMB, RGP1, RGPD1, RGPD3, RGS18, RHBDF2, RHCG, RHEB, RHOA, RHOB, RHOC, RHOD, RHOF, RHOH, RHOV, RHPN1.AS1, RIBC1, RILPL2, RIMBP3B, RIMBP3C, RIMKLB, RIN2, RIN3, RING1, RIPK4. RLF, RMND5A, RMND5B, RNASE12, RNASE6. RNASE7, RNASE8. RNASEK. RNASET2, RND1, RND3, RNF11, RNF114, RNF122, RNF125, RNF126P1, RNF13, RNF130, RNF144B, RNF148, RNF167, RNF181, RNF186, RNF19B, RNF213, RNF26, RNF31, RNF4, RNF40, RNF5, RNF6, RNH1, RNPEP, RNPEPL1, RNPS1, RNU12, ROBO1, RORC. RP2, RPA1, RPA4, RPIA. RPL10, RPL12, RPL13A, RPL19, RPL22, RPL23AP32, RPL23P8, RPL24, RPL26L1, RPL31P11, RPL37, RPL38, RPL5, RPL6, RPL8, RPN1, RPRD1A, RPRD2, RPRM, RPRML, RPS15A, RPS15AP10, RPS18, RPS19BP1, RPS2, RPS20, RPS21. RPS25, RPS26P11, RPS27, RPS27A, RPS29. RPS3A, RPS4Y1, RPS5, RPS6KA1, RPS6KA3, RPS9, RPTN, RRAD, RRAGA, RRAGC, RRBP1, RRM2, RRP1, RRP12, RRS1, RS ADI, RSL24D1, RTCA, RTF1, RTN1, RTN4, RUNDC3A, RUNX3, RUSC2, RXFP3, RXFP4, RXRA, RYK, RYR1, S100A10, S100A11, S100A14, S100A16, S100A4, S100A6, SIOOB, S1PR4, SAA1, SAMD4B, SAMD8, SAMHD1, SAMSN1, SAP18. SAP25, SARNP. SARS. SAT1, SBDS, SBF1. SBF1PL SBF2, SBK1, SBNO1, SCAF1, SCAF8, SCAMP4, SCAP, SCARB1, SCARNA10, SCARNA13, SCARNA14, SCARNA15, SCARNA16, SCARNA17, SCARNA18, SCARNA3, SCARNA5, SCARNA6, SCARNA9, SCD, SCGB2A2, SCIMP, SCN1B, SCN3B, SCNN1A, SCNN1B, SCNN1G, SCP2D1, SCPEP1, SCYL2. SDCBP, SDCBP2, SDE2, SDHAF1, SDHC, SDR42E1, SDS, SEC11A, SEC14L1, SEC14L1P1, SEC23A, SEC31A, SEC63, SECTM1, SEL1L3, SELPLG, SELT, SEMA3C, SEMA3F, SEMA4A, SEMA4B, SEMA4C, SEMA4D, SEMA4G, SEMA7A, SERBP1, SERINC3, SERINC5, SERPINB1, SERPINB12, SERPINB13, SERPINB2, SERPINB5, SERPINB7, SERPINB9, SERPINE1. SERPINF1, SERPING1, SERPINH1, SERTAD1, SERTAD2. SESN2, SET, SETD6. SETD7, SF3A1, SF3A2, SF3A3, SF3B1, SF3B2, SF3B3, SFI1, SFN, SFPQ, SFT2D2, SFTPA1, SFXN1, SFXN3, SGK223, SGMS1, SGPL1, SGSM2, SGTB, SH2B2, SH2B3, SH3BGRL, SH3BGRL2, SH3BP4. SH3BP5L. SH3D21, SH3GL1, SH3GL1P1, SH3GL1P2, SH3GLB2, SH3RF3.AS1, SH3TC1. SH3YL1, SHB, SHBG, SHFM1, SHKBP1, SHMT2, SHROOM3, SIGLEC10, SIGLEC14, SIGLEC16, STGLEC5, SIK1, SIPA1, SIPA1L1, SIRT7, SIT1, SKP1, SLA, SLA2, SLAIN2, SLBP, SLC11A2, SLC12A7, SLC15A1, SLC15A3, SLC15A4, SLC18A3, SLC19A2, SLC1A1, SLC1A4, SLC1A5, SLC1A6, SLC20A1, SLC20A2, SLC22A3, SLC25A19, SLC25A29, SLC25A3, SLC25A39, SLC25A44, SLC25A51P1, SLC25A52, SLC26A6, SLC28A3, SLC2A4RG, SLC30A1, SLC34A3, SLC35E4, SLC35F5, SLC36A4, SLC37A2, SLC38A1, SLC38A2, SLC39A1, SLC39A14, SLC39A8, SLC3A2, SLC41A1, SLC41A2, SLC43A3, SLC44A5, SLC45A4, SLC4A1, SLC4A11, SLC5A2, SLC6A6, SLC7A1, SLC7A11, SLC7A5P1, SLC7A5P2, SLC7A6, SLC7A7, SLC7A8, SLC9A3R1, SLC9A7. SLCO2A1. SLCO2B1, SLCO3A1, SLCO4A1, SLCO4C1, SLFN5. SLIRP, SLPI, SLURP 1, SMA5, SMAD4, SMAP2, SMARCA4, SMARCC2, SMARCD2, SMARCE1, SMCHD1, SMEK3P, SMG1P1, SMG5, SMG6, SMG7, SMIM5, SMOC2, SMOX, SMPDL SMPD3, SMPD4, SMS, SMTN, SMU1, SMURF1, SNAI1, SNAPIN, SNCG. SNF8, SNHG1, SNHG12. SNHG5, SNHG6, SNHG9, SNORAIO, SNORA12. SNORA16A, SNORA21, SNORA27, SNORA36C, SNORA39, SNORA42, SNORA43, SNORA46, SNORA48, SNORA49, SNORA50, SNORA52, SN0RA5A, SNORA62, SNORA64, SNORA65, SNORA66, SNORA68, SNORA70B, SNORA70E, SNORA70G, SN0RA71B, SN0RA71D, SNORA74A, SNORA75, SNORA79, SN0RA81, SNORA84, SN0RD17, SNORD94, SNRNP40, SNRPA, SNRPA1, SNRPB, SNRPD1, SNRPD2, SNRPD2P2, SNRPD3, SNRPE, SNRPG, SNTA1, SNTB1, SNW1, SNX1, SNX13, SNX17, SNX21, SNX3, SNX8, S0AT1, SOCS2, SOCS3, SOD1, SOLH, SON, SORBS3, SORD, SORT!, SOWAHB, SOWAHC. SOWAHD, SOX1, SOX11, SOX14, SOX15, SOX21, SOX3, SOX7, SPACA4, SPAG1, SPAG7, SPAG8, SPARC, SPATA20, SPATA31C1, SPATA31C2, SPATCI, SPC24, SPCS1, SPCS2, SPDYC, SPDYE7P, SPECC1, SPG21, SPHAR, SPHK1, SPIC, SPIN1, SPIN4, SPINK5, SPINK6, SPINK7, SPINT1, SPNS2, SPOCD1, SPP1, SPPL2C. SPPL3, SPRED1, SPRED2, SPRR2C. SPRR2G, SPTBN1, SPTBN2, SPTSSA, SPTY2D1, SPZ1, SQRDL, SRA1, SRC, SREK1IP1, SRF, SRGAP2B, SRM, SRP14, SRP9, SRPK1, SRPR, SRRM1, SRSF1, SRSF2, SRSF5, SRSF6, SRSF7, SRSF8, SSBP2, SSBP3, SSFA2, SSNA1, SSR1, SSR3, SSR4, SSTR4, SSX3, SSX6, SSX7, ST13, ST13P4, ST20, ST3GAL1, ST3GAL2, ST8SIA4, STAG1. STAP2, STARD3NL, STARD5, STARD7. STARD8, STATE STAT5A, STAT5B. STAT6, STCE STEAP4, STH, STIPE STK24, STK25, STK38L, STK4, STK40, STMN3, STOM, STRAP, STRC, STRN, STRN3, STT3A, STX11, STX4, STX5, STX7, STXBP2, STXBP5, SUCLG1, SUCO, SUGT1, SULF2, SULT1A2. SULT2B1, SUMF2, SUMO1P1, SUMO1P3, SUMO3, SUMO4, SUN1, SUPT6H, SURF1, SURF6, SUSD1, SUSD2, SYCEE SYMPK. SYNGAP1, SYNGR2, SYTL1 , SYTL3, SZRD1, SZT2, TAAR1, TAAR5, TAAR6, TAAR8, TAB2, TAB3, TAC1, TACC1, TACC2, TACSTD2, TAF12, TAF13, TAF1C, TAGLN, TAGLN2, TALDO1, TA0K1, TAPI, TAP2, TAPT1, TARP, TARSL2, TAS2R1, TAS2R14, TAS2R19, TAS2R20, TAS2R38, TAS2R40, TAS2R41, TAS2R43, TAS2R50, TAS2R7, TAS2R8, TAS2R9, TAX1BP3, TBC1D1, TBC1D10A, TBC1D12, TBC1D14, TBC1D17, TBC1D20, TBC1D3, TBC1D30, TBC1D9, TBCA, TBL1XR1, TBX20, TBX6, TBXAS1, TCEA1, TCEB1, TCEB2, TCEB3, TCF25, TCHH, TCIRG1, TCN1, TCN2, TCPE TCP11, TCP11L2, TDG, TDGF1P3, TDP2, TDRD9, TECR, TEDDM1, TEN1, TENM2, TERC, TERF2, TES, TEX10E TEX2. TFAP4, TFE3. TFPI. TFRC. TGFA. TGFB2, TGFBE TGFBR1, TGM1, TGM2, TGM3, TGM5, THAP11, THAP9.AS1, THBD, THEM4, THEMIS2, THOC3, THOC6, THOP1, THRAP3, THRB, THTPA, THY1, TIAM1, TIAM2, TIFAB, TIGD1, TIGD2, TIMM10, TIMM17A. TIMM23, TIMP2, TINF2. TIP ARP, TJAP1, TJP2, TLE4, TLK2, TLN1, TLR2, TLR4. TM4SF1, TM4SF19, TM6SF2, TM7SF2, TM9SF3, TMA7, TMBIM1, TMBIM4, TMBIM6, TMC5, TMC8, TMCC3, TMED2, TMED3, TMED7, TMEM102, TMEM106A, TMEM106C, TMEM110, TMEM114, TMEM117, TMEM123, TMEM127, TMEM132A, TMEM133, TMEM134, TMEM140. TMEM141, TMEM147. TMEM14C, TMEM158, TMEM161A, TMEM165, TMEM167A, TMEM167B, TMEM176B, TMEM184B, TMEM185A, TMEM19, TMEM2, TMEM203, TMEM219, TMEM229A, TMEM246, TMEM3OB, TMEM39A, TMEM40, TMEM41B, TMEM52, TMEM57, TMEM59, TMEM63B, TMEM66. TMEM86A, TMEM98, TMEM99, TMEM9B, TMOD4. TMPRSS1 IE, TMPRSS13, TMX2, TNC. TNF. TNFAIP2. TNFAIP3, TNFAIP6, TNFRSF1OB, TNFRSF1OC, TNFRSF1OD, TNFRSF12A, TNFRSF14, TNFRSF18, TNFRSF1A, TNFRSF1B, TNFRSF4, TNFRSF9, TNFSF1O, TNFSF12, TNFSF13B, TNIP1, TNIP3. TNK2, TNKS1BP1, TNKS2, TNNC1, TNNC2, TNNT1, TNNT2, TNPO2, TNS3, TOB2P1, TOLLIP, TOMI, TOM1L2. TOMM22. TOMM34, TOMM40, TOMM40L, TOMM6, TOMM7, TOP1P1, TOR3A, TP53BP2, TP53INP2, TPD52L3, TPI1, TPM2, TPM3, TPM4, TPP1, TPP2, TPRG1, TPRG1L, TPSB2, TRA2B, TRABD, TRAF3, TRAF3IP2, TRAF4, TRAFD1, TRAK1, TRAM1, TRAM1L1, TRAPPCI, TRAPPC2L, TRAPPC5. TRAPPC6A, TRAPPC8, TRAPPC9, TREML5P, TREX1, TRIBI, TRIB2. TRIL, TRIM22. TRIM27, TRIM29, TRIM33, TRIM54. TRIM62. TRIM65. TRIM69, TRIM73, TRIO, TRIP10, TRIP12, TRIP13, TRIP6, TRMT112, TRPM1, TRPS1, TRUB2, TSC22D1, TSC22D3, TSC22D4, TSEN2, TSN, TSNARE1, TSPAN13, TSPAN14, TSPAN2, TSPAN31, TSPAN33, TSPY2, TSPY3, TSPYL1. TSPYL4, TSR3, TST, TSTA3, TSTD1, TTBK1, TTC39A. TTC3P1. TTYH2, TTYH3, TUBA1C. TUBA4A, TUBB2A, TUBB4A, TUBE1, TUBG1, TUBG2, TUBGCP2, TUFT1, TUG1, TULP4, TWF1, TWF2, TXLNA, TXN2, TXNL4A, TYK2, TYMP, TYMS, TYRO3, TYW1B, U2AF1, U2SURP, UACA, UBAC2, UBAP1, UBAP2L, UBASH3B, UBD, UBE2B, UBE2C, UBE2D1, UBE2F, UBE2H, UBE2J2, UBE2L3. UBE2M. UBE2N, UBE2Q2P1, UBE2R2. UBE2S, UBE2W, UBE2Z, UBE4B, UBL4B, UBL5, UBQLN2, UBQLNL, UBR3, UBR4, UBTD1, UBTFL1, UBXN2B, UCA1, UCHL3, UCP2, UFC1, UFD1L, UGT1A10, UGT1A7, UGT1A8, UGT1A9, ULK1, ULK3, UNC45A, UNC93B1, UPB1, UPF2, UPK1A, UPRT, UQCR11, UQCRQ. USE1, USF2, USMG5, USO1, USP11, USP15, USP17L2, USP17L6P, USP2, USP22, USP24, USP26. USP32. USP38, USP47, USP53. USP6NL, UST, UTPI5. UTP18, UTP3, UTS2R, UXT, VAC14, VAMP8, VARS, VASH1, VASN, VASP, VAT1, VAV1, VAV2, VBP1, VDAC2, VDAC3, VDR, VEGFA, VENTX, VENTXP1, VENTXP7, VIPR1, VN1R1, VN1R2, VN1R4, VN1R5, VNN1, VOPP1, VPS13C, VPS28, VPS37B, VPS37C, VPS4B, VSIG2, VSNL1, VWF. WARS, WAS, WASH1. WASH3P, WBP2, WDFY3, WDFY4, WDR1, WDR13, WDR26, WDR43, WDR59, WDR5B, WDR6, WDR61, WDR75, WDR82, WDR91, WHAMMP1, WIPF1, WIPF2, WIPI1, WIPI2. WSB1, WTH3DI, WWC1, WWC2.AS2, WWP2, WWTR1, XCL2, XKRX, XP07. XPOT. XRCC5, XRCC6, XRN1, XRRA1, XYLT1, YBX1, YBX2, YEATS2, YES1, YOD1, YPEL2, YPEL3, YTHDC1, YTHDF3, YWHAG, YWHAH, YWHAQ, ZAK, ZBED6, ZBP1, ZBTB1, ZBTB10, ZBTB16, ZBTB25, ZBTB38, ZBTB4, ZBTB7A, ZBTB7C, ZBTB8OS, ZC3H12C, ZC3H3, ZCCHC13, ZCCHC16, ZCCHC3, ZCCHC7, ZCRB1, ZDHHC12, ZDHHC13. ZDHHC9, ZEB1, ZEB2, ZFANDE ZFAND2A, ZFAND3. ZFAND5, ZFAND6, ZFP36LE ZFP36L2, ZFPM1, ZFYVE16, ZFYVE26, ZHX2, ZMAT2, ZMIZ1, ZMIZ2, ZMYM4, ZMYND10, ZNF114, ZNF124, ZNF154, ZNF165, ZNF192, ZNF207, ZNF215, ZNF224, ZNF252P.AS1, ZNF267, ZNF284, ZNF292, ZNF330, ZNF331, ZNF385A, ZNF395, ZNF398, ZNF410, ZNF415. ZNF426. ZNF432. ZNF468. ZNF485. ZNF507. ZNF516. ZNF528. ZNF543. ZNF551, ZNF571, ZNF589, ZNF593, ZNF595, ZNF598, ZNF662, ZNF672, ZNF678, ZNF709, ZNF710, ZNF737, ZNF750, ZNF767, ZNF77, ZNF782, ZNF783, ZNF789, ZNF800, ZNF808, ZNF831, ZNF844, ZNF91, ZNF92, ZNF93. ZNHIT2, ZNRF1, ZNRF2P1, ZNRF4, ZRANB1, ZSCAN12P1, ZSWIM4, ZSWIM6, ZWINT, ZYX, and ZZEFE

[0113] In certain embodiments, the genes in a gene set are selected from the genes recited in Table 4. In certain embodiments, the genes in a gene set comprise one or more of the gene sets recited in Table 4.

[0114] In certain embodiments, the genes in a gene set are selected from: A2M, A2M. AS 1, A2ML1, AACS, AADAC, AADACL2, AAED1 , AATF, AATK, ABCA1 , ABCA12, ABCA2, ABCA5, ABCB10, ABCB6, ABCC1, ABCD3, ABCE1, ABCF1, ABCG1, ABCG4, ABHD1, ABHD12, ABHD12B, ABHD16A, ABHD16B, ABHD2, ABHD5, ABHD8, ABI1, ABB, ABL2, ABLIM1, ABP1, ABT1, ABTB1, ABTB2, ACAA1, ACAA2, ACAD11, ACAD8, ACAD9, ACADVL, ACAP1, ACAP2, ACAP3, ACAT2, ACBD3, ACBD4, ACER1, ACER2, ACINI, ACOT11, ACOT7, ACOT9, ACOX1, ACPI, ACP5, ACPP, ACSF2, ACSL1, ACSL3, ACSL5, ACSS1, ACTA2, ACTBL2, ACTG1P4, ACTL10, ACTL7A, ACTL9, ACTN1, ACTN4, ACTR1A, ACTR2, ACTR3, ACTRT1, ACTRT2, ADAMIO. ADAMI 1, ADAM15, ADAM19, ADAMI A, ADAM21P1. ADAM23, ADAM30, ADAM8, ADAM9, ADAMTS1, ADAMTS10, ADAMTS15, ADAMTS4, ADAMTSL5, ADAP2, ADAR, ADCK5, ADCY7, ADH5, ADIPOR1, ADIPOR2, ADM, ADORA2A, ADPGK, ADRA2C, ADRB1, ADRB2, ADRBK1, ADRBK2, ADSL, ADSSL1, ADTRP, AES. AFF1, AFF4, AFTPH. AGAP3, AGAP5, AGFG2, AGPAT9. AGRN, AGTPBP1, AGXT, AHCTF1, AHCY, AHCYL1, AHNAK, AHNAK2, AHSA2, AIDA, AIF1, AIF1L, AIFM3, AIM1, AIM1L, AJAP1, AJUBA, AK1, AK2, AKAP13, AKAP17A, AKIRIN1, AKNA, AKR1A1, AKR1B1, AKR1B10, AKR1CL1, AKR7A2P1, AKT1S1, AKT2. AKT3. AKTIP, ALAS2, ALCAM, ALDH2, ALDH3A1, ALDH3B2, ALDH5A1, ALDH9A1, ALDOA, ALDOC, ALG14, ALG2, ALKBH5, ALKBH6, ALKBH7, ALOX12, ALOX12B, ALOX15, ALOX15B, ALOX5, ALOX5AP, ALOXE3, ALPL, ALPP, ALYREF, AMBRA1, AMD1, AMICA1, AMMECR1, AMN, AMOTL1, AMOTL2, AMPD2, AMPD3, AMZ2, ANAPC2, ANAPC7, ANGPTL4, ANKFN1, ANKH, ANKLE2, ANKRD10. ANKRD11, ANKRD12, ANKRD13A, ANKRD13B, ANKRD13C, ANKRD16, ANKRD20A9P, ANKRD22, ANKRD23, ANKRD24, ANKRD33B, ANKRD35, ANKRD36, ANKRD36BP1, ANKRD37, ANKRD44, ANKRD52, ANKRD65, ANKS1A, ANKS3, ANLN, ANO1, ANO 10, ANO8, ANO9, ANP32AP1, ANP32B. ANP32C, ANP32D, ANP32E, ANPEP, ANXA11, ANXA2P1, ANXA2P2, ANXA2P3, ANXA2R, ANXA3, ANXA4, ANXA5, ANXA9, AP1G1, AP1M1, AP1M2, AP1S2, AP2A1, AP2M1, AP2S1, AP3B1, AP3D1, AP3S1, AP4S1, AP5B1, APBB1, APH1A, API5, APLP2, APMAP, APOA1BP, APOB, APOBEC3A, APOBEC3C, APOBEC3G, APOBR, APOCI, APOC1P1, APOE, APOL3, APP. APPL2, APRT, AQP1, AQP3. AQP5. AQP7P1. AQP8. AQP9. ARAF. ARAP1. ARAP2, ARAP3, ARCN1, AREG, ARF1, ARF3, ARF4, ARF5, ARFGAP3, ARGFXP2, ARGLU1, ARHGAP1, ARHGAP10, ARHGAP15, ARHGAP17, ARHGAP18, ARHGAP23, ARHGAP25, ARHGAP27, ARHGAP29, ARHGAP31, ARHGAP32, ARHGAP33, ARHGAP40, ARHGAP42, ARHGAP9. ARHGDIB, ARHGEF10L, ARHGEF12, ARHGEF17, ARHGEF18, ARHGEF19, ARHGEF2, ARHGEF26, ARHGEF28, ARHGEF35, ARHGEF37, ARHGEF4, ARID3B, ARID4A, ARIH1, ARIH2, ARL14, ARL17A, ARL4C, ARL5A, ARL5B, ARL6IP4, ARL6IP5, ARL8A, ARL8B, ARMCI, ARMC2. ARMC5. ARNTL. ARNTL2, ARPC1A, ARPC1B, ARPC3, ARPC4. ARPC5, ARPC5L, ARPP19, ARRB1, ARRB2, ARRDC1, ARRDC2, ARRDC3, ARRDC4, ARSF, ASAHI, ASAP1, ASAP2, ASAP3, ASB9P1, ASCC2, ASCL4, ASH1L, ASH1L.AS1, ASL, ASMTL, ASNA1, ASPDH, ASPSCR1, ASS1, ASTL, ASXL1, ATAD1, ATF4, ATF6, ATG16L2, ATG3, ATG4B, ATG9A, ATG9B, ATHL1. ATL2, ATL3, ATMIN, ATN1, ATOH1. ATOH7, ATOX1, ATP10B. ATP11B. ATP11C, ATP12A, ATP13A1, ATP13A2, ATP13A4, ATP1A1OS, ATP1B1, ATP1B2, ATP1B3, ATP2A2, ATP2A3, ATP2B2, ATP2B4, ATP2C2, ATP5A1, ATP5B, ATP5C1, ATP5D, ATP5E, ATP5F1, ATP5G1, ATP5G2, ATP5H, ATP5I, ATP5J2, ATP5L2. ATP5O, ATP6AP1, ATP6AP2, ATP6V0A1, ATP6V0B. ATP6V0C, ATP6V0D1, ATP6V0E1, ATP6V1B2, ATP6V1C1, ATP6V1C2, ATP6V1E1, ATP6V1H, ATP7A, ATP9B, ATXN10, ATXN2, ATXN3, ATXN3L, ATXN7L3, ATXN7L3B, ATXN80S, AUP1, AURKAIP1, AURKAPS1. AZGP1P1. AZINI, B3GALNT1. B3GALT4, B3GALT6, B3GAT1. B3GNT5, B4GALNT3, B4GALT1, BABAM1, BAG1, BAG3, BAG6, BAGE2, BAHCC1, BAIAP2, BAK1, BAMBI, BARX2, BATF3, BAX, BAZ1A, BBS9, BBX, BCAR4, BCAS1, BCAS2, BCAS3, BCKDK, BCL11B, BCL2A1, BCL2L1, BCL2L11, BCL6, BCL9L, BCLAF1, BCOR, BCR, BCS1L, BDH1, BEST1, BEST4, BHLHA15, BHLHE22, BHLHE23, BHLHE40, BICD2, BIN2, BIN3, BIRC3, BIRC5. BLID, BLMH. BLNK, BLOC1S1, BLOC1S3, BLOC1S4, BLVRB, BLZF1, BMP1, BMP2, BMP2K, BMPR1A, BMPR2, BMS1P4, BNC1, BNIP2, BNIP3, BNIPL, BOC, BOD1L1, BOLA2B, BOLA3, BOP1, BPIFB3, BPIFC, BRAF, BRAP, BRCC3, BRD2, BRD4, BRD7, BRD9, BRI3, BRIX1, BRK1, BRSK1, BRWD1, BSDC1, BSG. BSPRY, BST2, BTBD16, BTBD2, BTBD3, BTBD6. BTBD7, BTF3, BTF3P11. BTG1, BTG2, BTK, BUD31, BZRAP1, BZW1, BZW2, ClOorflO, ClOorfll, C10orfl l6, C10orfll8, C10orfl2, C10orfl28, C10orf54, C10orf55, C10orf62, C10orf76, C10or®9, CllorflO, CllorBl. Cllorf58, Cllorf84, Cllor®, Cllorf96, C12orf29, C12orf44, C12orf57, C12orf68. C14orfl59, C14orfl62, C14orfl69, C15orf39, C15orf41. C15orf52, C15orf62, C16orf3, C16orf59. C16orf70, C16orf72, C16orf82. C16orf92, C17orfl07, C17orf49, C17orf59, C17orf62, C17orf82, C17orf85, C17or®6, C19orfl0, C19orf33, C19orf43, C19orf53, C19orf59, C19orf6, C19orf66, C19orf73, Clorfl06, Clorfl09, Clorfll6, Clorfl98. Clorf21. Clorf210, Clorf229, Clorf233, Clorf35, Clorf50, Clorf54, Clorf65, C1QA. C1QBP, C1RL.AS1. C2. C20orfl l l, C20orfl l2, C20orfl51, C20orf26, C21orfl l9, C22orfl 3, C22orf28, C22orf32, C2orfl 8, C2orf54, C2orf57, C2orf81, C3AR1, C3orf52, C3orf74, C4orf52, C5orf20, C5orf46, C5orf55, C6orfl, C6orfl20, C6orfl32, C6orfl36, C6orfl41, C6orfl5, C6or£226, C6orf47, C6orf48, C6orf62, C7orf43, C7orf65, C8orf33, C8orf58, C8orf73, C9orfl23, C9orfl42. C9orfl56, C9orfl63, C9orfl69, C9orfl72, C9orf47, C9orf53, C9orf78, C9orf89, C9orf91, CA12, CAB, CA2, CA4, CAB39, CACNB1, CACNB4, CACYBP, CAHM, CALB2, CALCOCO1, CALM1, CALM2, CALML3, CAMKID, CAMK4, CAMKK2, CAMP, CAMSAP2, CAMTA2, CANX, CAP1, CAPG, CAPN1, CAPN14. CAPNS1, CAPNS2, CAPRIN1, CAPZA1, CAPZA2. CARD11, CARD16, CARD8, CARHSP1, CASC3, CASK, CASKIN1, CASP3. CASP4, CASP9. CASS4, CAST, CASZ1, CAT, CATSPER2, CAV2, CBFA2T3, CBLB, CBLC, CBWD5, CBX3, CBX4, CBX5, CBX6, CC2D1A, CC2D1B, CCAR1, CCDC101, CCDC107, CCDC111, CCDC12, CCDC124, CCDC130, CCDC142, CCDC153, CCDC163P, CCDC19. CCDC25, CCDC28B, CCDC3, CCDC50. CCDC54, CCDC57, CCDC64, CCDC64B, CCDC66, CCDC69, CCDC7, CCDC71L, CCDC8, CCDC84, CCDC85B, CCDC87, CCDC88B, CCDC88C, CCDC89, CCDC90A, CCDC91, CCDC93, CCDC96, CCER1, CCIN, CCL1, CCL17, CCL2, CCL20. CCL21, CCL24. CCL26, CCL27, CCL3, CCL3L3. CCL4, CCL5, CCM2, CCNB1, CCNC, CCND2, CCNDBPL CCNE1, CCNG2, CCNH, CCNI, CCNK, CCNL1, CCR5, CCR8, CCRL2, CCRN4L, CCT3, CCT4, CCT6A, CCT7, CCT8, CCT8L2, CD101, CD109, CD14, CD151, CD164, CD177, CD1A, CD1E, CD207, CD22, CD226. CD247, CD248, CD27, CD274, CD28, CD2AP, CD2BP2, CD300A, CD300E. CD34. CD36, CD38, CD3D, CD3E. CD40. CD40LG, CD48. CD52, CD58, CD6, CD63, CD68, CD69, CD7, CD72, CD81, CD82, CD8A, CD9, CD93, CD96, CD97, CD99, CDA, CDC123, CDC14A, CDC14C, CDC27, CDC34, CDC37, CDC42, CDC42BPB, CDC42EP1, CDC42EP3, CDC42SE1, CDC42SE2, CDC73, CDCA5, CDCP1, CDH1, CDH16, CDH26, CDH3, CDIPT, CDK11B, CDK17, CDK2, CDK3, CDK5R2, CDK5RAP3, CDKAL1, CDR1, CDRT15L2, CDRT15P1, CDRT15P2, CDS2, CDV3, CDY2A, CDY2B, CDYL, CEACAM19, CEACAM3, CEACAM5, CEBPA, CEBPA.AS1, CEBPD, CECR1, CECR2, CECR6, CELF5, CELSR1, CELSR2, CEMP1. CENPB, CENPP, CENPT, CEP35O, CEP72, CEP76, CERK, CERS1. CERS2, CERS3, CERS5, CERS6, CES2, CES4A, CETN1. CFD. CFL2. CFLAR, CFP, CGA. CGNL1, CHCHD10. CHCHD2. CHCHD3. CHD1. CHD2. CHD4, CHD6, CHFR, CHI3L2, CHIAP2, CHIC2, CHKB, CHMP1A, CHMP1B, CHMP2A, CHMP2B, CHMP4B, CHMP4C, CHMP5, CHP1, CHP2, CHRNA9, CHRNB1, CHRNE, CHST14, CHST15, CIAO1, CIB1, CIC. CIDEA, CIDEC, CIITA, CIR1, CIRBP. CISD2, CISH, CIZ1, CKAP4, CKB. CKS1B, CKS2, CLASP1, CLASRP, CLCA2. CLCA4, CLCN3, CLCN6, CLCN7, CLDN17, CLDN19, CLDN22, CLDN23, CLDN25, CLDN3, CLDN4, CLDN7, CLDN8, CLDN9, CLDND1, CLECIOA, CLEC14A, CLEC16A, CLEC2A, CLEC2B, CLEC4A, CLEC4E, CLEC5A, CLEC7A, CLEC9A, CLIC4, CLIP1, CLIP4, CLK1, CLK2P, CLK3, CLN3. CLN8. CLNS1A, CLPTM1. CLPX. CLSTN1, CLSTN2, CLTB, CLTC, CLU, CMAS, CMIP, CMTM3, CMTM6, CMTM7, CN5H6.4, CNBP, CNEP1R1, CNIH, CNKSR3, CNN2, CNN3, CNNM3, CNNM4, CNOT1, CNOT3, CNOT6L, CNOT7, CNPPD1, CNPY3, CNST, CNTNAP3, CNTROB, COASY, COBLL1, COCH. COG1, COG3, COIL, COL12A1, COL15A1. COL16A1. COL17A1, COL18A1, COL1A1, COL1A2. COL27A1. COL3A1, COL4A1. COL4A2, COL4A5, COL5A1. COL7A1, COL9A2, COL9A3, COMP, COMT, COP A, COPB2, COPE, COPS2, COPS6, COPS8, COPZ1, COQIOB, COQ4, COQ5, CORO1A, CORO1B, COROIC, CORO2A, COTL1, COX17, COX20, COX4I1, COX5A, COX5B, COX6A1, COX6B1, COX6C, COX7B, COX7C, COX8A, CP A3, CPAMD8, CPD, CPE, CPEB4. CPM, CPNE3. CPSF1, CPT1A, CR2, CRABP2, CRB3, CRBN, CREB1, CREB3, CREBBP, CREBL2, CREBRF, CREBZF, CREG1, CRELD2, CRIP1, CRISPLD2, CRK, CRKL, CRLF3, CRNN, CROT, CRSP8P. CRTAM, CRTAP. CRTC2, CRYZ, CRYZL1, CSAD, CSDA, CSDAP1. CSF1, CSF1R, CSF2, CSF3, CSGALNACT2, CSK, CSNK1D, CSNK2A1, CSNK2A2, CSNK2B, CSRNP1, CSRP1, CSRP2, CST6, CST7, CSTA, CSTF2T, CTAGE10P, CTAGE4, CTAGE6P, CTAGE9, CTBP1, CTBP2, CTBS, CTC1, CTDNEP1, CTDSP1, CTDSPL2, CTIF, CTLA4. CTNNA1, CTNNB1, CTPS1, CTR9, CTRB2, CTSA, CTSB. CTSD. CTSG, CTSL1, CTSL2. CESS, CTSW, CTSZ, CTTNBP2NL, CUL1, CUL3, CUL4B. CUTA, CUX1, CWC25, CWF19L1, CXADRP2, CXCL14, CXCL16, CXCL17, CXCR1, CXCR2, CXorfl, CXorf27, CXorf49, CYB561D1, CYB5R1, CYBA, CYBB, CYC1, CYCS, CYCSP52, CYFIP1, CYP1A1, CYP1B1, CYP20A1, CYP21A1P, CYP21A2, CYP24A1, CYP27B1, CYP2EE CYP3A5, CYP4B1, CYP4F11, CYP4F12, CYP4F2, CYP4Z2P, CYP51A1, CYP8B1, CYSLTR1, CYSLTR2, CYSTM1, CYTH1, CYTH4, DAAM1, DAAM2, DAB2, DAB2IP, DACT2, DADE DAGLA, DAK, DAP, DAP3, DAPK1, DAPK3, DAPL1, DAPP1, DARC, DARS, D AZAPE DAZAP2, DBF4, DBI, DBIL5P2, DBNDD2, DBNL. DCAF12, DCAF12L2, DCAF13P3. DCAF4L1, DCAF4L2, DCAF7. DCAF8L2, DCHSE DCN. DCP1A. DCSTAMP, DCTN1, DCTN3. DCTN5. DCUN1D1, DCXR, DDAE DDB1, DDHD1, DDI1, DDIT4, DDR1, DDRGK1, DDT, DDX10, DDX18, DDX19B, DDX21, DDX24, DDX39B, DDX3X, DDX3Y, DDX5, DDX51, DDX53, DDX6, DDX60, DDX60L, DEDD, DEF6, DEFA1B, DEFB1, DEGS2, DEK, DENND1A, DENND1C, DENND2C, DENND2D, DENND3. DENND4A. DENND4B, DENND6B, DEPDC1, DEXI, DGAT2, DGCR11, DGCR2, DGCR6L, DGCR9, DGKA, DGKD, DGKI, DHCR24, DHCR7, DHDDS, DHFR, DHRS3, DHRS4L2, DHRS9, DHX29, DHX32, DHX34, DHX9, DIAPH1, DICER1, DIO2, DIO3, DIO3OS, DIP2B, DIRC2. DIS3L, DKFZP434A062, DKFZP434H168, DKFZp434L192, DKFZp566F0947, DKK3, DLD. DLEU2L, DLG5, DLX3, DLX5, DMRTC2, DMTF1, DMXL2, DNAJA2, DNAJA4, DNAJB1, DNAJB14, DNAJB2, DNAJB3, DNAJB6, DNAJB7, DNAJB9, DNAJC1, DNAJC11, DNAJC13, DNAJC14, DNAJC19, DNAJC21, DNAJC3, DNAJC5, DNAJC7, DNAJC8, DNASE1L1, DNASE1L2, DNASE1L3, DNASE2, DND1, DNM2, DNM3OS, DNTTIP2, DOC2B, DOCKIO, DOCK1 E DOCK6. DOCK8. DOCK9. DOK4. DOLK, DOT1L. DPH2. DPH3PE DPMI, DPM2, DPP7, DPP A3, DPPA5, DPRXP4, DPY19L2P4, DQX1, DRAPE DRD1, DRD5, DSC1, DSC2, DSCR9, DSG2, DSG3, DSTN, DTNBP1, DTX2,

[0115] DTX2P1 UPK3BPEPMS2P11, DUOX1, DUOXA1, DUSP10, DUSP11, DUSP14, DUSP16, DUSP2, DUSP21, DUSP22. DUSP4, DUSP5, DUSP6, DUSP7, DUSP8. DUX4L4, DVL1, DVL3, DYNC1I2, DYNC1LI2, DYNLLE DYNLRB1, DYNLT1, DYNLT3, DYSF, E2F4, E4F1, EAF1, EAPP, EBF2, EBLN1, EBLN2, EBNA1BP2, ECE1, ECEL1P2, ECHDC2, ECM1. EDEMI. EDEM2, EDF1, EDN1, EEF1A2, EEF1B2, EEF1D, EEF1E1, EEPD1, EFCAB4B, EFHD2, EFNA1, EFNA3, EFNBL EFNB2, EFR3B, EFS, EGFL8, EGLN1, EGLN2, EGLN3, EGR1, EGR2, EGR3, EHBP1L1, EHD1, EHF, EI24, EID1, EID2, EID2B, EID3, EIF1AX, EIF2AK1, EIF2AK3, EIF2AK4, EIF2B2, EIF2B5, EIF2C2, EIF2C3, EIF2C4, EIF2D, EIF2S2, EIF2S3, EIF3A, EIF3C, EIF3D, EIF3E, EIF3F, EIF3G, EIF3H, EIF3I, EIF3IP1, EIF3K, EIF3L, EIF4A3, EIF4B, EIF4E, EIF4E2, EIF4E3. EIF4EBP3, EIF4G1, EIF4G2, EIF4G3, EIF5, EIF5A, EIF5AL1, EIF5B, EIF6, ELF1, ELF3, ELK3, ELL, ELL3, ELM0D1, ELOF1, ELOVL1, ELOVL4, ELOVL6, ELOVL7, ELP5, EMB, EMC10, EMC3, EMC4. EMCN, EMD, EML3, EML4, EMP1, EMP2, EMP3, EMR1, ENCI, ENDOD1, ENG. ENO2. ENO3. ENPP1, ENTHD2. ENTPD1, ENTPD7. ENY2, EP300. EPB4L EPB41L3, EPC2, EPG5, EPHA1, EPHA2, EPHB3, EPHB4, EPHX2, EPHX3, EPM2AIP1, EPN1, EPOR, EPRS, EPS15, EPS15L1, EPS8L2, EPSTI1, EPT1, ERAP1, ERAS, ERBB2, ERBB2IP, ERBB3, ERC2.IT1, ERCC1, EREG, ERGIC1, ERGIC2, ERGIC3. ERH, ERLEC1, ERMP1, ERO IL, ERP29, ERP44, ERVV.l, ESPN, ESRPL ESRP2, ESYTL ESYT2, ESYT3. ETF1, ETFDH, ETHEL ETNK2, ETV3, ETV6, EVI2B, EVPL, EXOC3, EXOC5, EXOC6B, EXOC7, EXOC8, EXOSCL EXOSC2, EXOSC7, EXPH5, EYA3, EZH2, EZR, FUR, F13A1, F2, F2RL1, F3, F8A1, FAAH2, FABP4, FABP7, FABP9, FADS1, FAF1, FAIM2, FAM100B, FAM102A, FAM104B, FAM106A, FAM106CP. FAM 108 Al, FAM110A, FAM 11 OB, FAM HOC, FAM114A2, FAM118A. FAM120A, FAM120B, FAM122A, FAM123A, FAM126A, FAM126B, FAM127A, FAM127B, FAM129A, FAM129B, FAM131A, FAM132A, FAM133B, FAM134A, FAM134C, FAM135A, FAM136A, FAM138B, FAM13B, FAM153C, FAM157B. FAM160A1, FAM162A, FAM168A, FAM169A, FAM173A, FAM188A, FAM190A, FAM190B, FAM192A, FAM193B, FAM207A, FAM209A, FAM20C, FAM210A, FAM210B, FAM213B, FAM214A, FAM215A, FAM217B, FAM218A, FAM21A, FAM21B, FAM223A, FAM223B, FAM25B, FAM26D, FAM32A, FAM40A, FAM40B, FAM43A, FAM43B, FAM45A, FAM45B, FAM46C. FAM47B, FAM48B2, FAM49B, FAM50A, FAM53C, FAM58BP, FAM59A, FAM60A. FAM65B, FAM66C. FAM73B, FAM83A, FAM83C, FAM83F, FAM83G, FAM83H, FAM91A1, FAM92A1P2, FAM96B, FARSA, FAS, FASN, FASTK, FAT1, FAT2, FAU, FBL, FBLIM1, FBLL1, FBP1, FBXL12, FBXL3, FBXL5. FBXO10, FBXO11, FBXO25, FBXO3, FBXO31, FBXO36, FBXO45. FBXO6, FBXO7, FBXW12. FBXW4P1, FBXW5, FBXW7, FBXW9, FCER1A. FCGBP, FCGR1C, FCGR2A, FCGR2B, FCGR3A, FCGR3B, FCHO1, FCHO2, FCN1, FDCSP, FDFT1, FDPS. FDX1, FEM1B, FER1L4, FERMT1, FERMT3, FFAR1, FFAR2. FGD3, FGD4, FGF16. FGFBP1, FGGY, FGL2, FGR, FHL3. FH0D1, FIBIN, FIGN, FIS 1, FJX1, FKBP10, FKBP1A, FKBP2, FKBP4, FKBP5, FKBP8, FKBP9, FK.SG29, FLU, FLII, FLJ11235, FLJ13224, FLJ14107, FLJ16779, FLJ23867, FLJ30679, FLJ36777, FLJ42393, FLJ43663, FLJ45445, FLNB, FLNC, FLOT1, FLOT2, FLT3, FLVCR2, FMNL2, FMNL3, FMO2. FNBP1, FNBP4. FNDC3B, FNIP1, FNIP2, FNTA, FOS, FOSL1, FOSL2, FOXB2, FOXC2, FOXD2, FOXD2.AS1. FOXD3, FOXD4L1. FOXD4L5, FOXD4L6, FOXEI. FOXE3, FOXG1, FOXJ3, FOXK1, FOXL1, FOXL2, FOXN3 AS2, FOXO3, FOXO3B, FOXP3, FOXP4, FOXQ1, FOXR2, FOXS1, FP588, FPGS, FPR2, FPR3, FRAT1, FRAT2, FRMD4B, FRMD6, FRMD8, FRMPD1, FRY, FSCB, FSCN1, FSTL1. FTH1P3, FTMT, FTO. FTSJD2. FTX. FUBP1, FUK, FUNDC2, FURIN. FUS. FUT11, FUT2. FUT4, FUT8.AS1, FXC1, FXR1, FXYD4, FXYD5, FXYD6, FYB, FYCO1, FYN, FZD1, FZD10, FZD2, FZD7, FZD8, G3BP1, G3BP2, GAA, GABI, GABARAPL1, GABARAPL2, GABPA, GABPB1.AS1. GABRA1, GADD45A, GADD45B, GADD45G, GADD45GIP1, GAL, GALC, GALK1, GALNS, GALNT1, GALNT11, GALNT2, GALNT4, GAMT, GARS. GASL GAS2L1, GAS5. GAS5.AS1, GAS6, GAS7, GATA1, GATA3. GATAD2A. GATAD2B, GBA, GBA2, GBAP1, GBF1, GCA, GCC2, GCNT4, GDE1, GDF1, GDI1, GDI2, GDPD3, GEM, GEMIN2, GET4, GGA1, GGA3, GGCT, GGH, GGT6, GGT8P, GHDC, GHITM. GHRLOS2, GIGYF1, GIGYF2, GINS2, GIPC1, GIPR, GJA1, GJB3, GJB4, GJB5. GJB6, GJC3, GJD3. GK2. GLA, GLB1, GLB1L. GLB1L2, GLB1L3, GLCCI1, GLDC, GLDN, GLEL GLIPR2, GLIS2, GLOL GLRX, GLRX3, GLS, GLT1D1, GLT25D1, GLTP, GLTPD1, GLTSCR2, GLUD1, GLUD2, GLYR1, GMCL1P1, GMFG, GMIP, GMPPB, GNA12, GNA15, GNAI1, GNAI2, GNAI3, GNAT1, GNB1, GNB2, GNG2, GNG5. GNG8. GNL1. GNL2. GNL3, GNLY, GNPNAT1, GNPTG, GNRHR2, GNS, GOLGA1, GOLGA2, GOLGA3, GOLGA4, GOLGA5, GOLGA6C, GOLGA6D, GOLGA6L1, GOLGA6L5, GOLGA7, GOLGA7B, GOLGA8B, GOLGB1, GP6, GPAA1, GPBP1, GPBP1L1, GPC1, GPC4, GPCPD1, GPD2, GPER, GPHA2, GPI, GPLD1, GPNMB, GPR108. GPR110. GPR115, GPR126, GPR135, GPR137B, GPR141, GPR146, GPR148, GPR150. GPR15I. GPR157, GPR160, GPR21, GPR25, GPR27, GPR32. GPR45, GPR52. GPR56, GPR6, GPR62, GPR77, GPR87, GPR97, GPRC5A, GPRC5D, GPRIN2, GPS1, GPS2, GPSM1, GPSM3, GPT2, GPX1, GPX3, GPX4, GRAMD1A, GRAMD1B, GRAMD3, GRB2, GRB7, GRHL1, GRHL3, GRHPR, GRIK5, GRIN3B. GRINA, GRK6, GRM2. GRN, GRPEL1, GRPEL2, GRWD1. GSDMC, GSDMD, GSE1, GSK3A. GSK3B, GSN. GSPT1, GSPT2, GSTA4, GSTK1, GSTM2P1, GSTP1, GSTT2, GSTT2B, GTDC2, GTF2IRD1, GTF3C2, GTPBP1, GTPBP2, GTSF1L, GUK1. GUSBP1, GUSBP3, GYPC, GYSI, GZMH, H1F0, H1FNT, H1FX. H2AFB1, H2AFX, H2AFY. H2AFZ, H3F3C, HABP4, HADHA, HADHB, HARBI1, HARS, HAUS1, HAUS4, HAUS5, HAUS8, HAVCR1P1, HBA2, HBB, HBD, HBEGF, HBG2, HBP1, HCAR1, HCG26, HCG4, HCK, HCLS1, HCST, HDAC1, HDAC3, HDAC4, HDAC5, HDAC7, HDC, HDGF, HDHD2, HDLBP, HEATR7A, HEBP2, HECA. HECTD1, HEG1, HELB, HELZ2, HEPHL1, HERC2, HERC2P2, HERC2P4, HERC3, HERC4, HERPUD1. HERPUD2, HES4. HEXB, HEXIM1, HEXIM2, HGC6.3, HGS, HGSNAT, HIATL1, HIF1A, HIF1AN, HIGD1A, HIGD2A, HILS1, HINFP, HINT1, HIP1, HIP1R, HIPK1, HIPK2, HIPK3, HIRIP3, HIST1H1A, HIST1H1D, HIST1H1E, HIST1H2AA, HIST1H2AB, HIST1H2AE, HIST1H2AI, HIST1H2AK, HIST1H2BA, HIST1H2BB, HIST1H2BC, HIST1H2BD, HIST1H2BE, HIST1H2BG, HIST1H2BH, HIST1H2BI, HIST1H2BL, HIST1H2BN, HIST1H2BO, HIST1H3A, HIST1H3B, HIST1H3C, HIST1H3E, HIST1H3F, HIST1H3G, HIST1H3I, HIST1H3J, HIST1H4A, HIST1H4C, HIST1H4E, HIST1H4G, HIST1H4H, HIST1H4I, HIST1H4J, HIST1H4K, HIST1H4L, HIST2H2AB, HIST2H2AC, HIST2H2BC, HIST2H2BE, HIST2H3D. HIST3H2A, HIST3H2BB. HIST3H3. HIVEP2. HIVEP3. HK1. HK2, HLA.A. HLA.B, HLA.C, HLA.DMA, HLA.DOB, HLA.DQA2, HLA.DQB2, HLA.L, HLF, HLX, HMG20B, HMGA1, HMGB1, HMGB3, HMGB3P1, HMGCR, HMGCS1, HMGN1, HMGN2, HMOX2, HN1, HN1L, HNF4G, HNRNPAO, HNRNPA1, HNRNPA1L2, HNRNPA2B1, HNRNPA3, HNRNPA3P1, HNRNPAB, HNRNPC, HNRNPF. HNRNPH1, HNRNPH2. HNRNPK, HNRNPL, HNRNPR, HNRNPU, HNRNPUL2, HNRPDL, HOMER2, HOMER3, HOOK2, HOOK3, HP1BP3, HPCAL1, HPD, HPDL, HPGD, HPGDS, HPRT1, HPS3, HPS5, HPS6, HPSE, HPX, HPYR1, HR, HRAS, HRC, HRCT1, HRH3, HRNR, HS3ST1, HS3ST6. HS6ST1. HSBP1, HSD11B1L, HSD11B2, HSD17B10. HSD17B4, HSD3B1, HSD3B7, HSDL2, HSF1, HSF4, HSH2D, HSP90AB1, HSP90AB2P, HSP90B1, HSPA13, HSPA14, HSPA1B, HSPA2, HSPA4, HSPA4L, HSPA5, HSPA7, HSPA8, HSPA9, HSPB1, HSPB3, HSPB6, HSPB9, HSPBAP1, HSPD1, HSPH1, HTR1A, HTR3A, HTR7P1, HTRA1, HTRA2, htps: / / url.us.rn. mimecastprotect. com / s / 6szRCpYo5xSzEnw9tGc4Ys?domain=par.sn, HUS IB, HUWE1, HYAL1, HYOU1, HYPK, IAH1, IARS, IBA57, ICMT, ICOS, ICOSLG, ICT1, ID1, ID2, ID4, IDE, IDH2, IDI1, IDS, IER3, IER5, IFFO2, IFI27, IFI35, IFI44, IFI6, IFIH1, IFIT2, IFIT3, IFITM1, IFITM10, IFITM2. IFITM3, IFITM4P, IFNA1, IFNA10, IFNA13, IFNA14, IFNA16, IFNA2. IFNA21. IFNA22P, IFNA4. IFNA5, IFNA8, IFNAR2, IFNE, IFNG, IFNGR1, IFNGR2, IFNW1, IFRD2, IFT43, IGBP1P1, IGF2BP2, IGFBP2, IGFBP3, IGFBP6, IGFBP7, IGFL1, IGFL2. IGFL3, IGFL4, IGFN1, IGIP, IGJ, IGSF6, IGSF9. IK. IKBKB, IKZF2, IKZF3. IL10RB, IL13. IL17RA. IL17RB, IL18. IL18BP, IL18RAP, IL 19, ILIA, IL1R1, IL1RAP, IL1RL2, IL20RB, IL22, IL22RA1, IL24, IL28A, IL2RA, IL2RB, IL2RG, IL3, IL36G, IL4I1, IL4R, IL6R, IL9R, ILF2, ILF3, ILK, ILKAP, ILVBL, IMP4, IMPA2, IMPDH1, IMPDH2, INF2, INGX, INO80B, INO80E, INPP5A, INPP5B, INPP5D, INPP5K, INS, INSIG1, INSMI, INSM2, INSR, INTS1, INTS12, IP6K1, IPO4, IPO7, IPPK. IQCB1, IQCG, IQGAP1, IQGAP2, IQSEC3, IRAK2, IRF1, IRF2. IRF2BP1, IRF2BP2, IRF3, IRF4, IRF5, IRF6, IRF7, IRF9, IRS4, IRX3, ISCU, ISGL5, ISG20, ISG20L2, ISM2, IST1, ITCH, ITFG2, ITGA1, ITGA2, ITGA3, ITGA5, ITGA6, ITGA8, ITGAL, ITGAM, ITGAV, ITGB1, ITGB2, ITGB4, ITGB5, ITIH5, ITK, ITM2C, ITPA, ITPK1, ITPKC. ITPR2. ITPRIPL2. ITSN2, IVL. IVNS1ABP, IZUMO4, JAG2. JAK1, JAK2, JAK3, JARID2, JAZF1, JHDM1D, JMJD6, JMJD8, JMY, JOSD2, JRKL, JTB, JUN, JUND, KAAG1, KANK1, KANSL1.AS1, KAT2B, KAT5, KAT6A, KAT7, KATNBL1, KBTBD13, KBTBD2, KBTBD7, KCMF1, KCNA10, KCNA3, KCNAB2, KCNJ11, KCNJ15. KCNJ2, KCNJ2.AS1, KCNK1, KCNK7, KCNQ1, KCNQ1OT1, KCNQ3, KCTD10, KCTD11. KCTD12, KCTD17. KCTD3, KCTD5, KCTD6, KDELR2. KDM2A. KDM2B, KDM3A, KDM4B, KDM4C, KDM5A, KDM5B, KDM5D, KDM6B, KEAP1, KHDRBS1, KHSRP, KIAA0020, KIAA0146, KIAA0195, KIAA0226, KIAA0247, KIAA0284, KIAA0391, KIAA0556, KIAA0664, KIAA0754, KIAA0930, KIAA1109, KIAA1191, KIAA1199, KIAA1324, KIAA1383, KIAA1430, KIAA1432, KIAA1467.

[0116] KIAA1468, KIAA 1551, KIA Al 598, KIAA1737, KIAA1919, KIAA2013, KIFI3A, KIF13B, KIF19, KIF1B, KIF21A, KIF2B, KIF3C, KIF5B, KIFC3, KIR2DL4, KIR3DL2, KLC3, KLFIO, KLF11, KLF14, KLF2, KLF3, KLF4, KLF5, KLF6, KLF9, KLHDC2, KLHDC3, KLHDC9, KLHL14. KLHL18, KLHL26, KLHL28, KLHL9, KLK1, KLK11, KLK12. KLK14, KLK6, KLK7, KLK8, KLK9, KLLN, KLRK1, KPNA1, KPNA4, KPNA6, KPNA7, KPNB1, KRBOX1, KRR1, KRT13, KRT16P2, KRT19, KRT19P2, KRT25, KRT26, KRT27, KRT31, KRT33A, KRT33B, KRT34, KRT37, KRT38, KRT39, KRT4, KRT71, KRT72, KRT73, KRT74, KRT75, KRT77, KRT78, KRT8, KRT81, KRT83, KRT85, KRT86, KRT8P41. KRT9, KRTAP1.1, KRTAP1.3, KRTAP1.5, KRTAP10.1, KRTAP10.10, KRTAP1O.11, KRTAP10.12, KRTAP10.2, KRTAP10.4, KRTAP10.5, KRTAP10.6, KRTAP10.7, KRTAP11.1, KRTAP12.1, KRTAP12.3, KRTAP12.4, KRTAP13.1, KRTAP13.2, KRTAP13 3, KRTAP13.4, KRTAP15.1, KRTAP17.1, KRTAP19.1, KRTAP19.3. KRTAP19.4, KRTAP19.5, KRTAP19.6, KRTAP19.7, KRTAP19.8, KRTAP2.1, KRTAP2.2, KRTAP2.3, KRTAP2.4, KRTAP20.3, KRTAP21.2, KRTAP22.2, KRTAP23.1, KRTAP24.1, KRTAP25.1, KRTAP26.1, KRTAP27.I, KRTAP3.1. KRTAP3.2, KRTAP3.3, KRTAP4.1, KRTAP4.i l. KRTAP4.12, KRTAP4.3, KRTAP4.5, KRTAP4.6, KRTAP4.7, KRTAP4.9, KRTAP5.10, KRTAP5.i l, KRTAP5.3, KRTAP5.4, KRTAP5.5, KRTAP5.6, KRTAP5.7, KRTAP5.9, KRTAP6.2, KRTAP6.3, KRTAP7.1, KRTAP8.1, KRTAP9.1, KRTAP9.2, KRTAP9.3, KRTAP9.9, KTN1, KXD1, LAD1, LAGE3, LAMA3, LAMA5, LAMB2P1, LAMB3, LAMC2, LAMP2, LAMT0R3. LAMT0R4, LAMT0R5, LANCL2, LAPTM4A. LARP1, LASPI, LAT, LATS1. LAX1, LAYN. LBH, LCE1A. LCE1D, LCE3B, LCE3C, LCK, LCP2, LCTL, LDB1, LDHA, LDHAL6B, LDLR, LDLRAD4, LDLRAP1, LD0C1, LEF1, LEFTY 1, LENEP, LENG8, LENG9, LEO1, LEPROT, LETMD1, LFNG, LGALS1, LGALS2. LGALS3, LGALS3BP, LGALS4, LGALS7B, LGALSL, LGMN, LIF, LIG1, LILRA3, LILRB1, LILRB3, LIMA!. LIMD1, LIMD2, LIME1, LIMK2, LIMSI, LIN28A, LIN37, LINC00115, LINC00162, LINC00167, LINC00244, LINC00273, LINC00308, LINC00341, LINC00346, LINC00460, LINC00477, LINC00488, LINC00494, LINC00515, LINC00526, LINC00552, LINC00597, LINC00602, LINC00622, LINC00638, LINC00641, LIPA. LIPE, LIPH. LIPK, LIPM, LIPN, LITAF. LLPH. LMBR1L, LMF2, LMNA. LM01. LM07, LMTK2, LMTK3. LNX1.

[0117] LOC100093631, LOC100126784, LOC100128023, LOC100128292, LOC100128505, LOC100128573, LOC100129034, LOC100129794, LOC100129917, LOC100129961, LOC100130673, LOC100130992, LOC100131496, LOC100132247. LOC100132287. LOC100132356. LOC100132831. LOC100132832. LOC100133612. LOC100133957. LOG 100190940, LOC 100190986, LOC 100192204, LOC 10021 546, LOC 100240734, LGC100270746, LOC100271836, LOC100272217, LOC100286922, LOC100287042, LGC100288069, LOC100288432, LOC100288748, LOC100288778, LOC100288814. LOC100288846. LOC100289341. LOC100289361. LOC100289511. LOC100303749. LGC100335030, LOC100499194, LOC100499489, LGC100505540, LOC100505622, LOC100506123, LGC100506730, LGC100506994, LGC100507127, LOC100507206, LGC100507217, LGC100507299, LGC100507634, LGC100630918, LOC143666, LOC144742. LOC145474. LOC146880, LOC148696, LOC149086, LOC150185, LOC150197. LOC152217. LOC158376, LOC158696, LOC202781, LOC254100, LOC255512, LOC282997, LOC283070, LOC283299, LOC283663, LOC284023, LOC284578, LOC284648, LOC285359, LOC286367, LOC286437, LOC338758, LOC339807, LOC340113. LOC341056, LOC349196, LOC374443, LOC375196, LOC388499. LOC388553. LOC388796, LOC389332, LOC390705, LOC392364, LOC399815, LOC400027, LOC401010, LOC401074, LOC401321, LOC401397, LOC440434, LOC440461. LOC441454, LOC441455, LOC494127, LOC541471, LOC553103. LOC554206. LOC606724, LOC613038, LOC641515, LOC642361, LOC643387, LOC643955, LOC644172, LOC644189, LOC644649, LOC644656, LOC644936, LOC645166, LOC645638, LOC646329, LOC646471, LOC646862, LOC646903, LOC646999, LOC647012, LOC648987, LOC649395, LOC650293, LOC650623. LOC653653. LOC654342, LOC727849, LOC728024, LOC728554, LOC728643. LOC728752. LOC728819, LOC729020, LOC729080, LOC729121, LOC729176, LOC729737, LOC732275, LOC84931, LOC90246, LOC91450, L0NRF1, LPAR2, LPAR6, LPCAT1, LPCAT4, LPHN2, LPIN1, LPIN2, LPIN3, LPL, LPPR2, LRCH4, LRG1, LRIG3, LRMP, LRP1, LRP10, LRP4, LRP5, LRRC10, LRRC10B, LRRC15, LRRC30, LRRC37A4P, LRRC37A6P, LRRC45. LRRC47, LRRC59, LRRC6, LRRC73, LRRFIP1, LRRFIP2, LRRK1, LSM12, LSM3, LSM4, LSM7, LSP1P3, LSR, LST1, LTA, LTA4H, LTB, LTB4R2, LTBP4, LTBR, LTK, LUC7L, LUC7L3, LUM, LURAP1L, LY6D, LY6E, LY6G5B, LY6G6D, LY6G6E, LY6G6F, LY75, LY96, LYNX1, LYPD2, LYPD5, LYPD6B, LYPLA1, LYPLA2, LYSMD1, LYZL4. M6PR. MAB21L1, MAB21L2, MACF1, MAD2L2. MAEA, MAF. MAF1. MAFB, MAFG, MAFK. MAGEA5. MAGEA9B, MAGEB4, MAGEE 1, MAGEE2, MAGEF1, MAGEL2, MAGT1, MAL, MAL2, MALL, MALT1, MAN1A1, MAN1A2, MAN2A1, MAN2A2, MANBA, MANBAL, MANF, MANSC1, MAO A, MAP1LC3A. MAP1LC3B2, MAP1S, MAP2, MAP2K1, MAP2K2, MAP2K4, MAP2K7. MAP3K1, MAP3K11. MAP3K14, MAP3K6. MAP3K8, MAP3K9, MAP4, MAP4K1, MAP4K4, MAP7, MAP7D1, MAPK13, MAPK14, MAPK3, MAPK6, MAPK7, MAPK8IP3, MAPK9, MAPKAPK2, MAPKAPK3, MAPKBP1, MAPRE1, MAPT.IT1, MARCKS, MARCKSL1, MARCO, MARK2P9, MARK4, MARS, MARS2, MASI. MAST1, MAST2, MAST3, MAST4, MASTL, MAT2A, MATK. MATN2. MATR3, MAU2, MBD1, MBD2, MBD3L1, MBD6, MBNL2, MBOAT2, MBOAT7, MBP, MC1R, MC3R, MC4R, MC5R, MCC, MCL1, MCOLN1, MCOLN2, MCU, MDFI, MDGA1, MDH1, MDH2, MDK, MDM2, MDM4, MEI, MEA1, MECP2, MEDIO, MED12, MED13, MED13L, MED15, MED16. MED18, MED25, MED6, MED8. MEF2A, MEGF9, MEIS3P1, MEMO1, MEPCE, MERTK, MESDC2. MEST, METAP2. METRNL, METTL1, METTL3. METTL9, MEX3C, MFAP2, MFAP3L, MFAP4, MFN1, MFN2, MFNG, MFRP, MFSD1, MFSD10, MFSD11, MFSD3, MFSD6, MGAM, MGAT3, MGAT4A, MGAT4B, MGAT5, MGC12916, MGC16025, MGC16121, MGC16142, MGC2752, MGC3771, MGC39372, MGEA5. MGLL, MGRN1, MGST3, MICAL1, MICAL2, MICALCL, MIC ALLI. MID2, MIEN1, MIER1, MIER2, MINA, MINK1, MINPP1, MIPEP, MIR1307, MIR181D, MIR205HG, MIR31HG, MIR3907, MIR490, MIS18BP1, MITD1, MKL1, MKLN1, MKNK2, MKRN1, MKRN3, MKRN7P, MKRN9P, MLF1IP, MLF2, MLKL, MLL, MLL2. MLL4, MLL5, MLLT1, MLLT4, MLLT6, MLX, MMADHC, MMP1, MMP10, MMP13, MMP14, MMP19, MMP2, MMP25, MMP27, MMP7, MMRN2, MNDA, MOAP1, MOB1A, MOB1B, MOB3A, MOB3B, MOB4, MOCOS, MOCS3, MOGS, MORC2, MOS, MOSPD3, MOVIO, MPC1, MPC2, MPDU1, MPEG1, MPHOSPH6, MPLKIP, MPP7, MPPE1. MPRIP, MPV17, MPV17L, MPZL1. MPZL2, MPZL3, MRC1, MRC2, MREG. MRFAP1, MRGPRX4, MRI1, MRPL14, MRPL15, MRPL24, MRPL33, MRPL36, MRPL4, MRPL42P5, MRPL43, MRPL53, MRPL55, MRPS10, MRPS16, MRPS18B, MRPS18C, MRPS21, MRPS26, MS4A4A, MS4A6A, MSANTD3, MSC. MSGN1, MSH5, MSI1, MSL2, MSMO1, MSN, MSRB1, MST1, MST1P2, MST1R, MSTO1, MSTO2P. MSX2P1, MT1A, MT1DP, MT1E, MT1IP, MT1M, MT1X, MT2A, MT3, MT A3, MTCH2, MTDH, MTFP1, MTHFD2, MTHFR, MTHFS, MTMR1, MTMR10, MTMR11, MTMR14, MTMR3, MTMR9, MTPN, MTR, MTRF1L, MTRNR2L10, MTRNR2L3, MTRNR2L4, MTRNR2L7, MTRNR2L8, MTVR2, MTX1, MUC15, MUC2, MUC20, MUC4, MUCL1, MUL1, MVD, MVK, MVP. MX2, MXD4, MXI1, MY ADM, MYCBPAP. MYD88. MYH11. MYH14. MYH4, MYH6, MYH7B, MYH9, MYL12A, MYL12B, MYL9, MYOIO, MYO15B, MYO18A, MYO1B, MYOID, MYO1E, MYO1F, MYO1G, MYO5A, MYO5B, MYO7B, MYOF, MYZAP, MZB1, MZT2B, N4BP2L1, NAA20, NAA50, NAAA, NAB2, NABP1, NACAP1, NACC1, NACC2, NADK, NAGA. NAGK, NANOG, NANOGNB, NANOS1, NANOS2, NANS, NAP1L1 , NAP1L2, NAP1L4, NAPA, NAPRT1, NARF, NASP, NAT8B, NAT9, NBEAL1, NBEAL2, NBN, NBPF10, NBPF14, NBR1, NCF1, NCF1B, NCF2, NCF4, NCK1, NCKAP1, NCKAP1L, NCL, NCOA1, NCOA2, NCOA3. NCOA7, NCOR2, NCR3LG1, NCSTN. NDEE NDFIPE NDFIP2. NDN, NDNL2, NDRG1, NDST1. NDST2, NDUFA11, NDUFA13, NDUFA3, NDUFA4, NDUFA4L2, NDUFA6, NDUFA9, NDUFAF3, NDUFAF4P1, NDUFB1, NDUFB10, NDUFB11, NDUFB2, NDUFB4, NDUFB5, NDUFB7, NDUFB9, NDUFS2, NDUFS3, NDUFS5, NDUFS6, NDUFS8, NDUFV1, NDUFV2, NEC API, NEC AP2, NEDD4, NEDD4L, NEDD8, NEFM. NEIL3, NEK11, NEK7, NELF, NEMF, NET1, NEU1, NEU2, NEU3, NEURL3, NEURL4, NF AMI, NFAT5, NFATC2IP, NFE2L2, NFE2L3, NFIC, NFIX, NFKB1, NFKB2, NFKBIB, NFKBID, NFKBIE, NGFRAP1, NGLY1, NGRN, NHLRC1, NHP2, NHP2L1, NICN1, NINJ1, NINJ2. NIPAL1, NIPAL2, NIPAL4, NIT2, NKG7, NKPD1, NKX2.6, NLK, NLRC3, NLRC5, NLRPE NLRP10, NLRP3, NLRX1, NME3, NMRAL1, NOL12, NOL6, NOLC1, NOPIO, NOSIP, NOTCH1, NOTCH2NL, NOTCH3, NPC1, NPC2, NPEPPS, NPL0C4, NPM1, NPM3, NPPA, NPR1, NPR2, NPRL2, NQ02, NR1D1, NR1H2, NR1H3, NR2C2AP, NR3C1, NR4A1, NRADDP, NRARP, NRAS, NRBF2. NRBP1, NRBP2, NRD1, NREP, NRIP1, NRP2, NSF, NSFL1C, NSFP1, NSG1, NSMAF, NSUN2, NSUN5, NT5C, NTAN1, NUAK1, NUAK2, NUB1, NUCKS1, NUDCD2, NUDT3, NUDT4, NUDT5, NUDT9P1, NUMA1, NUP50, NUP54, NUP93, NUP98, NUPL1, NUPL2, NUS1, NUTF2, NXF1, NXF5, OAF, OAS3, OAZ1, OBP2A, OCLN, ODC1, ODF3B, ODF4, OGDH, OGFR, OGFRL1, OGT, OLFM1, OLFML2A, OLIG3, OPTN, OR10A2. OR10A3, OR10A4, OR10A5, OR10A7, OR10AD1, OR10C1, OR10G2, OR10G3, OR10G4, OR10G7, OR10G8, OR10G9, OR10H1, OR10H2, OR10H3, OR10J1, OR10J3, OR10J5, OR10K1, OR10K2, OR10P1, OR10Q1, OR10R2, OR10S1, OR10T2, OR10V1, OR10W1, OR10X1, OR10Z1, OR11A1, OR11G2, OR11H2, OR11H4, OR12D2, OR12D3, OR13C3. OR13C4, OR13C5, OR13C8, OR13C9, OR13D1, OR13F1, OR13H1, OR13J1, OR14A16, OR14C36, OR14I1, OR14J1, OR1A1, OR1A2, OR1C1, OR1D2, OR1D4, OR1D5, OR1E2, OR1G1, OR1I1, OR1J1. OR1J2, OR1J4, OR1K1, OR1L1, OR1L4, OR1L6, OR1L8, 0R1M1, OR1N1, OR1N2, OR1Q1, OR1S1, OR1S2, OR2A1, OR2A12. OR2A14, OR2A2. OR2A20P. OR2A25, OR2A4. OR2A42, OR2A5. OR2AE1, OR2AG1. OR2AG2, OR2AK2. OR2AT4, OR2B11, OR2B2, OR2B3, OR2B6, OR2C1, OR2D2, OR2D3, OR2F1, OR2G3, OR2G6, OR2H2, OR2J2, OR2J3, OR2K2, OR2L1P, OR2L2, OR2L3, OR2M1P, OR2M2, OR2M3, OR2M4, OR2M5, OR2M7, OR2S2, OR2T1, OR2T10, OR2T12, OR2T2, OR2T35, OR2T6, OR2V2, OR2W3, OR2W5, OR2YE OR2Z1, OR3A1, OR3A2. OR3A4P, OR4A47, OR4A5, OR4B1, OR4C12, OR4C13, OR4C15, OR4C16, OR4C6, OR4D1, OR4D10, OR4D11, OR4D2, OR4D5, OR4D6, OR4D9, OR4E2, OR4F15, OR4F17, OR4F5, OR4F6, OR4K1, OR4K13, OR4K14, OR4K15, OR4K5, OR4L1, 0R4M1, OR4M2, OR4N2, OR4N3P, OR4N4, OR4N5, OR4P4, OR4S1, OR4X2, OR51A2. OR51A4, OR51B2, OR51B4, OR51B6, OR51D1, OR51F1, OR51G1, OR51G2, OR51I1, OR51I2, OR51L1, 0R51M1, OR51Q1, OR51S1, OR51T1, OR51V1, OR52A1, OR52A5, OR52B2, OR52B4, OR52D1, OR52E2, OR52E4, OR52E6, OR52H1, OR52I1, OR52J3, OR52K1, OR52K2, OR52L1, OR52M1, OR52N1, OR52N2. OR52N4, OR52N5, OR52R1, OR52W1, OR56A1, OR56A3. OR56A4, OR56A5, OR56B1, OR56B4. OR5A1, OR5A2, OR5AK2. OR5AK4P, OR5AN1. OR5AP2, OR5AR1, OR5AS1, OR5AU1, OR5B12, OR5B17, OR5B2, OR5B21, OR5C1, OR5D13, OR5D16, OR5D18, OR5E1P, OR5F1, OR5H1, OR5H14, OR5H15, OR5H2, OR5I1, OR5J2, OR5K1, OR5K2, OR5K4, OR5L1, OR5L2, 0R5M1, OR5M10, 0R5M11, OR5M3, OR5M8, OR5M9, OR5P2. OR5P3, OR5R1. OR5T2, OR5W2, OR6A2, OR6B1, OR6B2, OR6B3, OR6C1, OR6C3, OR6C4, OR6C65, OR6C68, OR6C70, OR6C74, OR6C75, OR6C76, 0R6F1, OR6K2, OR6K3. OR6K6, 0R6M1, 0R6N1, OR6N2, 0R6P1, 0R6Q1, 0R6T1. 0R6V1, 0R6W1P, 0R6Y1. OR7A10, OR7A17, OR7A5, 0R7C1. OR7C2, OR7D4, OR7E37P, 0R7G1, OR7G2, OR7G3, 0R8A1, OR8B12, OR8B2, OR8B8, 0R8D1, 0R8G1, OR8G2, OR8G5, 0R8H1, OR8H2, OR8I2, 0R8J1, OR8K3, 0R8U1, OR9A2, 0R9G1, 0R9I1, OR9K2, 0RM1, ORMDL2, OS9, OSBP2, OSBPL1A, OSBPL2, OSBPL3, OSBPL8, OSBPL9, OSM, OSMR, OSTC, OTUB1. OTUB2, OTUD1, OTUD5, OTUD6A, OVCH2. OVGP1, OVOL1, OVOL2, OXCT2, 0XR1, P2RX4, P2RX6. P2RX7, P2RY1. P2RY10, P2RY13, P2RY2, P2RY4, P4HA1, P4HB, PA2G4, PABPC3, PABPN1, PACSIN2, PADI1, PADI3, PAF1, PAFAH1B1, PAFAH1B2, PAFAH1B3, PAG1, PAIP1, PAIP2, PAK1, PAK2, PAK4, PALMD, PANK3, PAOX, PAPL, PAPOLA. PAPOLB, PAQR5, PAQR7, PAQR9, PARI, PAR4. PARD3, PARD6B, PARD6G. PARM1. PARN. PARP10, PARP12, PARP14, PARP4, PARP6, PARP8, PARP9, PARVB, PARVG, PAWR, PBX2, PBX3, PCBP1, PCDH1, PCDHB1, PCDHB10, PCDHB11, PCDHB12, PCDHB13, PCDHB15, PCDHB16, PCDHB17, PCDHB18, PCDHB2, PCDHB3, PCDHB4, PCDHB5, PCDHB8, PCDHB9. PCDHGB8P, PCF11, PCGF3. PCGF6, PCIF1, PCK1, PCMTD2, PCNA. PCNAP1, PCNP, PCNXL3. PCNXL4, PCP4L1, PCSK6. PCSK7, PDCD4, PDCD6. PDE1B, PDE4B, PDGFRA, PDGFRB, PDHA2, PDHX, PDIA2, PDIA3, PDIA3P, PDIA4, PDIA6, PDK2, PDK4, PDLIM2, PDLIM4, PDLIM5, PDLIM7, PDPK1, PDS5A, PDSS1, PDXK. PDZD2, PDZK1IP1, PEA15, PEBP1, PECAM1, PEF1, PEG10, PELI1, PELP1, PEPD, PERI, PER4. PERP, PEX10, PEX13, PEX5, PFDN5, PFKFB2. PFKFB3, PFKL. PFKP, PFN1P2, PFN3, PGA4, PGAM1, PGAM4, PGAP3, PGBD4, PGF, PGK1, PGK2, PGLS, PGLYRP2, PGLYRP3, PGLYRP4, PGM3, PGRMC1, PGRMC2, PGS1, PHB, PHC1, PHC3, PHF10, PHF12, PHF19, PHF20L1, PHF23, PHF5A, PHGDH, PHKG2, PHLDA1, PHLDA2, PHLDB3. PHOSPHO1, PHPT1, PHTF2. PI15, PI4K2A. PI4KA, PI4KAP1. PI4KAP2, PIAS1, PIAS3, PIC ALM, PIEZO 1, PIEZO2, PIGC, PIGH, PIGM, PIGT, PIGV, PIH1D1, PIK3AP1, PIK3C2B, PIK3CB, PIK3CD, PIK3R1, PIK3R2, PIK3R5, PIKFYVE, PILRB, PIM1, PIM2, PIM3, PIN1P1, PINK1, PINLYP, PION, PIP4K2C, PIP5K1A, PIP5K1C, PIP5K1P1, PIPSL, PISRT1, PITPNA, PJA2. PKD1, PKD1P1, PKDREJ, PKLR, PKN1. PKN3, PKP3, PLA2G12A, PLA2G2F, PLA2G3, PLA2G4B, PLA2G4D. PLA2G4E. PLA2G4F, PLA2G7, PLA2R1, PLAT, PL AU, PLB1, PLBD1, PLCB2, PLCD1, PLCD3, PLCG1, PLCH2, PLCXD1, PLD2, PLD3, PLEC, PLEKHA2, PLEKHA3, PLEKHA5, PLEKHA6, PLEKHA8, PLEKHB2, PLEKHF2, PLEKHG1, PLEKHG4B, PLEKHM1, PLEKHM3, PLEKHN1, PLEKHO2, PLEKHS1, PLIN2, PLK2, PLK3. PLLP, PLP2, PLS3, PLSCR1, PLSCR3, PLTP, PLVAP, PLXNA1, PLXNA3, PLXNA4, PLXNB2, PLXNC1, PLXND1, PM20D1, PMAIP1. PMCHL1, PMEL, PMEPA1, PML, PMM1, PMP22, PMS2P1, PMS2P3, PMS2P5, PMVK. PNKD, PNKP. PNMAL2, PNN, PNPLA1, PNPLA2, PNPLA3, PNPLA6, PNPLA7, PNRC2, PODXL, POGLUTL POGZ, POLD4, POLDIP2, POLDIP3, POLG, POLR2A, POLR2B, POLR2E, POLR2F, POLR2G, POLR2J, POLR2J3, POLR2L, POLR3E, P0M121, POM121C, POM121L2, POM121L4P, POMZP3, POR, POU2F3, POU3F1, POU3F2, POU3F3, POU3F4. POU5F1B, POU5F1P3, POU5F1P4, POU5F2, PP12613, PPAE PPA2, PPAN, PPAP2B. PPAP2C, PPAPDC2, PPARG, PPARGC1B, PPCS, PPDPF, PPFIA1, PPFIA3, PPFIA4, PPFIBP1, PPFIBP2, PPIA, PPIAL4A, PPIAL4C, PPIAL4E, PPIAL4F, PPIB, PPL, PPM1A, PPM IF, PPM IM, PPP1CA, PPP1CC. PPP1R10, PPP1R11, PPP1R12C, PPP1R13B, PPP1R13L, PPP1R14A. PPP1R14B, PPP1R14C, PPP1R18. PPP1R2P3, PPP1R2P9, PPP1R3E, PPP1R9B, PPP2CA, PPP2R1A, PPP2R2A, PPP2R3B, PPP3R1, PPP3R2, PPP4C, PPP4R1, PPP4R2, PPP6R1, PPP6R3, PPT1, PPT2, PPTC7, PQLC1, PQLC2, PRCP, PRDM1, PRDM8, PRDX2, PRDX3, PRDX5, PRDX6, PRELID1, PRELP, PREP, PREXI, PRF1, PRG1, PRICKLE2, PRKAR1A, PRKCA, PRKCB, PRKCD, PRKCH, PRKCI. PRKCSH, PRKD2, PRKD3, PRKRA, PRKRIR, PRKX, PRM1, PRM3, PRODH, PROM2, PRORSD1P, PROS1. PRPF19. PRPF38B, PRPF39, PRPF40A, PRPF8, PRR13, PRR14, PRR14L, PRR18, PRR19, PRR23A, PRR23B, PRR24, PRR9, PRRC1, PRRC2A, PRSS22, PRSS27, PRSS3, PSAPL1, PSAT1, PSCA, PSEN1, PSENEN, PSIMCT. l, PSMA1, PSMA4. PSMA6, PSMA7, PSMB1, PSMB10, PSMB3. PSMB7, PSMB8, PSMB9, PSMC2. PSMC3, PSMC4, PSMC5, PSMC6. PSMD1 1, PSMD14, PSMD2, PSMD3, PSMD4, PSMD6, PSMD7, PSMD8, PSME1 , PSME2, PSME3, PSME4, PSMF1, PSMG3, PSORS1C2, PSPN, PSTPIP1, PTBP3, PTENP1, PTGER3, PTGER4, PTGES2, PTGES3, PTK6, PTK7, PTOV1, PTP4A1, PTP4A2, PTP4A3, PTPLB, PTPN1, PTPN11. PTPN13. PTPN2, PTPN22, PTPN3. PTPN5, PTPN6. PTPN7, PTPRC, PTPRE, PTPRJ, PTRF, PTRH1, PTRHD 1, PTTG1, PTTG1IP, PTTG2, PTTG3P, PURB, PVRL1, PVRL4, PXDC 1, PXK, PXMP4, PXN, PYCARD, PYGO2, QARS, QPCT, QPCTL, QPRT, QRFP, QRICH1, QSOX1, QTRT1, R3HCC1L, R3HDM1, R3HDM4, RAB11A, RAB11FIP5, RAB12. RAB I 3. RAB14, RAB18, RAB1B, RAB21, RAB23, RAB25, RAB26. RAB27B, RAB30. RAB34, RAB35, RAB38. RAB3B, RAB3D, RAB3GAP1, RAB40C, RAB43, RAB4B, RAB5A, RAB5B, RAB5C, RAB6A, RAB6C, RAB7A, RAB7L1, RAB8B, RAB9BP1, RABAC1, RABEP2, RABGEF1, RABGGTA, RABIF, RABL2A, RABL6, RAC1, RAC2, RACGAP1P, RAD17, RAD21, RAD23A, RAD23B, RAE1, RAET1E, RALB, RALBP1, RALGAPA1, RALGAPA2. RALGAPB, RALGDS, RALY, RAN, RANBP1, RANBP2, RANBP3, RANBP9, RANGAP1, RAP1A, RAP1B, RAP1GAP, RAP2B, RAP2C, RAPGEF3, RAPGEF4, RAPGEF5, RAPGEFL1, RAPH1, RARG, RARRES1, RARRES2, RARS, RARS2, RASA4, RASA4CP, RASAL1, RASAL3, RASGEF1B, RASGRP1, RASGRP4, RASL11A, RASSF2, RASSF3, RASSF4, RASSF5, RASSF7, RAVER1, RBI, RB1CC1, RBBP4, RBCK1, RBF0X2, RBM10, RBM12B.AS1, RBM15B, RBM17, RBM23, RBM25, RBM3, RBM39, RBM4, RBM6, RBM8A, RBMS1, RBMS2, RBMX, RBMX2, RBPE RBPJ, RBPMS2, RBX1, RC3H1, RCAN3. RCC2, RCN1, RDBP, RDH1O, RDH12. RDH13, RDH5, RDH8, RDX. REC8. RECQL4, REEP4, REEP5, REG1P, REL, RELA, RELB, RELT, REP15, REPSI, REPS2, RER1, REST, REXO1L1, REXO2, RFC1, RFESD, RFK, RFNG, RFPL3, RFTN1, RFWD2, RGL2, RGP1, RGPD1, RGPD3, RGPD8, RGS1O, RGS18, RGS2, RHBDD2, RHBDD3. RHBDF1, RHBDF2. RHCG, RHEB, RHOA, RHOB. RHOC, RHOD, RHOF, RHOH, RHOQ, RHOV, RHPN1.AS1, RIBCL RIMBP3B, RIMBP3C, RIMKLB, RIMS3, RINL RIN2, RIN3, RING1, RIPK1, RIPK2, RIPK4, RIT1, RLTPR, RMND5B, RNASE1, RNASE12, RNASE6, RNASE7, RNASE8, RNASEH2C, RNASEK, RNASET2, RND3, RNF103. RNF11, RNF113A, RNF114, RNF122, RNF125, RNF126P1, RNF130, RNF141, RNF144B. RNF149. RNF167. RNF169. RNF181, RNF186, RNF187, RNF19B. RNF20, RNF207, RNF213, RNF26, RNF31, RNF39, RNF4, RNF40, RNF5, RNF6, RNF7, RNHL RNMT, RNPEP, RNPEPL1, RNPS1, RNU12, ROBO3, ROCK1, R0M01, RORC, RP2, RPA2, RPA4, RPE, RPIA, RPL10, RPL10A, RPL10L, RPL12. RPL13, RPL13A, RPL13AP20, RPL13AP3, RPL13AP6, RPL13P5. RPL19, RPL23A, RPL23AP64, RPL23P8, RPL24, RPL26L1, RPL31P11, RPL36A, RPL36AL, RPL39, RPL5, RPL6, RPL7L1, RPL8, RPL9, RPLP0P2, RPP21, RPRM, RPRML, RPS15A, RPS15AP1O, RPS18, RPS19BP1, RPS2, RPS20, RPS21, RPS25, RPS26, RPS26P11, RPS27, RPS27A, RPS3A, RPS4Y1, RPS5, RPS6KA1, RPS6KA2, RPS6KA3, RPS6KA4, RPS6KB2, RPS6KCL RPS9, RPSAP58, RPTN, RRAGA, RRAGC, RRAS2, RRBP1, RREB1, RRM2, RRN3P2, RRPL RRP12, RRP7A, RRP7B, RRS1, RSAD2, RSC1A1, RSL24D1, RSU1, RTCA, RTEL1, RTFDC1, RTN4, RUFY1, RUFY3, RUFY4, RUNX3, RUSC2, RUVBL2, RXFP3, RXFP4, RXRA, RYBP, RYK, RYR1, RYR3, S1OOA1O, S1OOA11, S100A14, S100A16, S100A4, S100A6. S100A7, S1OOB. S1PR4. SAAL SAFB. SAMDL SAMD3. SAMD8. SAMD9. SAP130, SAP18, SAP25, SAP30, SAP3OBP, SAPCDL SAR1A, SARNP, SARS, SASHL SAT1, SAT2, SBDS, SBF1, SBK1, SBNO1, SBNO2, SCAF1, SCAF4, SCAMP3, SCAMP4, SCAP, SCARF1, SCARNA10, SCARNA12, SCARNA13, SCARNA14, SCARNA15, SCARNA16. SCARNA18, SCARNA2, SCARNA3, SCARNA5, SCARNA6, SCARNA9, SCCPDH, SCD, SCEL, SCGB2A2, SCGB2B2, SCIMP, SCN3B, SCNM1, SCNN1A, SCNN1B, SCP2. SCP2D1, SCYL2, SCYL3, SDAD1, SDC4, SDC4P, SDCBP, SDCBP2, SDE2, SDF2, SDF4. SDHA. SDHC, SDHD, SDR16C5, SDR42E1, SDR9C7, SEC11A, SEC11C, SEC14L1P1, SEC16A, SEC22B, SEC23A, SEC23B, SEC24A, SEC24C, SEC31A, SEC61A1, SEC61B, SEC61G, SEC63, SECISBP2L, SECTM1, SEL1L, SEL1L3, SELK, SELL, SELPLG, SELT, SEMA3C, SEMA3F, SEMA4A, SEMA4B, SEMA4C, SEMA4D, SEMA4G, SEMA6B, SEMA7A, SEPHS2, SEPPI, SERBP1, SERINC2, SERINC3, SERINC5. SERP1, SERPINA12, SERPINA3, SERPINA9. SERPINB12. SERPINB13, SERPINB2, SERPINB5, SERPINB6, SERPINB7, SERPINB8, SERPINB9, SERPINE1, SERPINF1, SERTAD1, SERTAD2, SESN3, SET, SETD1B, SETD4, SETD7, SETX, SF1, SF3A1, SF3A2, SF3A3, SF3B1, SF3B3, SF3B5, SFI1, SFMBT2, SFN, SFR1, SFSWAP, SFT2D2. SFTPA1, SFXN3, SGK223. SGMS1, SG0L2, SGPL1, SGPP1, SGPP2, SGSM3, SGT A, SGTB, SH2B2, SH2D3A, SH2D4A, SH3BGRL, SH3BGRL2, SH3BP1, SH3BP5L, SH3D19, SH3D21, SH3GL1, SH3GL1P2, SH3GL3, SH3GLB2, SH3PXD2A, SH3RF2, SH3RF3.AS1, SH3TC1, SH3YL1, SHB, SHBG, SHC1, SHFM1, SHISA5, SHKBP1, SHMT2, SH0C2, SHPK, SHR00M3, SIAH2, SIDT2, SIGLEC16, SIGLEC5. SIK1, SIN3A, SIN3B. SIPA1, SIPA1L1. SIRPA. SIRPBL SIRT6. SIRT7. SIT1, SKA2, SKAP2. SKP1, SLA, SLA2, SLAIN2, SLAMF1, SLAMF6, SLAMF7, SLAMF8, SLC10A5, SLC10A6, SLC11A2, SLC12A6, SLC12A7, SLC12A9, SLC15A1, SLC15A4, SLC16A1, SLC16A10, SLC16A6, SLC17A3, SLC17A5, SLC18A3, SLC19A2, SLC1A1, SLC1A6, SLC20A2, SLC22A3, SLC22A31, SLC22A7, SLC25A11, SLC25A2, SLC25A23. SLC25A25, SLC25A29, SLC25A3, SLC25A30, SLC25A33, SLC25A37, SLC25A38, SLC25A39, SLC25A44, SLC25A5, SLC25A51P1, SLC25A52, SLC26A4, SLC26A6, SLC26A9, SLC27A5, SLC28A3, SLC2A14, SLC2A4RG, SLC30A1, SLC31A1, SLC34A3, SLC35A5. SLC35B1, SLC35E1, SLC35E4, SLC35F3, SLC35F5, SLC35G3, SLC35G5, SLC36A4, SLC37A2, SLC38A1, SLC38A2, SLC38A3, SLC39A14, SLC39A4, SLC39A7, SLC39A8, SLC3A2, SLC40A1, SLC41A1, SLC41A2, SLC44A1, SLC44A4, SLC44A5, SLC45A4, SLC46A2, SLC4A1, SLC4A11, SLC4A2, SLC4A7, SLC50A1, SLC52A2, SLC5A1, SLC5A2, SLC6A1 L SLC6A14, SLC6A19, SLC6A20, SLC6A6, SLC6A8. SLC7A1, SLC7A11. SLC7A5. SLC7A5P1, SLC7A5P2, SLC7A7, SLC7A8, SLC9A3R1, SLC9A7, SLC9A8, SLC02A1, SLC03A1, SLC04C1, SLFN5, SLIRP, SLITRK1, SLK, SLM02, SLPI, SLTM, SLU7, SLURP1, SMA5, SMAD2, SMAD3, SMAD5, SMAD7, SMAGP, SMARCB1, SMARCD2, SMARCE1, SMC3, SMC5, SMCR5, SMEK1, SMEK3P, SMG1P1, SMG5. SMG6. SMG7, SMIM3. SMIM4, SMIM5, SMIM7. SMNDCL SM0C2. SMOX, SMPD1, SMPD3, SMS, SMTN, SMU1, SNAP23, SNAP29, SNAPCI, SNAPC2, SNAPIN, SNCG, SND1, SNF8, SNHG12, SNHG4, SNHG5, SNHG6, SNHG9, SN0RA1, SNORAIO, SNORA12, SNORA14A, SNORA14B, SNORA16A, SNORA24, SNORA27, SNORA28, SNORA2A, SNORA30, SNORA31, SNORA34, SNORA36A, SNORA36C, SNORA38, SNORA39, SNORA41, SNORA42, SNORA43, SNORA46, SNORA47, SNORA48, SNORA49, SNORA50, SNORA52, SNORA55, SNORA57, SNORA58, SNORA5A, SNORA5C, SNORA6. SNORA62, SNORA64, SNORA65. SNORA66, SNORA67, SNORA68, SNORA70, SNORA70D. SNORA70E. SNORA70F. SNORA70G. SNORA71A, SNORA71B, SNORA71C, SNORA71D, SNORA74A, SNORA74B, SNORA75, SNORA77, SNORA79, SNORA7B, SNORA81, SNORA84, SNORA9, SNORD15A, SNORD17, SNORD94, SNRNP200, SNRNP40. SNRNP48, SNRNP70, SNRPA1, SNRPB, SNRPD2, SNRPD2P2, SNRPD3, SNRPE, SNRPF, SNRPG, SNTA1, SNTB1, SNX1, SNX13. SNX21, SNX25, SNX27, SNX29, SNX3, SNX32, SNX4, SNX6, SNX8, SNX9, SOAT1, SOCS2, SOD1, SOLH, SON, SORD, SORL1, SORT1, SOWAHB, SOWAHC, SOX12, SOX14, SOX2, SOX21, SOX3, SOX7, SOX9, SP1, SP140L, SP2, SPACA4, SPAG1, SPAG7, SPAG8, SPAG9. SPATA13. SPATA20, SPATA31C2, SPCS2. SPDYC, SPDYE7P, SPG11, SPG21, SPHAR. SPHK1, SPI1. SPIC. SPIN4, SPINK5, SPINK6, SPINK7, SPINT1, SPINT2, SPIRE1, SPNS2, SPOCD1, SPP1, SPPL2A, SPRED2, SPRR2C, SPRR2G, SPRY2, SPSB1, SPTAN1, SPTBN2, SPTLC1, SPTLC2, SPTLC3, SPTSSA, SPTY2D1, SPZ1, SRA1, SRBD1, SRC, SRCIN1, SREBF2, SREK1, SREK1IP1, SRF, SRP14, SRP72, SRP9, SRPK1, SRPR, SRRME SRRM5. SRSF1, SRSF11, SRSF2, SRSF3. SRSF4, SRSF5, SRSF6, SRSF7, SRSF8, SRSF9, SSBP3, SSBP4, SSFA2, SSH1, SSH2, SSNA1 , SSR1 , SSR2, SSR3, SSR4, SSR4P1, SSU72, SSX3, SSX6, SSX7, STI 3. STH. ST20, ST3GAL2, ST3GAL4, STAB1, STAM2, STAP2, STARD10, STARD3, STARD3NL, STARD5, STARD8, STAT1, STAT2, STAT5B, STAT6, STC1. STC2, STEAP3, STEAP4, STH, STIP1, STK10, STK17B, STK24, STK25, STK38L, STK4, STK40, STMN3, STRADB, STRAP, STRN, STRN3, STX11, STX16, STX1B, STX4, STX5, STX6, STX7, STX8, STXBP2, STXBP6, SUB1, SUCLG1, SUCO, SUDS3, SUGT1, SULF2, SULT1A2, SULT2B1, SUMF2, SUMO1P1, SUMO1P3, SUMO2, SUMO4, SUN1, SUPT4H1, SUPT5H, SUPT6H, SURF1, SURF4. SUSD2, SVIL. SWAP70, SYAP1. SYCE1, SYF2, SYMPK, SYNCRIP, SYNGAP1.

[0118] SYNGR2, SYPL1, SYT11, SYT5, SYT7, SYT8, SYTL1, SYTL3, SZRD1, SZT2, TAAR1, TAAR3, TAAR5, TAAR6, TAAR9, TAB2, TAB3, TAC1, TACC2, TACSTD2, TADA2B, TAF10, TAF13, TAF1C, TAF1L, TAF7, TAGAP, TAGLN, TAGLN2. TALDO1, TANCI, TAOK1, TAOK3, TARDBP, TARP, TARS, TAS1R3, TAS2R1, TAS2R13, TAS2R14, TAS2R16, TAS2R19, TAS2R20, TAS2R3, TAS2R38, TAS2R39, TAS2R4, TAS2R40, TAS2R43, TAS2R50, TAS2R60, TAS2R7, TAS2R8, TAS2R9, TATDN1, TAX1BP3, TBC1D1, TBC1D10B, TBC1D14, TBC1D17, TBC1D20, TBC1D22B. TBC1D23, TBC1D24, TBC1D25, TBC1D30, TBC1D5, TBC1D9, TBC1D9B, TBCA, TBRG1, TBX20, TBX6, TBXAS1, TCEA1, TCEA2, TCEAL4, TCEB1, TCEB2, TCEB3CL, TCF25, TCHH, TCHHL1, TCIRG1, TCN1, TCN2, TCP1, TCP11, TCP11L2, TCTEX1D4, TDG, TDGF1P3, TDP2, TDRD9, TEAD1, TEAD3, TECPR2, TECR, TEDDM1. TEN1, TENM2, TES, TESC, TESPA1, TET2. TEX101. TEX2, TEX264. TFAP2C. TFAP4, TFDP1. TFE3, TFPI. TFRC, TGFA, TGFB2, TGFBI, TGFBR1, TGM1, TGM3, TGM5, THAP11, THAP9.AS1, THBD, THBS1, THEM4, THEM5, THOC2, THOC3, THOC5, THOC6, THOP1, THRAP3, THRB, THTPA, THY1, TIAF1, TIAM1, TIAM2, TIE1, TIGD1, TIGD2, TIGD5, TIGIT, TIMM10, TIMM 17 A, TIMMDC1, TIMP1, TIMP2, TIMP3. TINF2, TIP ARP, TJAP1, TJP2, TK2, TKT, TKTL1, TLE3, TLE4, TLK2, TLN1, TLR4, TM4SF1, TM4SF19, TM6SF2, TM7SF2, TM9SF2, TM9SF3, TM9SF4, TMA7, TMBIM4, TMC5, TMC6, TMC8, TMCO1, TMCO3, TMED2, TMED3, TMED5, TMED9, TMEM102, TMEM106A, TMEM106B, TMEM106C, TMEM110, TMEM114, TMEM115, TMEM123, TMEM127, TMEM131, TMEM132A. TMEM133, TMEM134. TMEM141, TMEM147. TMEM14C, TMEM14E. TMEM154, TMEM158, TMEM165, TMEM167A, TMEM167B, TMEM183A, TMEM184A, TMEM184B, TMEM185A, TMEM185B, TMEM189, TMEM2, TMEM200C, TMEM203, TMEM205, TMEM214, TMEM229A, TMEM237, TMEM246. TMEM251, TMEM30B, TMEM33, TMEM38A, TMEM39A, TMEM40. TMEM41A, TMEM41B, TMEM45A, TMEM45B, TMEM52, TMEM54, TMEM55A, TMEM57, TMEM59, TMEM63B, TMEM65, TMEM66, TMEM79, TMEM86A, TMEM98, TMEM99, TMEM9B, TMOD3, TMOD4, TMPRSS11E, TMPRSS13, TMPRSS4, TMTC3, TMX1, TMX2, TNC, TNFAIP1, TNFAIP2, TNFAIP3, TNFAIP6, TNFAIP8, TNFAIP8L3, TNFRSFIOC, TNFRSF1OD, TNFRSF14, TNFRSF18, TNFRSF19, TNFRSF1A, TNFRSF4, TNFRSF6B, TNFSF1O, TNFSF11, TNFSF12, TNFSF13B, TNFSF8, TNKS1BP1, TNKS2, TNNC1, TNNC2, TNNI2, TNNT2, TNS4, TOB2P1, TOLLIP, TOMI, TOM1L1, TOM1L2, TOMM20, TOMM22, TOMM34, TOMM40, TOMM6. TOMM7, TOPI. TOP1P1, TOP1P2, TOP2A, TOP2B, TOPORS. TOR1AIP2, TOR3A, TOX. TOX4, TP53, TP53BP2. TP53INP2. TPBGL, TPD52L3, TPI1, TPM3, TPM4, TPP1, TPP2, TPPP3, TPR, TPRA1, TPRG1, TPRG1L, TPSB2, TPX2, TRA2B, TRABD, TRAF3, TRAF3IP2, TRAF4, TRAFD1, TRAK1, TRAK2, TRAM1, TRAM1L1, TRANK1. TRAPPC10, TRAPPC2L, TRAPPC3, TRAPPC5, TRAPPC6A. TRAPPC6B. TRAPPC8, TREM1. TREM2. TREML2, TREML3P. TREML5P, TREX1, TRIBI, TRIB3, TRIL, TRIM15, TRIM16, TRIM16L, TRIM25, TRIM28, TRIM29, TRIM33, TRIM39, TRIM54, TRIM62, TRIM65, TRIM69, TRIM73, TRIM8, TRIO, TRIP10, TRIP12, TRIP13. TRMT112, TRMT12, TRMT2A, TRMT6, TRPM2, TRPS1, TRPV2, TRPV3, TRUB2, TSC22D1, TSC22D4, TSEN34, TSN, TSNARE1, TSPAN2, TSPAN3, TSPAN31, TSPAN32, TSPAN5, TSPO, TSPY1, TSPY2, TSPY26P, TSPY3, TSPYL1, TSPYL4, TSPYL5, TSPYL6, TSR3, TSTA3, TSTD1, TTBK1, TTC1, TTC30A, TTC30B, TTC39A, TTC39B, TTC3P1, TTC4, TTC9, TTLL12, TTYH2. TUBA1A, TUBA1B, TUBA4A, TUBB, TUBB4A. TUBB6. TUBG1, TUBG2, TUBGCP2. TUBGCP5, TUBGCP6, TUFM, TUFT1, TUG1, TULP3, TULP4, TUSC1, TWF1, TXLNA, TXN, TXN2, TXNDC17, TXNDC5, TXNIP, TXNL1, TXNL4A, TYK2, TYRO3, TYRO3P, TYW1B, U2AF1, U2SURP, UACA, UBA1, UBA2, UBAC2, UBAP1, UBAP2, UBAP2L, UBASH3A, UBASH3B. UBE2B, UBE2C, UBE2D2. UBE2E1, UBE2F, UBE2G1, UBE2H. UBE2J1, UBE2J2, UBE2K, UBE2L3, UBE2L6, UBE2M, UBE2N, UBE2Q2P1, UBE2R2, UBE2S, UBE2T, UBE2V2, UBE2W, UBE3A, UBE4B, UBL3, UBL4B, UBL5, UBN2, UBQLN1, UBQLN2, UBR1, UBR2, UBR3, UBR4, UBTD1, UBTF, UBTFL1, UBXN1, UBXN4, UBXN6, UCA1, UCHL3, UCK2, UCP2, UFC1, UFD1L, UFSP1, UG0898H09, UGCG, UGP2. UGT1A10, UGT1A7. UGT1A8, UGT1A9. UHRF1, UHRF1BP1L, UHRF2. ULK1, ULKA, UNC119B, UNC45A, UNC5A, UNC93A, UNC93B1, UNG, UPF2, UPF3A, UPK1A, UPK3B, UPK3BL, UQCR11, UQCRB, UQCRC2, UQCRFS1, UQCRH, UQCRQ, URI1, UROD, USF2, USMG5, USO1, USP11, USP12, USP14, USP15, USP16, USP17L2, USP17L5, USP17L6P. USP2, USP22. USP25, USP26, USP28. USP3, USP32. USP36, USP38, USP4, USP47, USP53, USP54, USP6NL, UTP15, UTP18, UTP3, UTS2R, UXT, VAC14, VAMP2, VAMP3, VAMP8, VASN, VASP, VAT1, VAV1, VBP1, VDAC1, VDAC2, VDAC3, VDR, VEGFB, VENTXP1, VENTXP7, VEZF1, VEZT, VIL1, VIPR1, VKORC1, VMP1, VN1R1, VN1R2. VN1R4, VN1R5, VNN2, VNN3, VOPP1, VPREB1, VPS13A, VPS13C, VPS13D, VPS16, VPS18, VPS25, VPS26B, VPS28, VPS35, VPS37B, VPS37C, VPS39, VPS41, VPS4A, VPS4B, VPS52, VPS8, VPS9D1, VSIG2, VSIG8, VSNL1, VSTM4, VWCE, VWF, WAC, WAP AL, WARS, WAS, WASF2, WASH1, WASH3P, WASL. WBP1, WBP1L. WBP2. WBSCR22, WDFY2, WDFY3, WDRL WDR13. WDR47. WDR54, WDR55, WDR59, WDR5B. WDR61, WDR82, WDR83, WDR83OS, WDR91, WFDC3, WHAMM, WHAMMP1, WIPF2, WIPI1, WIPI2, WIZ, WLS, WNK2, WNT7B, WSB1, WSB2, WTAP, WTH3DI, WTIP, WWC1, WWC2.AS2, WWC3, WWP2, WWTR1, XCL2, XDH, XGPY2, XIST, XKRX, XPO6, XPO7, XPOT, XRCC5, XRCC6, XRN1, XRRA1, XYLT2, YAPL YBXL YBX2. YES1, YIF1A. YIF1B, YIPF3, YIPF5, YKT6, YME1L1, YOD1, YPEL2, YPEL3, YPEL5, YRDC, YTHDC1, YWHAB, YWHAE, YWHAH, YWHAQ, YY1, YY2, ZAK, ZAP70, ZBED4, ZBED6, ZBTB1, ZBTB10, ZBTB16. ZBTB17, ZBTB38, ZBTB4. ZBTB7A, ZBTB7C. ZBTB8OS, ZC2HC1 A, ZC3H11 A, ZC3H12A, ZC3H12C, ZC3H12D, ZC3H18, ZC3H3, ZC3H4, ZC3H7A, ZC3H7B, ZC3H8, ZCCHC13, ZCCHC16, ZCCHC3, ZCCHC7, ZCCHC8, ZDHHC13, ZDHHC18, ZDHHC20, ZDHHC21, ZDHHC5, ZDHHC7, ZDHHC9, ZEB1, ZFAND1, ZFAND2A. ZFAND3, ZFAND5, ZFAND6, ZFHX3, ZFP36L1. ZFP36L2, ZFP91. ZFPM1, ZFX. ZFYVE16. ZFYVE9, ZHX2, ZKSCAN1, ZMAT2, ZMIZ1, ZMIZ2, ZMYM2, ZMYM6, ZMYND10, ZMYND11, ZMYND15, ZNF1OO, ZNF1O7, ZNF114, ZNF124, ZNF154, ZNF160, ZNF165, ZNF177, ZNF215, ZNF224, ZNF23, ZNF24, ZNF252P.AS1, ZNF253, ZNF266, ZNF267, ZNF276, ZNF280D, ZNF284, ZNF304, ZNF331. ZNF33A, ZNF37A, ZNF385A, ZNF398, ZNF407, ZNF410, ZNF415, ZNF426, ZNF429, ZNF430, ZNF431, ZNF432, ZNF460, ZNF468, ZNF485, ZNF507, ZNF516, ZNF526, ZNF527, ZNF528, ZNF532, ZNF542, ZNF543, ZNF549, ZNF551, ZNF571, ZNF585A, ZNF586, ZNF589, ZNF592, ZNF593, ZNF595, ZNF598, ZNF610, ZNF616, ZNF618, ZNF638, ZNF655. ZNF662. ZNF668. ZNF675. ZNF678. ZNF683. ZNF684. ZNF692. ZNF7O8. ZNF71O. ZNF750. ZNF77, ZNF773, ZNF780A, ZNF783, ZNF789, ZNF791, ZNF8O, ZNF800, ZNF808, ZNF816, ZNF830, ZNF831, ZNF841, ZNF844, ZNF91, ZNF92, ZNF93, ZNFX1, ZNHIT2, ZNRF1, ZNRF2, ZNRF2P1, ZNRF4, ZRANB1, ZSCAN12P1, ZSWIM4, ZSWIM6, ZWINT, ZXDA, ZYX, and ZZEF1.

[0119] As used herein, the term "predictive training set" refers to a cohort of skin lesions wi th known clinical outcome (z.e., atopic dermatitis, psoriasis, and / or mycosis fungoides) and known genetic expression profile, used to define or establish all other skin lesions, based upon the genetic expression profile of each. Additionally, included in the predictive training set is the definition of "threshold points," which are points at which a classification of atopic dermatitis, psoriasis, and / or mycosis fungoides is determined, specific to each individual gene expression level.

[0120] In certain embodiments, analysis of genetic expression and determination of outcome is carried out using radial basis machine and / or partial least squares analysis (PLS), partition tree analysis, logistic regression analysis (LRA), K-nearest neighbor, neural netw orks, ensemble learners, voting algorithms, or other algorithmic approach. These analysis techniques take into account the large number of samples required to generate a training set that will enable accurate prediction of outcomes as a result of cut-points established with an in-process training set or cut-points defined for non-algorithmic analysis, but that any number of linear and nonlinear approaches can produce a statistically significant and clinically significant result. As used herein, the term "Kaplan-Meier survival analysis" is understood in the art to be also known as the product limit estimator, which is used to estimate the survival function from lifetime data. In medical research, it is often used to measure the fraction of patients living for a certain amount of time after treatment. JMP GENOMICS®, R, Python libraries including SciPy, SciKit, and numpy software or systems such as TensorFlow provides an interface for utilizing each of the predictive modeling methods disclosed herein, and should not limit the claims to methods performed only with JMP GENOMICS®, R, Python, or TensorFlow software.

[0121] As used herein, the term "altered in a predictive manner" refers to changes in genetic expression profile that identifies or determines a skin lesion to be atopic dermatitis, psoriasis, or mycosis fungoides, and / or predicts a patient’s response to an appropriate treatment for atopic dermatitis, psoriasis, or mycosis fungoides. Predictive modeling can be measured as: 1) identifies or determines a skin lesion to be atopic dermatitis, psoriasis, or mycosis fungoides; and / or 2) a linear outcome based upon a probability score from 0 to 1 that reflects the correlation of the genetic expression profile of a skin lesion with the genetic expression profile of the samples that comprise the training set used to identifies or determines a skin lesion to be atopic dermatitis, psoriasis, or mycosis fungoides. The increasing probability score from 0 to 1 reflects incrementally increasing accuracy of the diagnosis of atopic dermatitis, psoriasis, or mycosis fungoides.

[0122] After a skin lesion is determined to be atopic dermatitis (AD), psoriasis, or mycosis fungoides, a medical professional or team of medical professionals will recommend an appropriate treatment comprising one or more therapeutic options. In some embodiments, the methods disclosed herein can predict a patient’s response to an appropriate treatment for atopic dermatitis, psoriasis, or mycosis fungoides. and thus used by medical professionals to recommend an appropriate treatment. In determining an appropriate treatment, factors to consider include the type, location, and severity of the atopic dermatitis, psoriasis, or mycosis fungoides as well as the patient's overall physical health. Patients with atopic dermatitis, psoriasis, or mycosis fungoides typically are managed by a dermatologist.

[0123] As used herein, the terms "treatment," "treat," or "treating" refer to a method of reducing the effects of a disease or condition or symptom of the disease or condition (e.g. atopic dermatitis, psoriasis, and / or mycosis fungoides). Thus, in the methods disclosed herein, treatment and / or response to a treatment can refer to a 5%, 10%, 20%, 30%, 40%, 50%. 60%. 70%. 80%. 90%. or 100% reduction in the severity of an established disease or condition or symptom of the disease or condition (e.g. atopic dermatitis, psoriasis, and / or mycosis fungoides). For example, a method of treating a disease is considered to be a treatment if there is an at least 5% reduction in one or more symptoms of the disease in a subject as compared to a control. Thus, the reduction can be at least about a 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100% or any percent reduction between at least about 5% and 100% as compared to native or control or baseline levels. In some embodiments, response to a treatment could refer to an at least 5% reduction in one or more symptoms of the disease in a subject as compared to a control. Thus, the reduction can be at least about a 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100% or any percent reduction between at least about 5% and 100% as compared to native or control or baseline levels is considered a response to a treatment. It is understood that an appropriate treatment does not necessarily refer to a cure or complete ablation of the disease, condition, or symptoms of the disease or condition.

[0124] In some embodiments, Eczema Area and Severity Index (EASI) can be used to determine efficacy of a treatment and / or response to a treatment in subjects with atopic dermatitis (eczema). The EASI is a validated measure used in clinical settings to assess the severity and extent of atopic dermatitis (Hanifin et al., 2022, “The Eczema Area and Severity Index — A Practical Guide”, Dermatitis. 2022 May-Jun; 33(3): 187-192). EASI score is indicative to efficacy of a treatment. Four atopic dermatitis disease characteristics are assessed for severity by a physician or other qualified medical professional on a scale of 0 (absent) through 3 (severe). In addition, the area of atopic dermatitis involvement is assessed as a percentage by body area of head, trunk, arms and legs and converted to a score of 0 to 6. In certain embodiments of the present disclosure, administration of an effective appropriate treatment to a patient with atopic dermatitis results in a decrease in EASI score. For example, a decrease from baseline in EASI score of at least about 10%. 15%. 20%. 25%. 30%. 35%. 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% (e.g. EASI 50, EASI 75, EASI 90, or EASI 100) at w eek about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or later following administration of the treatment.

[0125] In some embodiments, Psoriasis Area and Severity Index (PASI) can be used to determine efficacy of a treatment and / or response to a treatment in subjects with psoriasis. The PASI includes scores on erythema, thickness, scaling, and percentage of body surface area (BSA) affected. In certain embodiments of the present disclosure, administration of an effective treatment to a patient with psoriasis results in a decrease in PASI score. For example, a decrease from baseline in PASI score of at least about 10%. 15%. 20%. 25%. 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% (e g. PASI 50, PASI 75, PASI 90, or PASI 100) at week 1, 2, 3. 4, 5, 6, 7, 8, 9, 10, 11, 12 or later following administration of the treatment.

[0126] In some embodiments. Physician Global Assessment (PGA) of Skin can be used to determine efficacy of an appropriate treatment and / or response to a treatment in subjects with psoriasis. Physician Global Assessment (PGA) of Skin refers to a 5-point, 0-4 measure that is a useful clinician assessment of psoriasis lesions on the skin based on degree of erythema, thickness, and scale averaged over the entire body. Each of the clinical signs are assessed on a 0-5 scale (0=clear, l=minimal, 2=mild, 3=moderate, and 4=severe). In certain embodiments of the present disclosure, administration of an effective appropriate treatment to a patient with psoriasis can result in an at least 2-fold, 3-fold, 4-fold, 5-fold, or 10-fold, or more than 10-fold improvement of psoriasis as assessed by Physician Global Assessment of Skin.

[0127] In some embodiments, an appropriate treatment of atopic dermatitis can include topical therapy comprising creams, foams, gels, lotions, oils, ointments, shampoos, or sprays. In some embodiments, an appropriate treatment of atopic dermatitis can include topical therapy comprising creams and ointments comprising one or more of antihistamines, antibiotics, calcineurin inhibitors, corticosteroids, j anus kinase (JAK) inhibitors (upadacitinib or abrocitinib), phosphodieterase-4 inhibitors (e.g. crisaborole), and antibodies (e.g. dupilumab or tralokinumab). In some embodiments, an appropriate treatment of atopic dermatitis can include corticosteroids (e.g. hydrocortisone, triamcinolone, clobetasol, fluticasone propionate, or mometasone furoate). In some embodiments, an appropriate treatment of atopic dermatitis can include calcineurin inhibitors (e.g., tacrolimus or pimecrolimus).

[0128] In some embodiments, an appropriate treatment of atopic dermatitis can include light therapy. Light therapy involves exposing the skin to controlled amounts of natural or artificial light (e.g. sunlight, or UVB broadband or UVB narrowband, or UVA). In some embodiments, an appropriate treatment of atopic dermatitis can include exposing the affected area to sunlight. In some embodiments, an appropriate treatment of atopic dermatitis can include exposing the affected area to UVB broadband light (about 280 nm to about 320 nm). In some embodiments, an appropriate treatment of atopic dermatitis can include exposing the affected area to UVB narrowband light (about 308 nm to about 312 nm). In some embodiments, an appropriate treatment of atopic dermatitis can include exposing the affected area to UV A light (about 315 nm to about 400 nm). In some embodiments, an appropriate treatment of atopic dermatitis can include oral or injected medication. In some embodiments, an appropriate treatment of atopic dermatitis can include antihistamines, antibiotics, cyclosporine, methotrexate, prednisone, mycophenolate and azathioprine. In some embodiments, an appropriate treatment of atopic dermatitis can include biologies (monoclonal antibodies, for example, dupilumab, lebrikizumab, or tralokinumab). In some embodiments, an appropriate treatment of atopic dermatitis can include j anus kinase (JAK) inhibitors, such as abrocitinib. baricitinib, delgocitinib, gusacitinib, ruxolitinib, SHR0302, tofacitinib and upadacitinib.

[0129] In some embodiments, an appropriate treatment of psoriasis can include topical therapy comprising creams, foams, gels, lotions, oils, ointments, shampoos, or sprays. In some embodiments, treatment of psoriasis can include topical therapy comprising creams and ointments comprising one or more of corticosteroids, vitamin D analogues, retinoids, calcineurin inhibitors, PDE4 inhibitors (apremilast), salicylic acid, and anthralin. In some embodiments, an appropriate treatment of psoriasis can include corticosteroids (e.g. hydrocortisone, triamcinolone, or clobetasol). In some embodiments, an appropriate treatment of psoriasis can include vitamin D analogues (such as calcipotriene or calcitriol). In some embodiments, an appropriate treatment of psoriasis can include retinoids (e.g. tazarotene). In some embodiments, an appropriate treatment of psoriasis can include calcineurin inhibitors (e.g., tacrolimus or pimecrolimus). In some embodiments, an appropriate treatment of psoriasis can include salicylic acid. In some embodiments, an appropriate treatment of psoriasis can include coal tar. In some embodiments, an appropriate treatment of psoriasis can include anthralin.

[0130] In some embodiments, an appropriate treatment of psoriasis can include light therapy. Light therapy is a first line treatment for moderate to severe psoriasis, either alone or in combination with medications. It involves exposing the skin to controlled amounts of natural or artificial light (e.g. sunlight, or UVB broadband or UVB narrowband, or UVA). In some embodiments, an appropriate treatment of psoriasis can include exposing the affected area to sunlight. In some embodiments, an appropriate treatment of psoriasis can include exposing the affected area to UVB broadband light (about 280 nm to about 320 nm). In some embodiments, an appropriate treatment of psoriasis can include exposing the affected area to UVB narrowband light (about 308 nm to about 312 nm). In some embodiments, an appropriate treatment of psoriasis can include exposing the affected area to UVA light (about 315 nm to about 400 nm). In some embodiments, an appropriate treatment of psoriasis can include psoralen plus ultraviolet A (PUVA), which involves taking a light-sensitizing medication (psoralen) before exposing the affected skin to UVA light. In some embodiments, light therapy comprises Goeckerman therapy, which combines coal tar treatment with light therapy.

[0131] In some embodiments, an appropriate treatment of psoriasis can include oral or injected medication. In some embodiments, an appropriate treatment of psoriasis can include steroids or retinoids (e g. acitretin). In some embodiments, an appropriate treatment of psoriasis can include phosphodiesterase 4 (PDE4) inhibitors (e.g. apremilast). In some embodiments, an appropriate treatment of psoriasis can include TYK2 inhibitors (e.g. deucravacitinib). In some embodiments, an appropriate treatment of psoriasis can include biologies against, for example. TNF, IL-12 / 23, IL-23, IL-17A, and / or IL-17R (monoclonal antibodies, e.g., adalimumab, bimekizumab, brodalumab, certolizumab, etanercept, golimumab, guselkumab, infliximab, ixekizumab, risankizumab, secukinumab, tildrakizumab, or ustekinumab). In some embodiments, an appropriate treatment of psoriasis can include methotrexate, cyclosporine, thioguanine, or hydroxyurea.

[0132] In some embodiments, an appropriate treatment of mycosis fungoides can include photodynamic therapy (e.g. psoralen and ultraviolet A (PUVA) therapy or extracorporeal photopheresis (ECP)), radiation therapy (e.g. total skin electron beam (TSEB) radiation therapy), chemotherapy, corticosteroids, retinoids (e.g. bexarotene), histone deacetylase (HD AC) inhibitors (e.g. lenalidomide or vorinostat), romidepsin, immunotherapy (e.g. interferons), targeted therapy (e.g. brentuximab vedotin or mogamulizumab). high-dose chemotherapy and radiation therapy with stem cell transplant, or immune checkpoint inhibitor therapy (e.g., PD-1 or PD-Ll inhibitor therapy).

[0133] In some embodiments, an appropriate treatment of mycosis fungoides can include topical therapy comprising creams, foams, gels, lotions, oils, ointments, shampoos, or sprays. In some embodiments, an appropriate treatment of mycosis fungoides can include corticosteroids (e.g. hydrocortisone, triamcinolone, or clobetasol). In some embodiments, an appropriate treatment of mycosis fungoides can include retinoids (e.g. acitretin, bexarotene, or tazarotene).

[0134] In some embodiments, an appropriate treatment of mycosis fungoides can include light therapy. Light therapy involves exposing the skin to controlled amounts of natural or artificial light (e.g. sunlight, or UVB broadband or UVB narrowband, or UVA). In some embodiments, an appropriate treatment of mycosis fungoides can include exposing the affected area to sunlight. In some embodiments, an appropriate treatment of mycosis fungoides can include exposing the affected area to UVB broadband light (about 280 nm to about 320 nm). In some embodiments, an appropriate treatment of mycosis fungoides can include exposing the affected area to UVB narrowband light (about 308 nm to about 312 nm). In some embodiments, an appropriate treatment of mycosis fungoides can include exposing the affected area to UVA light (about 315 nm to about 400 nm). In some embodiments, an appropriate treatment of mycosis fungoides can include psoralen plus ultraviolet A (PUVA), which involves taking a light-sensitizing medication (psoralen) before exposing the affected skin to UVA light.

[0135] In some embodiments, an appropriate treatment of mycosis fungoides can include oral or injected medication. In some embodiments, treatment of psoriasis can include steroids or retinoids (e.g. acitretin, bexarotene, or tazarotene). In some embodiments, an appropriate treatment of mycosis fungoides can include biologies (monoclonal antibodies, e.g.. brentuximab vedotin or mogamulizumab).

[0136] In some embodiments, an appropriate treatment of mycosis fungoides can include immune checkpoint inhibitor therapy. In some embodiments, an appropriate treatment of mycosis fungoides can include PD-1 or PD-L1 inhibitors (e.g. acrixolimab. atezolizumab, avelumab, camrelizumab, cemiplimab, cosibelimab. dostarlimab. durvalumab, nivolumab. pembrolizumab, retifanlimab, sintilimab, spartalizumab, tislelizumab, toripalimab, vopratelimab).

[0137] As used herein, the terms "responsive" or "response to" refer to a patient that achieves a response to a treatment, i.e. a patient where the skin lesion is eradicated, reduced or improved, and thus an indication that the treatment is successful. Thus, in the methods disclosed herein, response to a treatment can refer to a 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% reduction in the severity of atopic dermatitis, psoriasis, and / or mycosis fungoides. A "non-responder" patient includes patients for whom the skin lesion does not show reduction in severity or improvement after the therapy.

[0138] In yet another aspect, this disclosure provides for kits comprising primer pairs suitable for the detection and quantification of nucleic acid expression of at least 5 genes. In some embodiments, the at least 5 genes in the gene set are selected from ACTR3BP2, ANP32AP1, ARL8B, ATP2B2. ATP6V0CP3, C3orf36, CASKIN1, CCDC88B, CLDN19, CXCL3. EEF2K, ELL, EMC4, FAM134C, FAM83F, FOXO3B, GLUD2, HN1, HOMER1, HRNR, HSPA7, IL17A, KRTAP10.3, LOC100130673, LRRC10, LRRK1, MY ADM, MYH9, NANOGNB, NSFL1C, OR52I2. OR6K2, OVCH2, PCDHB3, PPP2R3B, RNASE1, SEL1L, SSR2, TAS2R8, TFRC, TUBB4A, VSIG8, WSB1, XPOT, and ZNF165. In some embodiments, the at least 5 genes in the gene set are selected from A2M, ARHGEF10L, ARRDC1, ASH1L.AS1, BAX, CD68, CD97, CPLX3, CUL1, GBAP1, GGT8P, GJA1, HSP90AA1, IER3. IFNA17. IL13, IL17A, LOC283070, LOC646214, LOC650293, MED13L, MLLT1, MTMR1, MTRNR2L8, 0CA2, OGFR, OR14J1, OST4, PKP1, PSMB7, PTPRE, RACGAP1P, RNF130, RNF213, SAP18, SH3BGRL, SNORA1, SNRNP70, TCEB3CL, TMEM123, TMEM39A, TNFAIP8, TOP1P2, UCKL1, and XDH.

[0139] In some embodiments, the at least 5 genes in the gene set are selected from the genes of Table 3. In certain embodiments, the genes in a gene set comprise one or more of the gene sets recited in Table 3. In some embodiments, the at least 5 genes in the gene set are selected from the genes of Table 4. In certain embodiments, the genes in a gene set comprise one or more of the gene sets recited in Table 4.

[0140] Kits can include any combination of components that facilitates the performance of an assay. A kit that facilitates assessing the expression of the gene or genes may include suitable nucleic acid-based and / or immunological reagents as well as suitable buffers, control reagents, and printed protocols. A "kit" is any article of manufacture (e.g., a package or container) comprising at least one reagent, e.g., a probe or primer set. for specifically detecting a marker or set of markers used in the methods disclosed herein. In some embodiments, a kit comprises one more probes capable of selectively hybridizing to at least five of the genes in Table 1 or Table 2. The terms "probe" and "oligonucleotide" (also "oligo"), when used in the context of nucleic acids, interchangeably refer to a relatively short nucleic acid fragment or sequence. "Primers" are probes capable, under the right conditions and with the right companion reagents, of selectively amplifying a target nucleic acid (e.g., a target gene). In the context of nucleic acids, "probe" is used herein to encompass "primer" since primers can generally also serve as probes. The article of manufacture may be promoted, distributed, sold, or offered for sale as a unit for performing the methods disclosed herein. The reagents included in such a kit comprise probes, primers, or antibodies for use in detecting one or more of the genes and / or gene sets that are useful for differentiating between atopic dermatitis and psoriasis lesions and non-lesional skin. Kits that facilitate nucleic acid based methods may further include one or more of the following: specific nucleic acids such as oligonucleotides, labeling reagents, enzymes including PCR amplification reagents such as Taq or Pfu, reverse transcriptase, or other, and / or reagents that facilitate hybridization. In addition, the kits disclosed herein may preferably contain instructions which describe a suitable detection assay. Such kits can be conveniently used, e.g., in clinical settings, to diagnose and evaluate patients exhibiting symptoms of atopic dermatitis or psoriasis, in particular patients exhibiting the possible presence of atopic dermatitis and psoriasis lesions. Embodiments:

[0141] Embodiment 1 : A method for diagnosing and treating a patient suspected of having atopic dermatitis, psoriasis, or mycosis fungoides, the method comprising:

[0142] (a) obtaining a diagnosis identifying a skin sample as atopic dermatitis, psoriasis, mycosis fungoides, or non-lesional from the skin sample from the patient, wherein the diagnosis was obtained by:

[0143] (1) determining the expression levels of at least 5 genes in a gene set;

[0144] (2) comparing the expression levels of the at least 5 genes in the gene set from the sample to the expression levels of the at least 5 genes in the gene set from a predictive training set to generate a probability score;

[0145] (3) providing the diagnosis identifying the skin sample as atopic dermatitis, psoriasis, mycosis fungoides, or non-lesional based on the probability score generated in step (2); and

[0146] (b) administering to the patient an appropriate treatment when the determination is made in the affirmative that the patient has atopic dermatitis, psoriasis, or mycosis fungoides. Embodiment 2: The method of embodiment 1, wherein the at least 5 genes in the gene set are selected from ACTR3BP2, ANP32AP1, ARL8B, ATP2B2, ATP6V0CP3, C3orf36, CASKIN1, CCDC88B, CLDN19, CXCL3, EEF2K, ELL, EMC4. FAM134C, FAM83F, F0X03B, GLUD2, HN1, H0MER1, HRNR, HSPA7, IL17A, KRTAP10.3, LOC100130673, LRRC10, LRRK1 , MY ADM, MYH9, NANOGNB, NSFL1C, OR52I2, OR6K2, 0VCH2, PCDHB3, PPP2R3B, RNASE1, SEL1L, SSR2, TAS2R8, TFRC, TUBB4A, VSIG8, WSB1, XPOT, and ZNF165.

[0147] Embodiment 3 : The method of embodiment 2, wherein the at least 5 genes in the gene set are used to diagnose the patient as having mycosis fungoides.

[0148] Embodiment 4: The method of embodiment 2, wherein the at least 5 genes in the gene set are used to diagnose the patient as having atopic dermatitis or psoriasis.

[0149] Embodiment 5: The method of embodiment 1, wherein the at least 5 genes in the gene set are selected from A2M, ARHGEF10L. ARRDCL ASH1L.AS 1. BAX, CD68, CD97. CPLX3, CULL GBAP1, GGT8P, GJA1, HSP90AA1, IER3, IFNA17, IL13, IL17A, LOC283070, LOC646214, LOC650293, MED13L, MLLT1, MTMR1, MTRNR2L8, OCA2, OGFR, OR14J1, OST4, PKP1, PSMB7, PTPRE, RACGAP1P, RNF130, RNF213, SAP18, SH3BGRL, SNORAL SNRNP70. TCEB3CL, TMEM123, TMEM39A, TNFAIP8, TOP1P2, UCKL1, and XDH. Embodiment 6: The method of embodiment 5, wherein the at least 5 genes in the gene set are used to diagnose the patient as having atopic dermatitis.

[0150] Embodiment 7 : The method of embodiment 5, wherein the at least 5 genes in the gene set are used to diagnose the patient as having psoriasis.

[0151] Embodiment 8: The method of any one of embodiments 1-7, wherein the skin sample is obtained using a non-invasive method.

[0152] Embodiment 9: The method of any one of embodiments 1-8. wherein the expression level of each gene in a gene set is determined by RNA-sequencing or by RT-PCR.

[0153] Embodiment 10: The method of any one of embodiments 1-9, wherein the probability score is between 0 and 1, and wherein a value of 1 indicates a higher probability of an atopic dermatitis, psoriasis, or mycosis fungoides lesion than a value of 0.

[0154] Embodiment 1 1: The method of any one of embodiments 1-10, wherein the probability score has a sensitivity of at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, and / or has a specificity of at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%.

[0155] Embodiment 12: The method of any one of embodiments 1-11, wherein the probability score has a positive predictive value (PPV) of at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, and / or has a negative predictive value (NPV) of at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%.

[0156] Embodiment 13: The method of any one of embodiments 1-12, wherein the expression levels of the genes are normalized.

[0157] Embodiment 14: A method for diagnosing a patient suspected of having atopic dermatitis, psoriasis, or mycosis fungoides the method comprising:

[0158] (a) obtaining a diagnosis identifying a skin sample as atopic dermatitis, psoriasis, mycosis fungoides, or non-lesional from the skin sample from the patient, wherein the diagnosis was obtained by:

[0159] (1) obtaining a skin sample from a patient suspected of having atopic dermatitis, psoriasis, or mycosis fungoides;

[0160] (2) determining the expression levels in the skin sample of at least 5 genes in a gene set;

[0161] (3) comparing the expression levels of the at least 5 genes in the gene set from the sample to the expression levels of the at least 5 genes in the gene set from a predictive training set to generate a probability score; and (4) providing the diagnosis identifying the skin sample as atopic dermatitis, psoriasis, mycosis fungoides. or non-lesional based on the probability score generated in step (2).

[0162] Embodiment 15: The method of embodiment 14, wherein the at least 5 genes in the gene set are selected from ACTR3BP2, ANP32AP1, ARL8B, ATP2B2, ATP6V0CP3, C3orf36, CASKINL CCDC88B, CLDN19, CXCL3, EEF2K. ELL. EMC4. FAM134C, FAM83F, FOXO3B, GLUD2, HN1, H0MER1, HRNR. HSPA7, IL17A, KRTAP10.3, LOC100130673, LRRC10, LRRK1, MY ADM, MYH9, NANOGNB, NSFL1C, OR52I2, OR6K2, OVCH2, PCDHB3, PPP2R3B, RNASE1, SEL1L, SSR2, TAS2R8, TFRC, TUBB4A, VSIG8, WSB1, XPOT, and ZNF165.

[0163] Embodiment 16: The method of embodiment 15, wherein the at least 5 genes in the gene set are used to diagnose the patient as having mycosis fungoides.

[0164] Embodiment 17: The method of embodiment 15, wherein the at least 5 genes in the gene set are used to diagnose the patient as having atopic dermatitis or psoriasis.

[0165] Embodiment 18: The method of embodiment 14, wherein the at least 5 genes in the gene set are selected from A2M, ARHGEF10L. ARRDCL ASH1L.AS 1. BAX, CD68, CD97. CPLX3, CULL GBAP1, GGT8P, GJA1, HSP90AA1, IER3, IFNA17, IL13, IL17A, LOC283070, LOC646214, LOC650293, MED13L, MLLT1, MTMR1, MTRNR2L8, OCA2, OGFR, OR14J1, OST4, PKP1, PSMB7, PTPRE, RACGAP1P, RNF130, RNF213, SAP18, SH3BGRL, SNORAL SNRNP70. TCEB3CL, TMEM123, TMEM39A, TNFAIP8, TOP1P2, UCKL1, and XDH.

[0166] Embodiment 19: The method of embodiment 18, wherein the at least 5 genes in the gene set are used to diagnose the patient as having atopic dermatitis.

[0167] Embodiment 20: The method of embodiment 18, wherein the at least 5 genes in the gene set are used to diagnose the patient as having psoriasis.

[0168] Embodiment 21 : The method of any one of embodiments 14-20, wherein the skin sample is obtained using a non-invasive method.

[0169] Embodiment 22: The method of any one of embodiments 14-21, wherein the expression level of each gene in a gene set is determined by RNA-sequencing or by RT-PCR.

[0170] Embodiment 23: The method of any one of embodiments 14-22, wherein the probability score is between 0 and 1, and wherein a value of 1 indicates a higher probability of an atopic dermatitis, psoriasis, or mycosis fungoides lesion than a value of 0.

[0171] Embodiment 24: The method of any one of embodiments 14-23, wherein the probability score has a sensitivity of at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, and / or has a specificity of at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%.

[0172] Embodiment 25: The method of any one of embodiments 14-24, wherein the probability score has a positive predictive value (PPV) of at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, and / or has a negative predictive value (NPV) of at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%.

[0173] Embodiment 26: The method of any one of embodiments 14-25, wherein the expression levels of the genes are normalized.

[0174] Embodiment 27: A kit comprising primer pairs suitable for the detection and quantification of nucleic acid expression of at least 5 genes.

[0175] Embodiment 28: The kit of embodiment 27, wherein the at least 5 genes in the gene set are selected from ACTR3BP2, ANP32AP1, ARL8B, ATP2B2, ATP6V0CP3, C3orf36, CASKIN1, CCDC88B, CLDN19, CXCL3, EEF2K, ELL, EMC4, FAM134C, FAM83F, FOXO3B, GLUD2, HN1, HOMER1, HRNR, HSPA7, IL17A, KRTAP10.3, LOC100130673, LRRC10, LRRK1, MY ADM, MYH9. NANOGNB. NSFL1C, OR52I2, OR6K2, OVCH2, PCDHB3, PPP2R3B, RNASEL SEL1L, SSR2. TAS2R8. TFRC. TUBB4A, VSIG8. WSBL XPOT, and ZNF165.

[0176] Embodiment 29: The kit of embodiment 27, wherein the at least 5 genes in the gene set are selected from A2M, ARHGEF10L, ARRDCl. ASH1L.AS1, BAX, CD68, CD97, CPLX3, CUL1, GBAP1, GGT8P, GJA1, HSP90AA1, IER3, IFNA17, IL13, IL17A, LOC283070, LOC646214, LOC650293, MED13L, MLLT1, MTMR1, MTRNR2L8, OCA2, OGFR, OR14J1, OST4, PKP1, PSMB7, PTPRE, RACGAP1P, RNF130, RNF213, SAP18, SH3BGRL, SNORA1, SNRNP70, TCEB3CL, TMEM123, TMEM39A, TNFAIP8, TOP1P2, UCKL1, and XDH.

[0177] Embodiment 30: The kit of embodiment 27, wherein the kit further comprises primer pairs suitable for the detection and quantification of nucleic acid expression of at least one control gene.

[0178] Embodiment 31: A method for predicting response to a treatment for a patient having atopic dermatitis and administering the treatment to the patient, the method comprising:

[0179] (a) obtaining a skin sample from the patient having atopic dermatitis,

[0180] (b) determining the expression levels of at least 5 genes in a gene set;

[0181] (c) comparing the expression levels of the at least 5 genes in the gene set from the sample to the expression levels of the at least 5 genes in the gene set from a predictive training set to generate a probability score; (d) providing an indication as to whether the patient responds to the treatment for atopic dermatitis based on the probability score generated in step (c); and

[0182] (e) administering the treatment to the patient.

[0183] Embodiment 32: The method of embodiment 31, wherein the expression level of each gene in a gene set is determined by RNA-sequencing or by RT-PCR.

[0184] Embodiment 33: The method of either embodiment 31 or embodiment 32, wherein the skin sample is obtained using a non-invasive method.

[0185] Embodiment 34: The method of any one of embodiments 31-33, wherein the expression levels of the genes are normalized.

[0186] Embodiment 35: The method of any one of embodiments 31-34, wherein the treatment is one or more of IL-4R inhibitor, an IL- 13 inhibitor, and a JAK inhibitor.

[0187] Embodiment 36: The method of any one of embodiments 31-35, wherein the treatment is selected from dupilumab, tralokinumab, upadacitinib, and abrocitinib.

[0188] Embodiment 37: The method of any one of embodiments 31-36, wherein the treatment is dupilumab.

[0189] Embodiment 38: The method of any one of embodiments 31-37, wherein the at least 5 genes in the gene set are selected from the genes disclosed in Table 3.

[0190] Embodiment 39: A method for predicting response to a treatment for a patient having psoriasis and administering the treatment to the patient, the method comprising:

[0191] (a) obtaining a skin sample from the patient having psoriasis,

[0192] (b) determining the expression levels of at least 5 genes in a gene set;

[0193] (c) comparing the expression levels of the at least 5 genes in the gene set from the sample to the expression levels of the at least 5 genes in the gene set from a predictive training set to generate a probability score; and

[0194] (d) providing an indication as to whether the patient responds to the treatment for psoriasis based on the probability score generated in step (c); and

[0195] (e) administering the treatment to the patient.

[0196] Embodiment 40: The method of embodiment 39, wherein the expression level of each gene in a gene set is determined by RNA-sequencing or by RT-PCR.

[0197] Embodiment 41 : The method of either embodiment 39 or embodiment 40, wherein the skin sample is obtained using a non-invasive method.

[0198] Embodiment 42: The method of any one of embodiments 39-41, wherein the expression levels of the genes are normalized. Embodiment 43: The method of any one of embodiments 39-42, wherein the treatment one or more of a PDE4 inhibitor, a TNF inhibitor, an IL- 12 / 23 inhibitor, an IL-23 inhibitors, an IL-17A inhibitor, an IL-17A / F inhibitor, an IL-17R, and a TYK2 inhibitor.

[0199] Embodiment 44: The method of any one of embodiments 39-43, wherein the treatment is selected from apremilast, etanercept, adalimumab, certolizumab, infliximab, ustekinumab, risankizumab, guselkumab, tildrakizumab, ixekizumab, secukinumab, bimekizumab. brodalumab. and deucravacitinib.

[0200] Embodiment 45: The method of any one of embodiments 38-42, wherein the treatment is risankizumab.

[0201] Embodiment 46: The method of any one of embodiments 39-45, wherein the at least 5 genes in the gene set are selected from the genes disclosed in Table 4.

[0202] EXAMPLES

[0203] The Examples that follow are illustrative of specific embodiments of the claimed invention, and various uses thereof. They are set forth for explanatory purposes only, and should not be construed as limiting the scope of the claimed invention in any way.

[0204] Example 1: Assessment of atopic dermatitis and psoriasis samples collected using a non-invasive sample collection technique

[0205] Sample and clinical data collection

[0206] The superficial epidermis of lesional and non-lesional skin from patients with AD or psoriasis from three dermatology centers in the United States was collected by gently scraping the skin ten times with a curette and immediately preserving in a proprietary buffer (see Figure 1). Samples were shipped at ambient temperature and frozen at -80° C upon receipt. RNA was isolated, and next generation sequencing was performed using Ampliseq (ThermoFisher). Differential expression of genes was assessed using DESeq2 and enrichment of DE Genes was assessed using Metascape.

[0207] Recent advances in the understanding of the molecular pathways underlying the pathophysiology of atopic dermatitis (AD) led to the development of multiple novel systemic drugs targeting those pathways. Currently, clinical presentation and patient comorbidities contribute heavily to the development of a therapeutic plan for patients with AD and psoriasis. On the other hand, the molecular mechanisms underlying each patient’s disease are not routinely considered when developing a treatment plan. Further confounding therapeutic selection, a subset of AD can mimic psoriasis. A recent study suggests that clinicians treat these cases empirically more often than consulting pathology. This is likely because biopsies are moderately invasive and can be inconclusive in many of these cases. An empirical approach could lead to delay in appropriate treatment of AD or psoriasis and increased cost to healthcare systems. Therefore, understanding individual patient’s disease at the molecular level could better inform treatment decisions. Indeed, candidate genes were differentially expressed in AD and psoriasis lesions relative to non-lesional skin and in AD relative to psoriasis lesions, demonstrating the feasibility of the scraping technique. However, an unbiased assessment of gene expression from skin scrapings of AD and psoriasis could identify additional genes which could be used in an algorithm to guide therapeutic selection. To obtain an unbiased molecular profde from AD and psoriasis samples collected using a noninvasive sample collection technique.

[0208] The objective was to obtain an unbiased molecular profile from AD and psoriasis samples collected using this non-invasive sample collection technique. The superficial epidermis of lesional and non-lesional skin from patients with AD or psoriasis from three dermatology centers in the United States was collected by gently scraping the skin ten times with a curette and immediately preserving the sample in a proprietary buffer. RNA isolated from samples was stored at -80°C until further use. Library preparation and next generation RNA sequencing was performed using the Ion AmpliSeq Transcriptome Human Gene Expression panel on the S5XL sequencer (ThermoFisher) at DC3 Therapeutics laboratories. Differential expression of genes was assessed using the DESeq2 program and R language; Metascape was used to assess enriched gene ontology of differentially expressed genes.

[0209] When comparing AD lesional and non-lesional skin, 1,633 transcripts were differentially expressed (absolute value of log2fold change >1.0 and padj < 05). Additionally, 4,468 transcripts were differentially expressed between psoriasis lesional and non-lesional skin. Further, principal component analysis demonstrated that lesional and non- lesional samples for both AD and psoriasis could be distinguished by their respective gene expression profiles. Gene ontology enrichment analysis revealed that innate and adaptive immune system and cytokine signaling genes were among the most common types of differentially expressed genes between lesional and non-lesional samples. Moreover, gene expression differed between lesional AD and psoriasis samples.

[0210] Taken together, these results suggest that next generation RNA sequencing is an unbiased approach to identify gene expression differences in AD and psoriasis samples collected by a non-invasive scraping technique. Clinical correlation with therapeutic outcomes may be used in conjunction with next generation sequencing to develop algorithms predicting therapeutic response in these common inflammatory skin diseases. Next generation sequencing provides an unbiased approach to identify gene expression differences in atopic dermatitis and psoriasis samples collected by a non-invasive scraping technique. Clinical correlation with therapeutic outcomes may be used in conjunction with next generation sequencing to determine molecular patterns of response or non-response in order to develop algorithms for predicting therapeutic response in these common inflammatory skin diseases.

[0211] Example 2: Gene Expression Differences Identified in Skin Samples of Early-Stage Mycosis Fungoides, Atopic Dermatitis, and Psoriasis

[0212] Updates in the molecular understanding of common and often debilitating skin diseases such as atopic dermatitis (AD) and psoriasis (PSO) led to the development of multiple targeted systemic drugs. Yet, molecular heterogeneity contributes to inconsistent clinical presentation and therapeutic response. Further, systemic treatment of presumed AD or PSO can lead to delays in both diagnosis and proper treatment of patients with a true diagnosis of mycosis fungoides (MF) - a potentially dangerous clinical mimic of AD and PSO that requires a rigorous histologic and molecular workup to diagnose. Therefore, a non- invasive method to distinguish MF from AD and PSO could accelerate accurate diagnoses and avoid inappropriate treatment of MF.

[0213] Presented herein is anon-invasive scraping technique to assess differences in gene expression profiles of MF samples, and to identify’ gene expression differences based on diagnosis of MF, AD, or PSO and response to targeted systemic AD or PSO therapies.

[0214] Methods: Lesional baseline samples were assessed from 76 patients (AD, n=24; PSO, n=48; and MF, n=4) enrolled in one of two IRB-approved studies (IDENTITY or SIGNAL- MF). The superficial epidermis was collected by gently scraping the skin ten times with a curette and immediately preserving in a proprietary buffer (see Figure 1 above). Library preparation and next generation RNA sequencing was performed using the Ion AmpliSeq Transcriptome Human Gene Expression panel on the S5 Prime sequencer (ThermoFisher). Clinical response to a subset of AD patients taking dupilumab was further assessed over 3 months using the eczema area and severity index (EASI). Gene expression was compared between MF, AD, and PSO. One chronic hand eczema sample and one psoriasis sample from a patient with concomitant eczema were excluded from diagnostic analysis. Further, gene expression was assessed based on response to therapy for the subset of AD patients taking dupilumab. Genes were considered differentially expressed if there was a log2fold change >| 1 ,0| and padj < 05. Figure 5A shows a workflow for the study presented herein. Figure 5Bshows that genes were differentially expressed in lesional skin samples from MF compared to PSO and AD. Figure 5Cshows the top 30 differentially expressed gene distributions for MF vs AD and PSO. Figure 5D shows the differentially expressed genes in lesional skin samples from MF compared to AD alone with top 30 differentially expressed distributions (Figure 5E). Figure 5F shows the differentially expressed genes in lesional skin samples from PSO compared to AD with top 30 differentially expressed gene distributions (Figure 5G). AD, atopic dermatitis; MF, mycosis fungoides, PSO, psoriasis.

[0215] Figure 6 shows volcano plots demonstrating differential gene expression between psoriasis / AD (i.e. not MF) and mycosis fungoides (MF) after matching for clinical features. In the data shown, PSO / AD (“not MF”) is the reference group, so there are genes downregulated in MF (left) and upregulated in MF (right) by comparison. Figure 7 shows boxplots of differential gene expression patters of 45 candidate genes (using 3-fold repeated 4x cross validation).

[0216] A combination of 45 genes shown in Table 1 can distinguish between psoriasis / AD (i.e. not MF) and mycosis fungoides (MF) in a skin sample from a patient with a sensitivity of 0.9250000, a specificity' of 0.9916667, and having a positive predictive value of 0.9924242 and a negative predictive value of 0.9343434.

[0217] Table 1. Differentially expressed genes between psoriasis / AD and mycosis fungoides (MF).

[0218] Figure 8 shows volcano plots of differential gene expression between PSO and AD after matching for clinical variables such as age and location. In the data shown. AD is the reference group, so genes that are downregulated (left) in psoriasis and genes that are upregulated (right) in psoriasis when compared to AD. Figure 9 shows boxplots of differential gene expression after of 45 candidate genes between psoriasis and atopic dermatitis (using 3-fold repeated 4x cross validation).

[0219] A combination of 45 genes shown in Table 2 can distinguish betw een psoriasis (PSO) and atopic dermatitis (AD) in a skin sample from a patient with a sensitivity of 0.9895833, a specificity of 0.9371528, and having a positive predictive value of 0.9429287 and a negative predictive value of 0.9888393.

[0220] Table 2. Differentially expressed genes between psoriasis (PSO) and atopic dermatitis.

[0221] Robust gene expression was obtained from lesional PSO, AD, and MF samples collected by non-invasive skin scraping. Gene expression differences were observed between PSO, AD, and MF, and can distinguish responders to dupilumab or risankizumab. Thus, this demonstrates a non-invasive molecular diagnostic test distinguish between AD, PSO, and MF, and which also can be used to identify responders to the targeted AD therapy dupilumab or to the targeted psoriasis therapy risankizumab.

[0222] Figure 10A shows a workflow for identifying gene expression differences between responders and non-responders to a therapeutic for AD. Figure 10B shows that genes were differentially expressed in baseline skin scrapings obtained from super-responders (EASI90+ response at 3 months, n=5) to dupilumab, which blocks both IL-4 and IL- 13 signaling compared to those with EASI<90 (n=8) response. Figure IOC shows the top 30 differentially expressed gene transcripts. EASI, eczema area and severity index; EASI90+, 90% or greater improvement in EASI; EASK90, less than 90% improvement in EASE

[0223] Table 3. Genes for predicting response to a treatment for atopic dermatitis. Table 4. Genes for predicting response to a treatment for psoriasis.

[0224] All references cited in this application are expressly incorporated by reference herein.

Claims

WHAT IS CLAIMED IS:Claim 1 : A method for diagnosing and treating a patient suspected of having atopic dermatitis, psoriasis, or mycosis fungoides, the method comprising:(a) obtaining a diagnosis identifying a skin sample as atopic dermatitis, psoriasis, mycosis fungoides, or non-lesional from the skin sample from the patient, wherein the diagnosis was obtained by:(1) determining the expression levels of at least 5 genes in a gene set;(2) comparing the expression levels of the at least 5 genes in the gene set from the sample to the expression levels of the at least 5 genes in the gene set from a predictive training set to generate a probability score;(3) providing the diagnosis identifying the skin sample as atopic dermatitis, psoriasis, mycosis fungoides, or non-lesional based on the probability score generated in step (2); and(b) administering to the patient an appropriate treatment when the determination is made in the affirmative that the patient has atopic dermatitis, psoriasis, or mycosis fungoides.Claim 2: The method of claim 1, wherein the at least 5 genes in the gene set are selected from ACTR3BP2, ANP32AP1, ARL8B, ATP2B2, ATP6V0CP3, C3orf36, CASKIN1.CCDC88B, CLDN19, CXCL3, EEF2K. ELL. EMC4. FAM134C, FAM83F, FOXO3B, GLUD2, HN1, HOMER 1, HRNR, HSPA7, IL17A, KRTAP10.3, LOCI 00130673, LRRC10, LRRK1, MY ADM, MYH9, NANOGNB, NSFL1C, OR52I2, OR6K2, OVCH2, PCDHB3, PPP2R3B, RNASE1, SEL1L, SSR2, TAS2R8, TFRC, TUBB4A, VSIG8, WSB1, XPOT, and ZNF165.Claim 3: The method of claim 2, wherein the at least 5 genes in the gene set are used to diagnose the patient as having mycosis fungoides.Claim 4: The method of claim 2. wherein the at least 5 genes in the gene set are used to diagnose the patient as having atopic dermatitis or psoriasis.Claim 5: The method of claim 1, wherein the at least 5 genes in the gene set are selected from A2M. ARHGEF10L. ARRDC1, ASH1L.AS1. BAX, CD68, CD97, CPLX3, CUL1, GBAP1, GGT8P, GJA1, HSP90AA1, IER3, IFNA17, IL13, IL17A, LOC283070,LOC646214, LOC650293. MED13L, MLLT1, MTMR1, MTRNR2L8, 0CA2, OGFR, OR14J1, OST4, PKP1, PSMB7, PTPRE, RACGAP1P, RNF130, RNF213, SAP18, SH3BGRL, SNORA1, SNRNP70, TCEB3CL, TMEM123, TMEM39A, TNFAIP8, TOP1P2, UCKL1, and XDH.Claim 6: The method of claim 5. wherein the at least 5 genes in the gene set are used to diagnose the patient as having atopic dermatitis.Claim 7 : The method of claim 5, wherein the at least 5 genes in the gene set are used to diagnose the patient as having psoriasis.Claim 8: The method of any one of claims 1-7, wherein the skin sample is obtained using a non-invasive method.Claim 9: The method of any one of claims 1-8, wherein the expression level of each gene in a gene set is determined by RNA-sequencing or by RT-PCR.Claim 10: The method of any one of claims 1-9, wherein the probability score is between 0 and 1, and wherein a value of 1 indicates a higher probability of an atopic dermatitis, psoriasis, or mycosis fungoides lesion than a value of 0.Claim 11 : The method of any one of claims 1-10, wherein the probability score has a sensitivity of at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, and / or has a specificity of at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%. 98%, or 99%.Claim 12: The method of any one of claims 1-11, wherein the probability score has a positive predictive value (PPV) of at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, and / or has a negative predictive value (NPV) of at least 90%, 91%, 92%, 93%, 94%. 95%. 96%. 97%. 98%. or 99%.Claim 13: The method of any one of claims 1-12, wherein the expression levels of the genes are normalized.Claim 14: A method for diagnosing a patient suspected of having atopic dermatitis, psoriasis, or mycosis fungoides the method comprising:(a) obtaining a diagnosis identifying a skin sample as atopic dermatitis, psoriasis, mycosis fungoides, or non-lesional from the skin sample from the patient, wherein the diagnosis was obtained by:(1) obtaining a skin sample from a patient suspected of having atopic dermatitis, psoriasis, or mycosis fungoides;(2) determining the expression levels in the skin sample of at least 5 genes in a gene set;(3) comparing the expression levels of the at least 5 genes in the gene set from the sample to the expression levels of the at least 5 genes in the gene set from a predictive training set to generate a probability score; and(4) providing the diagnosis identifying the skin sample as atopic dermatitis, psoriasis, mycosis fungoides, or non-lesional based on the probability score generated in step (2).Claim 15: The method of claim 14, wherein the at least 5 genes in the gene set are selected from ACTR3BP2, ANP32AP1, ARL8B, ATP2B2, ATP6V0CP3, C3orf36, CASKIN1, CCDC88B, CLDN19, CXCL3, EEF2K, ELL, EMC4. FAM134C, FAM83F, F0X03B, GLUD2, HN1, H0MER1, HRNR, HSPA7, IL17A, KRTAP10.3, LOC100130673, LRRC10, LRRK1 , MY ADM, MYH9, NANOGNB, NSFL1C, OR52I2, OR6K2, 0VCH2, PCDHB3, PPP2R3B, RNASE1, SEL1L, SSR2, TAS2R8, TFRC, TUBB4A, VSIG8, WSB1, XPOT, and ZNF165.Claim 16: The method of claim 15, wherein the at least 5 genes in the gene set are used to diagnose the patient as having mycosis fungoides.Claim 17: The method of claim 15, wherein the at least 5 genes in the gene set are used to diagnose the patient as having atopic dermatitis or psoriasis.Claim 18: The method of claim 14, wherein the at least 5 genes in the gene set are selected from A2M, ARHGEF10L, ARRDC1, ASH1L.AS1, BAX, CD68, CD97, CPLX3, CUL1, GBAP1, GGT8P, GJA1, HSP90AA1, IER3. IFNA17. IL13. IL17A, LOC283070, LOC646214, LOC650293, MED13L, MLLT1, MTMR1, MTRNR2L8, OCA2, OGFR,0R14J1, 0ST4, PKP1, PSMB7, PTPRE, RACGAP1P, RNF130, RNF213, SAP18, SH3BGRL, SN0RA1. SNRNP70. TCEB3CL, TMEM123, TMEM39A, TNFAIP8, TOP1P2, UCKL1, and XDH.Claim 19: The method of claim 18, wherein the at least 5 genes in the gene set are used to diagnose the patient as having atopic dermatitis.Claim 20: The method of claim 18, wherein the at least 5 genes in the gene set are used to diagnose the patient as having psoriasis.Claim 21: The method of any one of claims 14-20, wherein the skin sample is obtained using a non-invasive method.Claim 22: The method of any one of claims 14-21, wherein the expression level of each gene in a gene set is determined by RNA-sequencing or by RT-PCR.Claim 23: The method of any one of claims 14-22, wherein the probability score is between 0 and 1 , and wherein a value of 1 indicates a higher probability7of an atopic dermatitis, psoriasis, or mycosis fungoides lesion than a value of 0.Claim 24: The method of any one of claims 14-23, wherein the probability score has a sensitivity of at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, and / or has a specificity' of at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%.Claim 25: The method of any one of claims 14-24, wherein the probability score has a positive predictive value (PPV) of at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, and / or has a negative predictive value (NPV) of at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%.Claim 26: The method of any one of claims 14-25, wherein the expression levels of the genes are normalized.Claim 27: A kit comprising primer pairs suitable for the detection and quantification of nucleic acid expression of at least 5 genes.Claim 28: The kit of claim 27, wherein the at least 5 genes in the gene set are selected from ACTR3BP2, ANP32AP1, ARL8B, ATP2B2, ATP6V0CP3, C3orB6, CASKINL CCDC88B, CLDN19, CXCL3, EEF2K, ELL, EMC4, FAM134C, FAM83F, FOXO3B, GLUD2, HN1, H0MER1, HRNR, HSPA7, IL17A, KRTAP10.3, LOC100130673, LRRC10, LRRK1, MY ADM, MYH9, NANOGNB, NSFL1C. OR52I2, OR6K2, OVCH2, PCDHB3. PPP2R3B, RNASE1, SEL1L, SSR2, TAS2R8, TFRC, TUBB4A. VSIG8, WSB1, XPOT, and ZNF165.Claim 29: The kit of claim 27, wherein the at least 5 genes in the gene set are selected from A2M. ARHGEF10L. ARRDC1, ASH1L.AS1. BAX, CD68, CD97, CPLX3, CUL1, GBAP1, GGT8P, GJA1, HSP90AA1, IER3, IFNA17, IL13, IL17A, LOC283070, LOC646214, LOC650293, MED13L, MLLT1, MTMR1, MTRNR2L8, OCA2, OGFR, OR14J1, OST4, PKP1, PSMB7, PTPRE, RACGAP1P, RNF130, RNF213, SAP18, SH3BGRL, SNORA1, SNRNP70. TCEB3CL, TMEM123, TMEM39A, TNFAIP8, TOP1P2, UCKL1, and XDH.Claim 30: The kit of claim 27, wherein the kit further comprises primer pairs suitable for the detection and quantification of nucleic acid expression of at least one control gene.Claim 31 : A method for predicting response to a treatment for a patient having atopic dermatitis and administering the treatment to the patient, the method comprising:(a) obtaining a skin sample from the patient having atopic dermatitis,(b) determining the expression levels of at least 5 genes in a gene set;(c) comparing the expression levels of the at least 5 genes in the gene set from the sample to the expression levels of the at least 5 genes in the gene set from a predictive training set to generate a probability score;(d) providing an indication as to whether the patient responds to the treatment for atopic dermatitis based on the probability score generated in step (c); and(e) administering the treatment to the patient.Claim 32: The method of claim 31 , wherein the expression level of each gene in a gene set is determined by RNA-sequencing or by RT-PCR.Claim 33: The method of either claim 31 or claim 32, wherein the skin sample is obtained using a non-invasive method.Claim 34: The method of any one of claims 31-33, wherein the expression levels of the genes are normalized.Claim 35: The method of any one of claims 31-34, wherein the treatment is one or more of IL-4R inhibitor, an IL- 13 inhibitor, and a JAK inhibitor.Claim 36: The method of any one of claims 31-35, wherein the treatment is selected from dupilumab. tralokinumab, upadacitinib, and abrocitinib.Claim 37: The method of any one of claims 31-36, wherein the treatment is dupilumab.Claim 38: The method of any one of claims 31-37, wherein the at least 5 genes in the gene set are selected from the genes disclosed in Table 3.Claim 39: A method for predicting response to a treatment for a patient having psoriasis and administering the treatment to the patient, the method comprising:(a) obtaining a skin sample from the patient having psoriasis,(b) determining the expression levels of at least 5 genes in a gene set;(c) comparing the expression levels of the at least 5 genes in the gene set from the sample to the expression levels of the at least 5 genes in the gene set from a predictive training set to generate a probability score; and(d) providing an indication as to whether the patient responds to the treatment for psoriasis based on the probability score generated in step (c); and(e) administering the treatment to the patient.Claim 40: The method of claim 39, wherein the expression level of each gene in a gene set is determined by RNA-sequencing or by RT-PCR.Claim 41 : The method of either claim 39 or claim 40, wherein the skin sample is obtained using a non-invasive method.Claim 42: The method of any one of claims 39-41, wherein the expression levels of the genes are normalized.Claim 43: The method of any one of claims 39-42, wherein the treatment one or more of a PDE4 inhibitor, a TNF inhibitor, an IL-12 / 23 inhibitor, an IL-23 inhibitors, an IL-17A inhibitor, an IL-17A / F inhibitor, an IL-17R, and a TYK2 inhibitor.Claim 44: The method of any one of claims 39-43, wherein the treatment is selected from apremilast, etanercept, adalimumab, certolizumab, infliximab, ustekinumab, risankizumab, guselkumab, tildrakizumab, ixekizumab, secukinumab, bimekizumab, brodalumab, and deucravacitinib.Claim 45: The method of any one of claims 38-42, wherein the treatment is risankizumab.Claim 46: The method of any one of claims 39-45, wherein the at least 5 genes in the gene set are selected from the genes disclosed in Table 4.

Images